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Abstract 
Since the human genome project was completed in 2003, extraordinary progress has been made 
in the field of genomics with the development of new sequencing technologies and the 
widespread introduction of next generation sequencing (NGS). The application of NGS initiated 
a new era in genomics by massively increasing the number and diversity of the sequenced 
genomes at lower cost. Human Molecular Genetics has greatly benefited from the use of NGS-
based strategies to identify human disease genes. In this thesis, I investigated the application of 
genetic techniques to investigate the molecular basis of autosomal recessively inherited disorders 
of unknown etiology. A range of disease phenotypes, including oligodontia and fetal 
akinesia/multiple pterygium syndrome (FA/MPS), were investigated in patient cohorts that 
included many cases with parental consanguinity. Using an autozygosity linkage analysis-based 
approach and Sanger sequencing of candidate genes resulted in the identification germline RYR1 
mutations in FA/MPS. Subsequently, using exome sequencing techniques, the molecular basis of 
FA/MPS was further elucidated by the identification of germline mutations in RYR1, NEB, 
CHRNG, CHRNA1 and TPM2. The application of NGS in genetically heterogeneous disorders 
such as fetal akinesia/multiple pterygium syndrome can enable better and less expensive 
molecular diagnostic services aimed at specific mutation spectra, though more extensive 
sequencing can lead to the identification of larger numbers of variants of uncertain significance.  
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1.1 The basics of Inheritance  
 
Knowledge towards understanding the basics of genetics and inheritance has been developed 
during the past 150 years. The way of passing on the traits from the parents to the offspring was 
not known until George Mendel discovered these basic principles through his work conducted 
between 1856 and 1863 using pea plants. He had chosen the peas due to their several distinctive 
varieties, and quick reproduction in order to observe the traits in offspring. Mendel found that the 
inheritance of certain traits such as height, colour, shape etc. follow particular patterns.  Mendel 
postulated that alleles are inherited in pairs (one from each parent), and furthermore that certain 
traits are inherited in a dominant manner while some are recessive which could be hidden in one 
generation and appear in subsequent ones. He also stated that the inheritance of one trait is not 
influenced by the inheritance of another. From his results, he derived three main theories of 
inheritance; these are now known as the law of segregation, the law of independent assortment 
and the law of dominance (Mendel & Bateson 1865). These laws became the foundation of 
modern genetics. According to Mendel’s principles, single gene disorders can be classified into 
four major groups based on their mode of inheritance; autosomal recessive disorders, autosomal 
dominant disorders, X-linked inheritance and Y-linked inheritance.  Table 1.1 shows all types of 
inheritance which based on Mendel’s principles. 
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Table	1.1	The	basic	modes	inheritance	for	single-gene	inherited	diseases	
Pattern of inheritance           Description  Examples  
Autosomal dominant One mutated allele can cause the disease  
usually one parent is affected. If a parent is affected 
each child of a pregnancy has 1:2 chance of being 
affected 
 Appears in every generation - vertical transmission 
(though de novo cases can occur)   
Huntington 
disease 
Marfan syndrome 
Autosomal recessive Two mutated alleles can cause the disease 
Parents are usually unaffected heterozygous mutation 
carriers 
Each pregnancy has 1:4 chance of being affected 
cystic fibrosis 
sickle cell disease 
X-linked dominant In females, a mutation in one of the two alleles can 
cause the disease. In males, they only have one X 
chromosome, therefore a mutation in only this allele 
can cause the disease. Affected males mostly have 
more severe symptoms of the disorder than females 
no male-to-male transmission 
Rett syndrome 
X-linked recessive In males one mutated allele is sufficient to cause the 
condition while in females both X chromosomes 
should be mutated in order to cause the disease. 
Consequently, females are usually unaffected carriers 
No male-to-male transmission but all daughters of an 
affected male will be mutation carriers. 
Haemophilia 
Fabry disease 
Y-linked Only males are affected 
Affected males pass the mutated gene to all their sons 
but to none of their daughters 
Y chromosome 
infertility, some 
cases of Swyer 
syndrome  
Mitochondrial Also known as maternal inheritance; only females 
can pass on the disease to offspring but both male 
and female can be affected 
It appears in every generation-vertical transmission 
Leber hereditary 
optic neuropathy 
(LHON) 
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1.1.1 Autosomal Recessive Disorders  
Autosomal recessive (AR) disorders manifest when the child inherits two mutated alleles (one 
allele from each unaffected parent). Each child born to healthy carrier parents has a 25% chance 
of being wild-type, 50% chance to be a heterozygous mutation carrier and 25% chance to be 
homozygous affected. The affected child may harbour homozygous alleles at the disease locus or 
be a compound heterozygote for two different mutations on separate alleles (Table 1.1). Known 
examples of these disorders include hemochromatosis (incidence 1:400), cystic fibrosis 
(incidence 1:2,500), phenylketonuria (incidence 1: 5,000) spinal muscular atrophy (1: 10,000). 
Cystic fibrosis (CF), is an autosomal recessive disorder that affects the pulmonary and digestive 
systems of the patient and is characterized by body secretion of sticky thick mucus in the lungs 
and airways of affected individuals instead of normal thinner mucus. Around 70,000 individuals 
are affected with this disorder worldwide (Cutting, 2015). It is caused by bialleleic mutations of 
the CFTR gene, and the severity of the disease is quite variable.  
Offspring of consanguineous unions are more likely to exhibit a recessive disorder than offspring 
of unrelated couples because consanguineous parents share genes from at least one common 
ancestor. As such, if it carries the same allele mutation, the child will be at high risk of inheriting 
both mutated copies and therefore become homozygously affected. The significance of 
consanguinity will be discussed in further detail later in this chapter. Most of the cases studied in 
my project were consanguineous families who had autosomal recessive diseases, and therefore the gene 
and pathogenic mutations were mostly expected to be homozygous. However, there is still a possibility 
that in some cases despite the family being consanguineous, that disease might be caused by compound 
heterozygous mutations or even a non-autosomal recessive manner such as autosomal dominant disorders 
that are caused by de novo mutation and so could result in an affected child with normal parents 
17	
	
1.1.2 Autosomal Dominant Disorders 
. Autosomal dominant (AD) mutations were previously reported in the phenotypes studied within 
this project. As described above (Table 1.1), a single mutated allele will be sufficient to cause the 
disease in this type of inheritance. If one parent is heterozygous for a dominant mutation, there is 
a 50% chance of the offspring being affected. In rare circumstances both parents may be carriers 
for the same dominant mutation, and in such cases, there will be a 75% chance that the child will 
be affected by either inheriting one mutated allele (50% chance) or by inheriting both mutated 
alleles (25% chance), and in this case the disease is expected to be very severe. There will be 
only a 25% chance that the child will inherit two wild type alleles and be healthy.  
A child might be affected by a dominantly inherited disorder despite having healthy non-carrier 
healthy parents. This can occur if there is a de novo mutation or if there is germline mosaicism in 
the parents in which the mutation will occur in some of the sperm or egg cells but not the 
somatic cells. Germline mosaicism can be observed with any inheritance pattern, but it is most 
commonly seen with autosomal dominant and X-linked disorders and the pedigree will resemble 
the autosomal recessive pattern of inheritance (Figure 1.1). A child who inherits a mutation from 
the mosaic parent will be affected with the disorder and will not show mosaicism. An example of 
this is the heterozygous de novo mutation (p.R954L) which was detected in KIF21A in two 
siblings who were diagnosed with congenital fibrosis of the extraocular muscles, whereas both 
parents were homozygous for the wild allele with apparent recessive inheritance. Further 
mutational screening revealed another heterozygous variation in another area of the gene in the 
father and in both affected siblings while the mother was normal. As a result, the authors 
suggested that the p.R954L mutation arose from the father haplotype who is thought to be a 
germline mosaic for the mutation (Khan et al., 2010).  
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Figure	1.1	A	pedigree	represents	germline	mosaicism	in	the	father	of	two	affected	children	
1.2 Main approaches to study genetic disorders 
 
Genetic diseases can be classified traditionally into three major types. First, monogenic disorders 
caused by mutations in a single gene which can be inherited in one of the above Mendelian 
patterns (Table 1.1) depending on the disease and the gene involved (e.g. Phenylketonuria and 
cystic fibrosis). Secondly, polygenic and/or multifactorial disorders which result from mutations 
in multiples genes or sometimes caused by a combination between genetic mutations and 
environmental factors, with these disorders not usually following any specific pattern of 
inheritance. Examples of these disorders are diabetes mellitus, schizophrenia and heart diseases. 
Third, chromosomal disorders that either caused by a loss or gain of part of (or an entire) 
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chromosome copy or may be by rearrangement of part of the chromosome such as by 
translocation and/or inversion. 
Over the past century-and-a-half, many methods and techniques have been developed to identify 
the genetic causes which underlie these disorders in order to help in the diagnostic process and 
also improve the treatment approach. Three major historical approaches have been established 
for studying genetic and genomic changes in the laboratory. First, is cytogenetics (which analyse 
the chromosomal changes). Second, is molecular genetics (which can study the structure and the 
function of genes at molecular level), or thirdly, it can be a combination of these two approaches 
that can be referred as molecular cytogenetics. In this project, all investigations carried out fell 
under the umbrella of molecular genetics, however, I will describe briefly how cytogenetics and 
molecular cytogenetics can be used.	
1.2.1 Cytogenetics  
1.2.1a Conventional cytogenetics  
Karyotyping is the conventional cytogenetic method used to check a patient’s set of 
chromosomes and test the numerical changes, such as the loss or gain of an entire chromosome 
or part of it under the microscope as well as structural changes. The technique was developed by 
Tjio and Levan more than 50 years ago. They were the researchers who first discovered the 
correct number of human chromosomes as being 46 (Tjio and Levan, 1956). An example of the 
chromosomal genetic disorders is Down syndrome which is characterized by the presence of an 
extra copy of chromosome 21 (trisomy 21). This method is also efficient in diagnosing some 
mental disorders, developmental delay, congenital abnormalities and recurrent miscarriages 
which are mainly caused by similar abnormalities in the chromosomes.  
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The most common method for karyotyping is the G-banding technique which is based on the 
application of Giemsa dye on the metaphase chromosomes in order to give non-fluorescent 
permanent staining for the chromosome which can thus be visualised under a standard 
microscope.  The main disadvantages of standard cytogenetics is that it takes long time and also 
has limited resolution. It can only detects large structural and chromosomal aberrations ranging 
from 5-10 Mb in size (Riegel, 2014) . In order to overcome this limitation, the molecular 
cytogenetic approach was developed.  
1.2.1b Molecular cytogenetics 
	 Three major molecular cytogenetic approaches are used to identify and analyse chromosomal 
abnormalities: fluorescent in situ hybridization (FISH), comparative genomic hybridization 
(CGH) and SNP-genotyping arrays.  FISH is a powerful technique that utilises a fluorescent 
probe to bind to a specific chromosomal region to enable the region to be visualised and 
localized with fluorescence microscopy in a metaphase or interphase stage. It is useful in 
karyotyping to detect the changes in chromosomes (e.g. copy number variation). Also, it is a 
sensitive and specific method for detecting abnormalities at a resolution up to few kilobases (kb) 
such as translocations, aneuploidy, deletions, inversions, or amplifications. CGH is a high-
throughput technique developed in the 1990s and utilised for the analysis of the whole genome to 
identify copy number variations/aberrations (CNVs/CNAs) that cannot be detected by 
conventional karyotyping or targeted FISH studies, however it is very helpful in the genetic 
diagnosis of cancer patients. Two DNA samples (tumour and normal) are used and compared to 
observe any difference between them  (Michels et al., 2007, Martin and Warburton, 2015). One 
of the main advantages of CGH is that it can be applied effectively to discover novel genetic 
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changes, as it does not really require prior knowledge of the chromosome imbalance that is 
involved (Speicher & Carter et al.2005).  
In addition, SNP arrays is a further molecular cytogenetic technique that can provide high 
resolution copy number data. Recently SNP arrays have been used to detect copy number 
variants in the human genome by utilising >946,000 probes with an average inter-marker 
distance of 680 base pairs. Also, SNP arrays can detect copy-neutral loss of 
heterozygosity/uniparental disomy (UPD), which cannot be detected by conventional 
cytogenetics or FISH techniques (Bentley et al., 2008, Mardis et al., 2009) 
1.2.2 Molecular Genetics   
 
Mutations at the DNA level can be inherited from the parents or might be acquired at some point 
of the person’s life. They arise in many different forms, including single nucleotide substitution, 
as both insertions and deletions. Based on their impact, they can either cause no effect, alter the 
gene product, or prevent the gene from functioning properly or completely. Loss of function 
mutations mostly cause harmful effects although on some occasions they can be beneficial 
(Loewe, 2008)  
1.2.2a Gene identification approaches:  
To identify these molecular changes, two main approaches have been developed over the years. 
Firstly, functional cloning which is a method that entirely based on the available data about the 
gene function in order to determine the suspected causative gene without the need to know the 
genomic location of the gene. The second approach is the positional cloning method. Unlike the 
first method, a specific region of interest is located in the chromosome and the causative gene is 
then identified within the located candidate region without knowledge of the gene function. In 
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practice, using the two methods together has been found to be more efficient and useful rather 
than relying only on just one approach (Deloukas et al., 1998).  
1.2.2a. i Candidate Gene Approach 
This approach was previously known as the functional cloning approach. It requires a detailed 
prior knowledge of a particular disease phenotype including the pathophysiology of the disease. 
As such it is mainly based on the assessment of the association of a particular candidate gene that 
is thought to be relevant to the disease.  The major difficulty with this approach is that, before 
selecting the potential candidate gene, the researcher should have adequate knowledge and 
understanding of the mechanism which underlies the studied disease and its pathophysiology 
such as the gene function, tissue expression pattern, role in known developmental pathways, 
homologies to other genes, and/or animal models. In contrast, one of the advantages of this 
method that it does not require the study of large families with both affected and unaffected 
individuals, but can be performed on small families with only parents and probands or it can 
even be carried out on unrelated patients and control subjects in some occasions. Furthermore, 
this approach can be effective for identifying the genes underlying common and complex 
disorders where the risk associated with any chosen candidate gene is quite small (Kwon and 
Goate, 2000a, Risch and Merikangas, 1996). 
Large number of disease-causing genes have been identified using this method, for example the 
identification of phenylalanine hydroxylase (PAH) that causes phenylketonuria (DiLella et al., 
1987). This method was the main approach for identifying the causing genes before the 
development of genetic mapping.  
However, it is still very helpful today especially when it is combined with the linkage mapping 
to identify the disease-causing gene amongst the huge number of genes provided by highly 
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advanced techniques such as next generation techniques. In fact, in the latter scenario, the 
researcher is dependent on this strategy to identify both the mutations and the causative genes. 
 By performing a linkage analysis prior to whole exome sequencing, the region of interest can be 
narrowed down to a smaller size. After identifying many suspected variants in different 
candidate genes, the list of variants can be filtered according their genetic function and according 
to any role of the candidate genes may play in the biological process, and also in terms of any 
previous studies on animal models. If the identified genes had any role in the biological pathway, 
then it is more likely to select further genes from the same pathway that may lead to specific 
disease or related conditions. For instance, the identification of several genes to be a part of the 
RAS-MAPK signal transduction pathway (PTPN11, SOS1, RAF1, KRAS, HRAS, BRAF, MEK1, 
and MEK2) with the pathway recognised to be responsible for causing a variety of genetic 
syndromes (Noonan syndrome, LEOPARD syndrome, Costello syndrome, and 
Cardiofaciocutaneous syndrome) that all have overlapping clinical phenotypes (Weismann et al., 
2005). Recently, an analysis of mouse mutants with some genes knocked out using systematic 
mutagenesis programs has greatly aided the approach of functional cloning.  
Furthermore, the completion of the mouse genome project was a very significant advance 
(Waterston et al., 2002) due to the high genetic similarities between human and mouse genomes. 
In this way, genetic disease-causing mutations in mice have been hypothesised to reflect similar 
diseases in humans. It has also been found that the combination of linkage mapping and a 
candidate gene approach is the most successful method of identifying disease genes (Kwon and 
Goate, 2000b). 
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1.2.2a.ii Positional cloning 
Positional cloning studies are used to identify the location of the disease-causing candidate genes 
in Mendelian disorders. The method requires families with multiple affected individuals and 
genetic markers of known chromosomal locations to perform linkage analysis from which to 
define a candidate segment on a chromosome (locus) which contains the disease-causing gene 
(Wicking and Williamson, 1991). Having pinpointed a candidate interval region, mutational 
screening for the selected candidate genes within the interval is performed. 
In the last decade, The Human Genome Project greatly helped this approach (Lander et al., 2001, 
Venter et al., 2001) as it provided physical and genetic maps for millions of polymorphisms and 
sequence repeats on the chromosome. In addition, it provided a comprehensive sequence 
analysis, which has collectively led to detailed maps of genes of known or unknown function 
throughout the human genome. In addition, the public databases provided by genome browsers 
such as UCSC, NCBI, and Ensembl include detailed information about a massive number of the 
genes and polymorphic markers that have been mapped throughout the whole genome and the 
maps. In Mendelian disorders, linkage analysis can achieve the direct mapping of any candidate 
genes to locate the candidate genetic segment on the chromosome. Then, from this localized 
segment, the candidate gene itself will be selected according to the available information about 
the gene activity, tissue expression, biological process and any previous work on animal models 
related to this candidate gene.  
The highly-advanced genotyping and sequencing project played a significant role in speeding up 
the process of gene mapping and identification considerably. Nevertheless, many genes are still 
not identified although more than 15,000 genes involved in human diseases are present on 
OMIM.	 
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1.3 Haplotype and genetic markers 
A haplotype is a group of adjacent alleles or DNA sequences (genes or polymorphisms) which 
tend to be inherited together and can thus be used as a helpful tool in genetic mapping and 
population studies. Genetic mapping depends on the behaviour of chromosomes at the time of 
meiosis because this is when the linked region containing the candidate genes is passed along as 
a block unit unless they are separated by crossing over between paired homologous chromosome 
that results in swapping genetic material, with this process acting as the source of genetic 
recombination. The closer the genes occur on the same chromosome, the higher the chance that 
they will be inherited as a single unit, because crossing over between two linked genes is 
infrequent (Morgan, 1911). Recombination fraction is defined as the genetic distance between 
two separate loci, and usually loci separated by recombination in 1% of meiosis are defined as 
being 1centiMorgan (cM) distant. This genetic distance is different from physical distance 
(measured in bp, kb, or Mb of  DNA). In addition, some chromosome regions have a higher 
frequency of cross over than others. The order of loci should be similar in genetic and physical 
maps, but the spacing may be different, and on average 1cM corresponds to 1Mb, although this 
can be variable across the genome. Linkage between two loci is considered to be present when 
recombination events occur less than 50% of the time, and results in a recombination fraction of 
<0.5 (Ott and Bhat, 1999) which consequently means that the loci are located on the same 
chromosome and lie close to each other. Genetic mapping in humans thus looks at a large 
number of loci and types them for genetic markers.  
Different genetic markers were developed over the years and have been used in genetic mapping 
studies including allozymes, Random Amplified Polymorphic DNA (RAPDs), Restriction 
Fragment Length Polymorphisms (RFLPs), Amplified Fragment Length Polymorphisms 
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(AFLPs), Sequence-Tagged Sites (STSs), microsatellites and SNPs. In practice, each type of 
markers presents slightly different advantages and disadvantages. For selecting the best genetic 
markers to use in any linkage mapping studies, three main characteristics need to be considered: 
(i) high polymorphic rate of the genetic marker, (ii) the spreading across the genome or 
chromosomal region that contains the candidate gene with good coverage (iii) the genotyping 
error rate should be relatively small. (Ball et al., 2010) All these features can be found with 
single nucleotide polymorphisms which make them along with microsatellites the most used 
markers in genetic mapping studies. Both SNPs and microsatellite markers have been utilised in 
my project.  
Microsatellite markers are short tandemly repeated DNA sequences from 2-5 bases with a high 
polymorphic rate (e.g. [CA] repeats 40 times in a sequence). An analysis of microsatellites can 
then be performed using polymerase chain reaction (PCR) by amplification of the region which 
contains the microsatellites using fluorescently-tagged primers followed by fragment analysis. 
Microsatellites occur on average nearly every 30,000 bases throughout the human genome 
(Stallings et al., 1991). Practically speaking, these are found to be very informative and 
successful in many mapping projects but they do have high error rates compared to SNPs (Ball et 
al., 2010). Because of advances in high-throughput sequencing technologies and bioinformatics, 
SNPs have been increasingly used in genetic mapping studies in Mendelian monogenic, 
multifactorial diseases and the detection of copy number variants (CNVs). These are distributed 
throughout the whole human genome with an average presence of one polymorphism each 300 
nucleotides , which means that the human genome contains nearly 10 million SNPs (Salisbury et 
al., 2003). SNPs are relatively less informative than microsatellites because they are less 
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polymorphic but in contrast they are significantly more abundant across the human genome with 
a far less error rate.  
1.4 Genetic Mapping projects  
In the recent years, human genome sequencing projects such as the international HapMap 
Consortium facilitated the use of SNP markers in mapping studies by providing around 11 
million polymorphisms across the genome. The International HapMap is one of the biggest 
established mapping projects which has had a great impact in the design and analysis of genome-
wide association studies.  Using 270 individuals originating from different ethnic populations, 
the project successfully provided the mapping locations of more than one million SNPs. This 
achievement was later named as Phase I of the project and the result was published in 2005. In 
Phase II of the HapMap Project and with genotyping of same individuals, they found a further 
2.1 million SNPs. Based on phase I and II, the HapMap project thus contains a catalogue of 
nearly 3.1 million SNPs in total which means one polymorphism occurs every 1kbp nucleotide 
(International HapMap et al., 2007). These 3.1 million SNPs represent nearly one third of all the 
estimated 10 million commonly published SNPs (MAF≥0.05) in the whole assembled human 
genome (International HapMap et al., 2007). As a result, genome wide scans using SNP markers 
can be done utilizing high throughput methods such as (‘SNP-chips’), which provide high 
resolution mapping information. The first applied SNP chip array was (GeneChip® 10K Xba 
Array) and it could scan more than 10,000 SNP markers in a single experiment (Affymetrix Inc, 
Santa Clara, CA). This 10K chip was subsequently successfully used in many mapping projects 
(Janecke et al., 2004, Gissen et al., 2004). Also, Affymetrix has developed the SNP array 
techniques and produced upgraded array chips including 100K, and 500K which genotype more 
than 100,000 and 500,000 SNP markers respectively. More recently, they released SNP Array 
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6.0 that contains more than 900,000 SNPs and similar number of markers to detect copy number 
variation. 
Many genetic mapping and linkage studies have been established over the last three decades and 
these have become a crucial part of the genetic maps and the gene identification approach by 
providing a high-density framework of genetic markers across the genome with known positions 
for both the known genes and the markers. An example of these developed maps is the Généthon 
map which mainly focused on the microsatellite markers (Weissenbach et al., 1992, Dib et al., 
1996). Another microsatellite map was constructed by genotyping nearly 8,000 markers based on 
the analysis of eight large, three-generation families (Broman et al., 1998). In 2002, a paper was 
published describing a genetic mapping project which was undertaken in Reykjavik, Iceland by 
genotyping 869 individuals from 146 families. The study provided a defined map of 5,136 
polymorphic microsatellite markers. Based on this particular map framework, around 2 million 
further SNPs have been located as well (Kong et al., 2002). These genetic maps can be very 
helpful in performing linkage studies and identifying genes in specific diseases and aiding the 
assembly of known DNA sequence for the human genome project.  
1.5 Consanguinity 
In clinical genetics, consanguinity is described as a union between two related individuals such 
as first and second cousins, with an inbreeding coefficient factor (F) not less than 0.0156 (Bittles, 
2001) where (F) measures the probability of passing on identical copies of the alleles from the 
related parents to their offspring, so that they become homozygous for that allele and are 
identical by descent (IBD). F thus relates to the risk for the child to be homozygous by descent 
for a particular genetic sequence. In contrast, the coefficient of relationship (R) is related to the 
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consanguineous couple themselves and measures how much genetic components they would 
expected to share by descent from a common ancestor (Table 1.2) The closer the biological 
relationship between couples, the greater is the likelihood of their child being homozygous 
alleles/mutations for the recessive genes implicated in disease. 
 
Table	1.2	The	degree	of	consanguinity	and	the	chance	of	passing	the	genetic	component	
Relationships	between	degrees	of	consanguinity	and	the	effect	on	F	and	R	and	consequential	risk	of	
autosomal	recessive	disease	in	offspring	(Adapted	from	Young,	1999)	
Relationship Degree of Relationships Shared genes (R) Inbreeding factor (F) 
 
First degree 
Parent-child 
Siblings 
½ ¼ 
 
Second degree 
Half siblings 
Uncle-niece 
Aunt-nephew 
¼ 1/8 
 
Third degree 
First cousins 
Half uncle-niece 
Half aunt-nephew 
1/8 1/16 
 
Fourth degree 
First cousins once removed 
Half first cousins 
1/16 1/32 
Fifth degree Second cousins 1/32 1/64 
	
1.5.1 Global Prevalence of consanguinity  
It is estimated globally that at least 20% of the human population live in communities with a 
preference for consanguineous marriage, and that nearly 15% of children across the world have 
consanguineous parents (Shami et al., 1990). In a number of specific communities and 
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populations, there is a preference towards consanguineous marriage and this has led to an 
increased expression of autosomal recessive disorders among these communities because the 
offspring is at a higher risk of inheriting homozygous recessive gene mutations from a common 
ancestor (Bittles et al., 1991, Bittles and Black, 2010, Hamamy et al., 2011). In contrast, no 
significant associations have been indicated in the genetic studies between the consanguineous 
marriages and the diseases inherited either in autosomal dominant conditions or for X-linked 
recessive conditions (Hamamy et al., 2007). Consanguineous marriage has been reported with 
high rate in some countries such as India, Pakistan Turkey, Arabian Gulf countries and in North 
Africa in varying rates (Figure 1.2) (Hamamy et al., 2007, Hamamy et al., 2011). 
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Figure	1.2	A	map	showing	the	prevalence	of	global	consanguinity	
(from	consang.net	resource	by	Allan	Bittles,	2015)	
	
 Though most of the communities with high rate of consanguinity are of Islamic background, 
there is no evidence that Islam or the prophet Mohammed encouraged marriage between 
relatives, in fact some Muslim scholars rather discouraged it. Therefore, it appears that the 
practice of consanguineous marriage is mainly cultural with the relatives wanting to strengthen 
their family ties and avoid the uncertainty of health or financial situations of a spouse coming 
from outside the family. In addition, economic factors could have become another reason for the 
increased average of blood relatives’ marriages, especially in communities where dowry 
payments are the norm, thus these costs being effectively reduced (Bittles, 2001, Modell and 
Darr, 2002).  In such communities, the early marriage is also quite common so the couples quite 
possibly would have more children with a consequentially increased chance of autosomal 
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recessive disorders occurring.  The effects of consanguineous marriage have been widely 
reported in many studies amongst different populations. The observed outcomes have included 
increased infant morbidity and mortality rates, as well as of congenital abnormalities, learning 
difficulties, blindness, cardiovascular diseases and neuromuscular disorders. One study review 
involved 38 studies from several populations in different countries and summarized an average 
increase of infant mortality by 4.4% amongst the children of first cousins couples compared with 
unrelated controls. Also, the stillbirths rates amongst infants of consanguineous couples were 
found to be slightly higher while the birth defects rate was nearly 2–3% higher compared to 
controls (Bittles and Neel, 1994).  
1.5.2 Consanguinity prevalence in Arabian countries  
In most Arab populations, there is a high rate of consanguineous marriage (e.g. first cousin 
marriages) which has been reported in many studies across these countries (Figure 1.3). This has 
had a significant effect in the increase of inherited recessive diseases. For example, the rate of 
consanguinity represents between 35-50% of all marriages in Jordan (Hamamy et al., 2007, 
Tadmouri et al., 2009). 
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Figure	1.3	diagram	shows	the	rate	of	first	cousin	marriages	in	Arab	countries	
Image	taken	as	displayed	in	the	paper	(Al-Gazali	et	al.,	2006)	
  
In Saudi Arabia, a study screened 16,638 families from 13 different regions across the country. 
They found that the overall national prevalence was significantly high (56%) and first cousin 
mating (third degree relatives) was the most common form of relationship. In further analysis, 
consanguinity was found to be higher in the rural areas (59.5%) compared to (54.5%) within 
urban areas which indicate a slightly lower preference among urban people. Surprisingly, the 
rapid improvement and civilization over the last three decades in the country as a result of the oil 
boom have not significantly affected this high rate of consanguinity (El-Mouzan et al., 2007, El 
Mouzan et al., 2008). According to many researchers, consanguineous marriage is a significant 
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factor in increasing the prevalence of autosomal recessive genetic disorders within Arab 
populations and consanguinity is suggested as a reason of the high postnatal mortality rate 
amongst offspring of consanguineous unions, compared to offspring of non-consanguineous 
parents (Hamamy et al., 2007, Tadmouri et al., 2009).	
A study focused on investigating the role of consanguinity in pregnancy outcomes involved 4498 
pregnant women in Saudi Arabia and identified that the rate of consanguinity was 54.3% 
including 31.4% of first cousins and 22.9% of other relatives. This very high rate of 
consanguineous marriages in the Saudi population could be due to the role of the family in 
arranging the marriages as well as to the social and cultural influences which try to keep the 
family together. In the results, the high frequency of deleterious pregnancy outcome was noted 
among the consanguineous compared to those of the non-consanguineous marriages. The rates of 
the most severe outcomes such as perinatal deaths, infant deaths and neonatal deaths were highly 
significant among the consanguineous with 62%, 60.3% and 57.9% respectively, and collectively 
was 5% higher the non-related marriages. Furthermore, a higher average of the other outcomes 
such as abortions, still births, prematurity, live births and low weight were reported when 
compared to the non-consanguineous marriages (Wong and Anokute, 1990) 
1.5.3 Effect of high consanguinity within Pakistani British in Birmingham  
In the UK, consanguineous marriage is very common for communities of Pakistani, Bangladeshi 
and Middle Eastern origin, some Indian groups, Irish travellers and some refugee groups (Bittles, 
2001, Modell and Darr, 2002). A study conducted in Birmingham UK reported that 
consanguinity was recorded at 0.4% of the North European couples compared to a highly 
significant rate (69%) of related Pakistani British couples with the vast majority (57%) of these 
marriages being first cousins. It was further reported that 7.9% of British Pakistani children are 
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born with genetic defects compared to only 4.3 % affected children of North European couples. 
The frequency of recessive disorders was 3.0–3.3% amongst the British Pakistani children, ~10 
times greater than the North European children (0.28%) (Bundey and Alam, 1993)  (figure 1.4). 
	
Figure	1.4	The	role	of	high	consanguinity	in	causing	recessive	diseases	
amongst Pakistani British community in Birmingham-UK (Bundey and Alam, 1993) 
	
Furthermore, in a study recruited between 2007 and 2011’the Born in Bradford study’ 
investigated a cohort of 13,776 babies and their families and identified that 1922 (37 %) of 5127 
babies of Pakistani British had first-cousin parents (Bhopal et al., 2014). Based on the born 
Bradford study (Sheridan et al. 2013), questionnaire data was obtained from the mothers of those 
children affected with at least one anomaly. In their results, the risk for congenital anomaly was 
doubled compared to the children of British origin; it was 6 % of the offspring of first-cousin 
parents and 5 % of other related couples (Sheridan et al., 2013). 
Because of the reported significant impact of consanguinity in causing genetic recessive 
disorders, it was strongly suggested that it might be preferable to offer a genetic counselling unit 
0
10
20
30
40
50
60
70
Pakistani British North European
69
0.4
3.3
0.28
7.9
4.3
pe
rc
en
ta
ge
consanguinity rate
recessive diseases frequency
children born with genetic defects
36	
	
for any related couples who intend to get married rather than simply attempting to convince them 
to avoid it. This suggestion was made due to the high traditional preference of consanguinity 
amongst these societies as previously explained. Such genetic counselling would include carrier 
testing for at-risk couples prior to their marriage. Also, a prenatal test would be suggested to 
detect any abnormality or severe disorders of the fetus during the first trimester of the pregnancy 
such as thalassaemia disorder. This test can be typically dome by chorionic villus sampling in the 
first trimester for severe disorders (Darr and Modell 1988) 
1.6 Autozygosity mapping 
1.6.1 Background about the technique  
 The homozygous locus which is inherited from both parents is called autozygous, and the 
method of identifying this locus is known as autozygosity mapping (Mueller and Bishop, 1993).  
The technique is found to be very effective in searching for homozygous regions by descent in 
consanguineous families affected by autosomal recessive disorders (Figure 1.5). The advances in 
genetic mapping techniques (in particular genotyping SNP assays) have greatly helped in 
implementing the homozygosity mapping technique for analysing autosomal recessive disorders 
in consanguineous families (Lander and Botstein, 1987). Though the parental consanguinity is 
considered as the main cause of the homozygosity, however, several other mechanisms might be 
involved such as linkage disequilibrium (LD) in a population which could result in a 
homozygous chromosomal segment. This is not autozygous however and is more likely be 
shorter. Heterozygous deletion of one chromosome is another cause of apparent homozygosity 
but it would be in very much shorter segments. Furthermore, homozygosity mapping  has been 
applied  on more complex disorders (i.e. schizophrenia), so the success of the strategy can be 
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seen to have been extended not  only for examining  monogenic but also for the identification of 
rare genomic variants in complex traits (Broman and Weber, 1999). 
Moreover, longer homozygous regions can also be caused by long deletions or chromosomal 
abnormalities such as uniparental disomy, when both copies of a chromosome or part of it are 
received from only one parent with no copies from the other parent. The efficiency of 
autozygosity mapping was confirmed in many studies which focused on investigating different 
disorders that follow in an autosomal recessive manner in consanguineous families. Over the last 
two decades, many autosomal recessively disorders (including lethal ones) have been studied 
with great success by utilizing this method of mapping to provide the genetic basis that could 
lead to identifying the disease-causing developmental genes in these disorders (Aligianis et al., 
2005, Morgan et al., 2006b). For instance, the technique successfully mapped the candidate 
genetic region that causes alkaptonuria disorder (Pollak et al., 1993). Therefore, the autozygosity 
mapping technique has proved itself to be a very useful approach and a powerful strategy to 
locate the disease-causing genes in these closed families. However, this method can’t be helpful 
in terms of finding the definite mutation which ultimately has to be achieved by direct gene 
sequencing. 
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	Figure	1.5	The	principle	of	autozygosity	mapping	
a specific mutation of a disease gene (indicated by the black line) can be passed on from a common 
ancestor (CA) to offspring and thus the product of a consanguineous marriage, can result in affected 
offspring (redrawn from thesis by Chirag Patel, 2012) 
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1.6.2 Advantages / disadvantages of autozygosity mapping  
As introduced above, the use of autozygosity mapping and positional candidate gene analysis has 
shown a high efficiency in identifying the recessive genes of consanguineous families, much 
more so than in non-consanguineous families. The technique is currently regarded as an efficient 
and successful approach for localising the disease gene amongst the consanguineous families, 
even in the presence of locus heterogeneity (Petukhova et al., 2009).  
The more affected individuals from a studied consanguineous family, the more efficient the 
method will be to identify the region of interest that is linked to the disease. As many autosomal 
recessive disorders are considered very rare among the population, however, it will often be 
difficult to identify a sufficient number of patients with the same phenotype to perform 
autozygosity mapping. In the case of a small family size, for example, (i.e. a family with two 
affected individuals) collaborative projects between several centres would be an alternative 
solution to obtain more information about the disease genotype. A limitation for the effect of this 
option in studying some disorders is when there is a ‘private mutation’ that could only be present 
in a number of families which would then be difficult to find it in other families even with the 
same phenotype.  
Furthermore, some autosomal recessive diseases in consanguineous families can be caused by 
compound heterozygous mutations, so in this case the disease locus might not be within a 
homozygous region at all, and would not be covered by the autozygosity mapping as the 
technique focuses only on the homozygous regions.  Moreover, some rare diseases are also 
extremely heterogeneous with more than one genetic locus for the disease, so it is also important 
to identify any previously mapped disease loci in such instances. Linkage studies performed in 
one large consanguineous family with multiple affected individuals would certainly be more 
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powerful than using several different families with one or two affected individuals. Once linkage 
is established in such a large family, other smaller consanguineous families could then be used to 
investigate the linkage at the same candidate region. Such approaches might help to overcome 
the problem of locus heterogeneity. 
1.7 DNA sequencing 
DNA sequencing is referred as the determination of the precise order of nucleotides [Adenine 
(A), Guanine (G), Cytosine (C), and Thymine (T)] within the DNA molecule/genome. The 
development of Sanger sequencing has enabled many advances in biology and medicine and 
improved understanding of the genetic basis of a large number of inherited diseases. The 
automation of this process also greatly facilitated the completion of the human genome project 
(Levy et al., 2007). The human genome project was officially started in 1990 and was completed 
in 2003 with the mapping of nearly 3 billion base pairs at a final cost of approximately $2.7 
billion. The Sanger method (First-Generation Sequencing) was the standard method for DNA 
sequencing since it was originally developed in the 1970s, until the advent of high throughput 
machines or next generation techniques at the beginning of the last decade. Next generation 
sequencing greatly reduced the time and the cost of sequencing provided the ability to sequence 
the entire human genome in a few days with highly reduced costs. These can be considered the 
two major methods for DNA sequencing.   
1.7.1 Sanger Sequencing method 
1.7.1a Main principle of the technique 
the discovery of double helix structure of DNA was firstly discovered in 1953 by the British 
scientists Watson and Crick (Watson and Crick, 1953). For their great discovery, they both won 
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the 1962 Nobel Prize in Medicine. Sanger sequencing was developed by Fredrick Sanger in 1977 
(Sanger et al., 1977) who began a new era in molecular biology and it is still used widely today. 
Until this, the accepted method of sequencing DNA was described by Maxam and Gilbert who 
first developed the chemical cleavage of DNA for sequencing. After the publication of  the 
Sanger method however,  Maxam–Gilbert sequencing became increasingly unfavorable due to 
the method’s complexity, its extensive use hazardous chemicals, and the implicit difficulties with 
scale-up  (Tipu and Shabbir, 2015b). The Sanger technique was based on a chain termination 
method by using dideoxy nucleotides (ddNTPs) in the presence of a specific primer, DNA 
polymerase and deoxy nucleoside triphosphates (dNTPs). The ddNTPs lack the hydroxyl group 
which is required to form a phosphodiester bond between nucleotides causing DNA polymerase 
to terminate DNA elongation which results in fragmented sequences of DNA with different 
sizes. The resulting fragments are then separated according to size using gel electrophoresis 
(Bayes et al., 2012). The used ddNTPs are normally radioactively or fluorescently labeled to 
enable detection in gel electrophoresis. The reaction is divided into four separate sequencing 
reactions, each reaction includes the standard deoxynucleotides (dATP, dGTP, dCTP and dTTP). 
Though this represented a remarkable achievement in developing DNA sequencing the main 
limitation of this chain-termination method was the non-specific primer binding to the target 
sequence which affects the accuracy of reading the DNA. Therefore, a new method called Dye-
terminator sequencing has been developed more recently. This depends on the labelling of the 
chain terminator ddNTPs, and sequencing can be done in a single rather than four as used in the 
labelled-primer method (Tucker et al., 2009)  
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1.7.1b The automation of the technique 
An automated sequencing of Sanger method was further developed by Prober and colleagues. It 
depends on fluorescent labelling to detect DNA fragments based on the use of fluorescent chain 
terminators. The method was based on four ddNTPs, each one is attached to a distinct succinyl 
fluorescein. The DNA fragments are resolved on polyacrylamide gel electrophoresis (PAGE) and 
then detected by a fluorescent system. Subsequent progress in the technique has resulted in 
identifying developing colour coding of terminating ddNTPs, allowing running the four ddNTPs 
in one tube reaction instead of four. Since then, many commercial companies have introduced 
different automated DNA sequencers. The use of PAGE still has had some limitations such as in 
the preparation of gels, the use of toxic chemicals, problems of gel loading, thickness and 
electrophoresis (Prober et al., 1987). In the early 1980s, the Capillary electrophoresis method 
was successfully developed using high purity fused silica capillaries which hold a sieving 
medium that allows DNA fragments to be separated based on their molecular size. A laser 
detector near the end of capillaries enable the detection of fluorescent signals emitted by 
incorporated labelled ddNTPs which is considered another important step towards the 
automation of Sanger sequencing. A further acceleration in the automated sequencing 
instruments was achieved by developing Capillary Array Electrophoresis (CAE) method which 
is based on the use of laser detector to scan 96 samples one by one across all 96. It only uses 1% 
of the amount of DNA in each sample to be scanned, however, while the remaining 99% is lost 
without detection. This limitation was covered by developing a new system that could detect 
signals from all capillaries simultaneously by the introduction of a sheath flow cuvette. DNA 
sequencing fragments were run as discrete streams from each capillary within the sheath fluid. A 
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laser beam focused into the cuvette skims beneath the capillary tips thus scanning all 96 
capillaries simultaneously (Tipu and Shabbir, 2015a)  
1.7.2 Next generation sequencing (NGS)                                                                                  
Since the discovery of DNA structure in 1953, a lot of rapid advancement in genomic 
technologies have been made, including the recent NGS techniques to understand the complexity 
and diversity of human genome in health and disease. One major advancement was the 
completion of Human Genome Project in 2003. Though this was a huge achievement in the 
genetic and genomic field, it revealed the need to accelerate the effort to develop more advanced 
sequencing technologies instead of relying on the limited throughput of Sanger-dye sequencing 
method. This would thus provide better understanding for the human genome by sequencing 
more genomes and running bigger databases. Therefore, a great competition was created that 
could help reducing the high costs of sequencing. In 2005, Life Sciences 454 launched the 
release of NGS platforms by introducing the 454 genome sequencer (Margulies et al., 2005). 
This saw a huge advancement in genomic sequencing which brought about a very competitive 
environment between companies (Goodwin et al., 2016). This competition also resulted in a 
sharp decrease in the cost of commercial sequencing kits which had a very positive impact on 
medical research and the associated economic cost in which whole exome sequencing (the 
coding part of the whole genome) for example might cost currently less than $1000 while the 
whole genome sequencing costs nearly $1500. This race in share marketing in genome 
sequencing resulted in a trend in the price falling significantly faster than in Moore’s law (Figure 
1.6). Moore’s law describes the concept that the power of computer technology doubles every 
two years. This law can also be applied to the progression in the power cand efficiency of NGS. 
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In fact, the abilities and efficiency of NGS has even overtaken Moor’s law in recent years, 
demonstrating how quickly this field is advancing. 
 
Figure	1.6	Diagram	shows	the	decrease	of	the	cost	of	genome	sequencing	
in comparison to Moore’s law (taken from National Human Genome Research website)	
 
In the UK, a massive genome project was launched in 2012 aiming to sequence 100,000 
genomes from a total of 75,000 individuals including 25,000 cancer patients (50,000 genomes; 
two genomes per patient) and three genomes for 17,000 rare diseases patients (with one genome 
for the patient and two genomes from healthy relatives. As such, around 17,000 rare disease 
patients and 33,000 healthy relatives will be studied. The 100K genomes project is planned to be 
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completed by 2017 with the main project goals to be of benefit for NHS patients and to build up 
a clinical and research genomic database which could greatly help in the genetic diseases and the 
gene discoveries (Genomics England) or (Peplow, 2016). 
1.7.2.1 Whole Exome sequencing (WES) 
1.7.2.1a Background about WES 
	
The Exome represents the coding part of the whole genome and is also known as targeted 
exome capture. For most genetic disorders, there are numbers of candidate genes that might 
be linked to the disease and thus the process of investigating every gene and sequencing it 
individually can be expected to be time consuming and expensive.  Exome sequencing as 
such is a revolutionary advance and a powerful strategy in understanding the genetic basis of 
Mendelian disorders by identifying the rare causative variants underlying rare mendelian 
phenotypes and perhaps complex traits as well. Since it was introduced, it has become a 
standard tool for many genomic researchers (Figure 1.7). It captures the highly interpretable 
coding region which represents 1% (about 38 Mb) of the whole human genome, so it is 
significantly less expensive than WGS and is faster to analyse as well. In addition, the 
majority (85%) of the reported genetic changes have been located in the exome (Wang et al., 
2013). Though, non-coding variations cannot be detected, these are less likely to be 
pathogenic. WES has also been applied to cancer and complex disorders studies. The exome 
thus represents a highly-enriched region of the genome in which to search for variants with 
large effect sizes enabling deeper sequencing, which thus permits base calling with higher 
confidence levels. Furthermore, exome sequencing is more cost-effective compared to the 
WGS, as a much smaller region is sequenced, which in turn also means that the overall 
redundancy of information is greatly reduced and will overall be faster to analyse and easier 
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to manage. These features make exome a favourable option over WGS for studying 
mendelian inherited diseases (Chilamakuri et al., 2014). 
	
Figure	1.7	the	published	papers	in	medical	research	which	applied	exome	sequencing	in	the	
period	(2009-2012)	
	
1.7.2.1b Main Principles of Exome Sequencing 
In principle, the general concept of next generation sequencing including WES is very similar to 
the Sanger sequencing method in which DNA polymerase catalyses the incorporation of 
fluorescently labelled deoxynucleotides (dNTPs) during the extension of a new DNA strand. In 
each cycle, at the point of incorporation, the nucleotides are detected by a process called 
fluorophore excitation. The main difference is that NGS can run millions of extension reactions 
in a massively parallel way rather than sequencing for a single DNA fragment as happens in the 
case of Sanger sequencing (Illumina 2015). Practically, exome sequencing includes three basic 
steps: sample preparation, raw data processing, and data interpretation (figure 1.8). Currently, the 
most commonly used method in this respect is a hybridisation-based capture approach (Rykalina 
47	
	
et al 2014) and the most widely used commercial enrichment kits using this approach include 
Agilent, NimbleGen and Illumina; and despite the slight differences between each kit, the main 
principle is almost the same.  	
1.7.2.1b.i	Library	preparation	and	sequencing		
 Initially, genomic DNA is randomly fragmented into various lengths, followed by adapter 
ligation at both ends of the target sequence. However, these two steps can be combined into a 
single step (tagmentation) which is found to create a high efficient library preparation process. 
Normally a volume of 50ng/µl  of genomic DNA should be enough to perform this step because 
significantly less DNA is lost at the fragmentation step. A massive collection of these adapter-
ligated fragments can then finally construct the genomic library. The library is then loaded in a 
specific cell where fragments are captured by specific oligonucleotides. Each fragment can then 
be amplified by PCR and hybridised to biotinylated RNA baits, which is designed to target the 
coding portion of the genome. Using streptavidin coated magnetic beads, biotinylated RNA baits 
are captured and pulled down while the other unhybridized and intronic regions are washed 
away. As a result, the library only contains the exomic regions. This captured coding DNA is 
amplified to produce sequence ready enriched targets (Figure 1.9) (Rykalina et al., 2014).  
Illumina uses sequencing by synthesis (SBS) technology for generating the exome data. During 
each single sequencing cycle, a fluorescently labelled dNTP is added to DNA template strand to 
produce nucleotide label which ultimately terminates polymerization. Following each dNTPs 
incorporation, a fluorescent image is produced to detect the nucleotide base and then cleaved to 
be followed by a further incorporation of the next base because all the four reversible terminator-
bound dNTPs (A,C,T,G) are present. This makes natural competition by which the bias is 
minimized and results eventually in highly accurate sequencing reads. A huge quantity of raw 
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data is produced which is technically received in a complex format, that in turn needs to be 
highly processed before final analysis and interpretation 
	
Figure	1.8	The	Exome	Sequencing	Workflow	
the diagram summarises the processes of library preparation, exome capture, target enrichment and 
sequencing; (the image as displayed at http://www.genomics.agilent.com). 
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	1.7.2.1b.ii	Raw	Data	Processing	and	interpretation	
For large-scale data, several key stages need to be done for computationally intensive data 
processing. Most exome sequencing providers are supporting FASTQ format, a text-based 
format containing the biological sequence. Before aligning the sequence to the reference 
genome, the quality FASTQ files are checked using a FASTQC tool utilizing a Phred quality 
score, a common algorithm used to assess the accuracy of the sequence, which is used as a 
standard quality scoring tool for most commercial sequencing technologies. In addition, further 
information such as GC content, read length distribution and the amount of sequence duplication 
can be provided by FASTQC (Bao et al., 2014). The next step is the alignment against the 
reference genome to identify any sequence variations such as single nucleotide polymorphism 
(SNP), insertions and deletions (indel) etc.  Many computing tools are used for this purpose to 
map short reads to the reference genome. A common example is Novoalign that is used by most 
next-generation sequencing (NGS) platforms, which was used in this study. Once they are 
aligned, SAMtools is used for converting SAMfiles (nearly 20-30Gb) into a compressed binary 
BAM file format (nearly 4-10Gb). At this stage, the aligned sequences are then checked against 
any duplicates and a realignment is performed for indels that may have resulted in sequencing 
slippage. The next step is variant calling and annotation using ANNOVAR, an efficient software 
that is incorporated to significant genomic databases such as dbSNP, 1000genomes, ClinVar, 
COSMIC and PolyPhen. Figure 1.9 shows the summary of the general raw data processing step. 
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Figure	1.9	Summary	of	the	Main	Stages	Involved	in	the	Process	of	Whole	Exome	Sequencing	
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1.7.2.1c	Major	platforms	for	WES	
Currently, there are three main exome capture kit providers: Agilent, NimbleGen and Illumina . 
The sample preparation methods are highly similar across these different technologies. As 
explained, Exome capture involves the capture of protein coding regions by hybridization of 
genomic DNA to biotinylated oligonucleotide probes (baits). The biotinylated DNA or RNA 
baits are complementary to targeted exons, which are hybridized to genomic fragment libraries. 
Magnetic streptavidin beads are used to selectively pull-down and enrich baits with bound 
targeted regions. The major differences between the technologies correspond to the choice of 
their respective target regions, bait lengths, bait density, molecules used for capture, and genome 
fragmentation method (Table 1.3).		
Table	1.2	Comparison	between	the	main	platforms	that	used	for	exome	sequencing	technology	
 NimblGen Agilent Illumina 
TruSeq 
Illumina 
Nextera 
Probe type DNA RNA/DNA DNA DNA 
Probe size (bp) 55-105 114-126 95 95 
Target Size (Mb) 64 50 62 62 
Number of target exons 368,146 185,636 201071 201071 
Reads remain after 
filtering (%) 
66 71 54 40 
Quality of coverage Very high Good good for 
UTR & 
miRNAs 
good for 
UTR & 
miRNAs 
Species Human, mouse & 
 3 plant species 
Human, mouse & 
 3 plant species 
Human Human 
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1.7.2.1d the strategy of exome sequencing for Mendelian inherited disorders 
Finding rare disease-causing alleles among such a huge number of exome variants is a major 
challenge when using exome sequencing to identify the novel disease genes in both Mendelian 
and complex disorders. Exome sequencing typically detects more than 20,000 single nucleotide 
variants; however, the vast majority (~95%) of these variants are non-pathogenic polymorphisms 
which are already present in the human public databases. Several factors are included in 
selecting the effective strategy for identifying the disease-causing rare variants against the exome 
background. These include: the expected pattern of inheritance according to the family pedigree 
or population structure; whether a phenotype is supposed to be caused by inherited or de novo 
variation; and the degree of locus heterogeneity for the trait. Therefore, the possible novelty for 
any suspected rare variants is assessed by filtering against the polymorphism database such as 
dbSNP and 1000 Genomes Project as well as in-house control databases. This step is expected to 
eliminate candidate variants down to nearly 2% of the total exome variants for each individual. 
Further filtering is used to reduce the candidate genes to keep only the high-priority candidates 
(if not only one) by identifying and selecting those genes circulating in the disease pathway and 
exclude the others.  
This allows for the sequencing of only a modest number of affected individuals, and then applies 
discrete filtering to the data to reduce the number of candidate genes to a minimum number of 
high-priority candidates (if not to a single one). This strategy has been effectively applied for 
rare Mendelian disorders (Bamshad et al., 2011). Some limitations are involved in applying this 
method, however. First, a small number of pathogenic alleles might be contained within dbSNP 
which are filtered out by this method. Second, the increase in the number of sequenced exomes 
and genomes could affect minor allele frequency (MAF) and therefore truly pathogenic variants 
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that might segregate in the general population at low but appreciable frequencies might be 
mistakenly eliminated.	 
1.7.2.2 Targeted Exome Sequencing  
As the NGS technology is rapidly advancing and because whole-genome and exome sequencing 
techniques are still expensive, targeted exome and gene panel capture have been recently 
developed to assess gene identification and genetic diagnosis. The gene multiple panels can be 
divided into two main categories i) panels which are designed to cover the associated genes for 
specific disorders and ii) those that are for wider categories of phenotypes or disorders ranging 
from nearly 10 genes up to hundreds or even thousands of genes (Zemojtel et al., 2014)   
Generally, these targeted panels are characterized by high accuracy and deep coverage. 
Furthermore, this option is more cost effective compared to the broader approaches. In addition, 
the data size resulting from these targeted panels is smaller than the more comprehensive 
approaches such as the whole exome or whole genome sequencing; therefore, the data analysis 
will be much easier and faster as well. Illumina have developed different panels that target 
specific regions of the genome in any given sample. These focused panels are designed to cover 
a select set of genes or gene regions that have been associated with a specific phenotype or even 
number of phenotypes. A well-known example of these panels is the ‘Trusight One’ panel which 
contains more than 4,800 genes involved in the clinical phenotypes associated with inherited 
human disorders. This panel is characterized by covering the most commonly ordered molecular 
assays and it was applied in my project to investigate patients diagnosed with multiple pterygium 
syndrome or foetal akinesia (more details in Chapter 6)   
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 Hence, by selecting this option, the focus has been shifted from the whole exome to enriched 
regions of the exome/genome that is relevant to human genetic diseases. This interpretable 
region can thus be referred to as the disease-associated genome (DAG). These multiple genes 
can be run across many samples in parallel rather than running multiple separate assays in order 
to both save time and reduce the associated cost.  This panel was successfully used in many 
recent studies that have investigated the Mendelian disorders and it has shown a high diagnostic 
rate. For instance, in a recent Japanese study, they applied the Trusight One panel to examine 17 
families with specific known diagnoses for different mendelian diseases such as Sotos syndrome, 
and Joubert syndrome to test the efficiency of this panel (Okazaki et al., 2016).  
The main disadvantage of this targeted exome approach is that; it can only detect the mutations 
in genes previously implicated in the studied disease, thus no novel genes can be detected out of 
those involved genes. Therefore, if a mutation responsible for the examined disease is positioned 
in a novel gene, this approach cannot successfully expedite genetic diagnosis. In this case, whole 
exome/genome sequencing would be the better option since it is designed to include all the 
coding genes (either the previously implicated ones or even the novel ones). In the case of 
disease caused by chromosomal mutations such as structural rearrangement or large copy 
number variations the best approach to be applied is still the whole genome sequencing because 
neither whole exome nor the targeted exome would be able to detect these variants (Gorokhova 
et al., 2015).  
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In my project we applied the targeted clinical Trusight One panel to investigate 53 patients who 
were affected with foetal akinesia because of the high diagnostic rate of this panel as well as the 
reduced cost compared to the whole exome option as the number of patients in the study was 
large.   
1.7.2.3 Sequencing depth and breadth of coverage 
Genomic technologies are developed continuously with the focus on providing a highly qualified 
sequencing at a lower cost per base so that the high cost of great depth sequencing can be 
reduced as well. This reduction of the cost per run allows for increasing the number of sequenced 
exomes/genomes which ultimately increases the statistical power of disease-gene identification. 
The coverage represents the average number of times for each nucleotide base to be sequenced, 
while the breadth of coverage is related to the percentage of sequencing a targeted region of 
interest (Sims et al. 2014). Good coverage is important to eliminate any sequencing errors or 
false positive that could occur during the sequencing process, therefore, the more the read is 
sequenced the least error can happen, which leads to more accurate and reliable data. Many 
studies have focused on investigating the maximum number of variants that can be identified at a 
low coverage rate to enable researchers to access a highly accurate and efficient degree of 
sequencing data at the lowest cost. For example, a study published in 2008 identified that 
sequencing a human genome using short read methodology at a read depth of 15X, resulted in 
detecting all the homozygous single nucleotide variants while the same number of heterozygous 
SNVs were detected at a read depth of 33X (Bentley et al., 2008). Recently, it was reported that 
the read depth of 35X was sufficient to achieve highly covered reads and this has become the 
standard for many sequencing projects (Sims et al., 2014).  
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Although the cost of NGS has rapidly decreased WGS remains a costly option for analysing an 
individual sample. This disadvantage has made exome sequencing a preferable option for many 
researchers besides the other advantages already mentioned (such as the short time expended on 
analysis and less storage requirements). Analysing some data from the 1,000 genomes project 
showed that the use of WGS with the depth coverage of 20X   across 95% of the consensus 
coding sequence (CCDS) exons required 200Gb of raw input sequencing (YRI and CEU 
samples) whereas similar percentage of targeted CCDS (~90% of the Agilent capture region and 
~85% of the NimbleGen capture region) with similar depth required less than 20Gb of raw input 
from WES. Therefore, exome sequencing achieves at least the same efficiency as whole genome 
sequencing with 10-20 folds less raw sequence data (Parla et al., 2011). Solution based hybrid 
capture enrichment is the most preferred option by many genetic researchers. On the other hand, 
exome sequencing has few disadvantages that need to be addressed such as uniformity of 
coverage, target specificity and consistency.  
1.8 Summary of genetic testing types and their applications in genetic diagnosis 
 NGS technology has made different types of tests available for the genetic diagnosis including 
single-gene tests, gene panel tests, exome sequencing and genome sequencing. Selecting the 
appropriate test is a big challenge to giving a successful genetic diagnosis. In fact, a review study 
published in 2015 has critically discussed the approach of selecting the best genetic test for the 
examined individual. According to the study, single-gene testing is mostly chosen in the case of 
a minimal locus heterogeneity with a clear clinical diagnosis based on distinctive clinical 
features. Also, an existing association between the diagnosed disease and a disease-causing gene 
needs to be already established.  Gene panel testing is more cost-effective than a single-gene 
approach and it should be the suitable test for heterogeneous disorders with otherwise unclear 
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clinical diagnoses such as disorders with overlapping phenotypes or disorders which share 
specific manifestations but in which the overall phenotypes are different. Such disorders are 
generally associated with multiple genes.  
Exome Sequencing (ES) and Genome Sequencing (GS) normally selected for the disorders with 
extreme heterogeneity and de novo mutations are the major mutation. Also, it is a good option in 
the case of a diagnosis which is very difficult to make or when there are at least two possible 
phenotypes for one patient. In addition, if there is no key phenotypic feature is present at the time 
of requesting the testing so the real underlying cause of the disease will be very difficult to 
identify. Examples of these disorders are Autism and Kabuki syndrome. ES was specifically 
selected in my project for studying foetal akinesia because of the high heterogeneity of the 
disorder plus because it has many overlapping phenotypes. It has an advantage over the gene 
panel in that it is less biased regarding which set of genes to test as the latter assumes that the 
abnormal clinical features are restricted to be associated within the included genes in the panel 
itself. Factors such as technical limitations involved in NGS technology, the risk of false positive 
especially for insertion or deletion and the weak coverage for a particular area make both ES or 
GS are not completely independent methods. Because of this for diagnosis, aCGH and Sanger 
sequencing are currently required as a complement method to cover the shortcomings of NGS in 
order to detect the full spectrum of mutations and to validate those findings which are identified 
by NGS approaches. In this way the differences and difficulties associated with the used 
technology, test interpretation, clinical significance, and ethical problems, need to be well 
considered by the clinician who selects the gene test because they ultimately affect the correct 
order and the diagnosis for the patient (Xue et al., 2015) 
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1.9 Exome sequencing for the studied disorders in this project 
As discussed earlier, exome sequencing is well justified as an efficient approach to identify the 
genetic causes underlying rare Mendelian disorders. This proven efficiency is supported by a 
range of genetic evidences. First, many genetic mapping studies that have been applied on the 
coding part of the genome have successfully identified the candidate genetic region which 
contain the disease-causing variants of monogenic disorders. Second, the majority of pathogenic 
variants associated with Mendelian disorders are located within the exome and therefore they are 
more likely to disrupt the protein function. Third, it has been found that rare coding variants 
could have pathogenic effect in most rare disorders while the noncoding variants are less likely 
to have any negative effect even when located in a conservative area. Accordingly, it has become 
a standard tool to discover genes in these disorders.  
A good example for these Mendelian disorders is the autosomal recessive disorders. Typically, 
the affected individual is most likely a homozygous carrier or in some cases is compound 
heterozygous with the pathogenic mutation while the parents are heterozygous carriers. Large 
families with multiple affected siblings compared with healthy individuals are the preferred 
subjects to carry out the genetic investigation for Mendelian disorders as they provide the 
opportunity to perform segregation analysis. This technique showed higher efficiency when it 
has been used in consanguineous families as their offspring are at high risk of carrying 
homozygous recessive mutations from a common ancestor. In 2009, the technique was applied to 
investigate Miller syndrome (OMIM263750), an autosomal recessive disorder, successfully 
identifying the causal variants in the DHODH gene (Ng et al., 2010).  Furthermore, the technique 
was also performed to diagnose two affected siblings of a consanguineous Pakistani family 
diagnosed with congenital oligodontia, another rare autosomal recessive, utilising the SureSelect 
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Human all Exon 50 Mb kit. In the results, a homozygous stop codon was identified in both 
individuals in the SMOC2 gene, which encodes the SPARC related modular calcium binding 2 
protein (OMIM # 607223) (Alfawaz et al., 2013). Another example for the efficiency of exome 
sequencing was a work published by Walsh and others at 2010, who applied exome sequencing 
together with homozygosity mapping in a consanguineous Palestinian family diagnosed with 
congenital deafness. A pathogenic mutation (p.Arg127*) was identified in the GPSM2 gene and 
was then reported as a cause of the disease in this particular family (Walsh et al., 2010).  
  Many other studies that have applied this method have produced promising results for a genetic 
diagnosis which can provide helpful information to the genetic counselling and diagnosis to both 
affected and unaffected carriers. Also, these disease-causing genes or disease variants can be 
used in identifying the risk identified by genetic screening tests such as pre-conceptive and 
prenatal screening. In addition, it can provide useful information which can be used in treatment 
approach. 
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1.10 Aim of the Project: 
In my project, I wanted to investigate the role of DNA sequencing in two different examples of 
rare Autosomal recessive disorders; congenital oligodontia, and lethal multiple pterygium 
syndrome (LMPS)/Fetal Akinesia. The primary shared aim of my project was to identify disease-
causing mutations of these particular phenotypes in view of the frequency of recessive diseases 
in the Saudi Population Furthermore I was particularly interested in consanguineous families 
likely to have recessively inherited cases of these phenotypes. Initially, I used autozygosity 
mapping and Sanger sequencing of single genes and then I proceeded to utilise NGS technique in 
particularly the targeted enriched methods (whole exome sequencing and clinical exome 
sequencing) to demonstrate the efficiency of this method in identifying the causing genes which 
underlie rare mendelian disorders.  
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2.1 Acquisition of patients  
2.1.1 Patients  
In this project, I studied two different congenital disorders. In the first year I investigated 
Oligodontia patients while during the second and third year, I studied patients diagnosed with 
Fetal Akinesia/ Lethal Multiple Pterygium syndrome. Molecular genetic investigations were 
undertaken in each disorder in which the underlying genetic causes were unknown yet. In both 
examined disorders, number of patients from different families most of them were 
consanguineous have been involved and they were from a variety of ethnic backgrounds 
(Pakistani, North Indian, Bangladeshi and mixed European descent, Arabs and Turkish).  Also 
few non consanguineous families were also involved. When available, DNA from unaffected 
family members was studied to check the segregation of interesting genetic variants. All of the 
families recruited in this project were initially patients seen that had been counseled by the West 
Midlands Clinical Genetics department. All of the clinical information available about these 
patients was therefore collected and provided by the West Midlands clinical genetics department 
2.1.1.i Congenital Oligodontia  
Patients affected with congenital oligodontia from Six different consanguineous families were 
selected for studying the genetic basis of this disorder.	Peripheral blood was obtained from the 
probands, their parents and, where possible, affected and unaffected siblings. Aa clinical dentist 
who examined the panoramic radiographs in the Birmingham Dental Hospital confirmed the 
diagnoses of congenital oligodontia in these patients. Dental examinations revealed congenital 
oligodontia i.e. six or more missing teeth were reported in one affected individual from each 
family.. Medical diagnosis was confirmed by a clinical dentist via clinical examinations and 
panoramic radiographs in Birmingham Dental Hospital.  
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2.1.1.ii Fetal Akinesia 
A total of 66 families that displayed clinical features of either multiple pterygium syndrome or 
fetal akinesia were selected for molecular genetic studies due to the phenotypic overlap between 
the two disorders. There was at least one individual in each of 36 families that displayed features 
consistent with non-syndromic FADS/LMPS without a known underlying genetic cause, while 
the remaining 30 families were diagnosed with the milder EVMPS phenotype. Consanguinity 
was recorded in nearly 50% of tested LMPS families and in only 20% of EVMPS families. 
Clinical information including family history, ethnicity and pregnancy history was collected 
from the families by clinical collaborators (Dr Julie Vogt, Professor Eamonn Maher and others). 
Relevant phenotypic information such as brain scans and muscle biopsy results were recorded 
where available. 
2.1.2 Consent and ethics approval 
Both studies have been approved by the South Birmingham Research Ethics Committee and the 
clinical research followed the principles outlined by the Declaration of Helsinki in 1964. An 
informed consent was obtained by the committee for all the families in all the studies in this 
project  
2.1.3 DNA extractions  
All genomic DNAs used in this project were kindly extracted by West Midlands Regional 
Genetics Molecular Genetics Laboratory mainly from blood samples, using Gentra System’s 
Puregene DNA Purification method according to the manufacturer’s instructions which based on 
salting-out precipitation. After cell lysis, the protein is precipitated, followed by DNA 
precipitation which is washed then with ethanol to be hydrated. Then, DNA will be ready to store 
at -80°C.  
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2.2 Materials: 
2.2.1 Chemical Reagents 
Reagents Supplier 
100bp DNA ladder Invitrogen 
1 kb DNA ladder Invitrogen 
1X TBE buffer (Tris-borate/EDTA) Geneflow 
Agarose Bioline 
BioMix RT Red Bioline 
CGRich Solution Roche 
DNAse, RNAse free water Gibco Invitrogen 
dNTPs Roche 
EDTA Fisher Scientific 
Ethanol VWR chemicals 
Ethidium Bromide Sigma 
FastStart Taq DNA polymerase Roche 
Genescan-500 LIZ size standard Applied Biosystems  
Hi-Di Formamide Applied Biosystems 
Magnesium Chloride (MgCl2) Roche 
Methanol VWR chemicals  
Micro CLEAN Web Scientific 
Primers Invitrogen 
Water, distilled (dH2O)   
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2.2 Kits 
Kit Supplier 
BigDye Terminator Cycle Sequencing Kit V3.1 Applied Biosystems 
BigDye 5X Sequencing Buffer Applied Biosystems 
Exosap IT Clean up Kit Amersham Pharmacia 
2.2.3 Other Materials 
Material Supplier 
0.1 ml combitips pipette tips Eppendorf  
1.0 ml combitips pipette tips Eppendorf  
5.0 ml combitips pipette tips Eppendorf  
2.3 Molecular Genetic Investigations: 
2.3.1 Sanger Sequencing of Candidate genes: 
2.3.1a Standard Polymerase Chain Reaction (PCR) 
Target DNA was  amplified by using PCR in order to give thousands of identical copies 
(replicates) of a specific DNA sequence. Each standard PCR reaction contained a sample of 
patient DNA to be amplified, in addition to two oligonucleotide primers that were designed to be 
complementary to a specific genomic region of interest, Taq polymerase was also included in the 
reaction. Taq polymerase is isolated from Thermus aquaticus, a bacterium that usually lives in 
hot springs; its main function in the PCR reaction is to initiate replication, by building each 
single strand of the target DNA cut by the primers into a new, double-stranded DNA (Chien et 
al., 1976). In addition to these reaction components, deoxyribonucleic triphosphates (dNTPs) are 
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also included, as they are the building blocks needed to create a new DNA strand. The dNTPs 
added consist of an equal mixture of four dinucleotide triphosphates: dATP, dTTP, dCTP and 
dGTP. Finally, 10X PCR Buffer II and MgCl2 solution are also included in the raction in order 
to provide a suitable environment and versatility for the reaction.  
 
Based on thermal cycling, each PCR consists of three main steps: denaturation, annealing and 
finally extension (elongation). Denaturation is achieved by heating the reaction to high 
temperatures (~95C’), which causes the disruption of the hydrogen bonds that hold the double 
strands of DNA together, resulting in the formation of single stranded DNA. The reaction 
temperature is then lowered to 50–65 °C, to allow the primers to anneal to the single-stranded 
DNA template. The ideal annealing temperature differs for each primer depending on a number 
of factors, including the CG% content of the primer sequence and the primer length. Taq 
polymerase enzyme normally works at temperatures of around 72 °C, which allows it to 
synthesize a new DNA strand which is complementary to the DNA template strand. 
2.3.1b Primer Design: 
Initially, primers were designed to bind to genomic sequences, which were approximately 20-80 
nucleotides upstream or downstream from encoding exons. Primers were were designed to 
amplify all the coding exons of the targeted genes plus intron-exon boundaries. This was mostly 
achieved by using primer design programs such as ExonPrimer and Primer3 
(https://ihg.gsf.de/ihg/ExonPrimer.html) after obtaining the genomic sequence of the gene of 
interest from Ensemble browser (http://www.ensembl.org/index.html). The length of the primers 
designed varied between 18-26bp. The annealing temperature for each primer was calculated 
manually using the following formula: (Annealing temperature = 60.9 + 0.41 x (%GC) – 
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600/primer length). Primers were always designed so that the final product size never exceeded 
600bp in length, in order to obtain the optimum products for Sanger sequencing. Therefore, large 
exons (>600bp) were covered with at least two pairs of primers which overlapped to ensure all of 
the exon could be sequenced clearly. All primer sequences are available in the Appendix.  
2.3.1c PCR conditions: 
Standard conditions were used to amplify the DNA template in a 25µl master mix reaction. The 
conditions were as follow: 
Reagent Volume 
2X BioMix Red* 12.5 µl 
Forward primer (5.0pmol) 0.5 µl 
Reverse primer (5.0pmol) 0.5 µl 
dH2O 10.5 µl 
DNA (20ng/µl ) 1.0 µl 
 
 
The BioMix Red contains: taq polymerase, dNTPS, buffer and 1.5mM MgCl2. For primers that 
contained a high GC content, 5µl  of a solution known as ‘GC rich solution’ was added to the 
25µl reaction. This required a reduction of 5µl of water to ensure a final reaction  
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Reagent Volume 
2X BioMix Red 12.5µl 
GC rich solution 5µl 
Forward primer (5.0pmol) 0.5µl 
Reverse primer (5.0pmol) 0.5µl 
dH2O 5.5µl 
DNA (20ng/µl) 1µl 
 
After preparing and gently mixing the master mix reaction, the PCR amplification was carried 
out using a Bio-tetrad or Bio-red thremal cycler using the following standard conditions. 
Each PCR reaction performed included a negative control (in which DNA was replaced with 
dH2O) in order to ensure that no contamination detected in the reaction (Table 2.1a).  
2.3.1d Touchdown PCR amplification  
For some primer sets, a touchdown PCR had to performed in order to increase the specificity of 
the region amplified. The reaction steps were identical to the above standard PCR protocol, 
except the annealing temperature was initially set to a higher temperature (65°C). This initial 
high temperature increases the specificity of the primers.  The temperature is then gradually 
reduced by 1°C each cycle for 10 cycles until it reaches the calculated optimum annealing 
temperature, or even a few degrees below, to maximise the yield of primer binding for producing 
a large amount of specifically amplified DNA (Table 2.1b). 
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Table 2.1 The designed program of standard PCR steps  
This table shows the three main stages involved in PCR amplification; denaturation, annealing and extension plus an 
initialization step before denaturation and a final extension step after elongation, but these latter two steps are not 
repeated during the cycle. A) the annealing tempreture for the standard PCR is changeable according to the primer 
CG% by using specific calculation (ranges from 50oC-64oC) and the cycle repeated 35-40 times. B) In touchdown 
PCR, the annealing step started at high temperature and then decreased by 1°C every next cycle (10 times) and 
finally amplified 55°C for the remaining 25 cycles. 
Step Temperature Time 
initial denaturation 95oC 5 min  
Denaturation 95oC, 45 sec  
Annealing Tm (50oC-64oC) 45sec            
Extension 72oC 1min   
final extension 72oC 5 min.  
 
Step 
Temperature Time 
initial denaturation 95oC 5 min  
Denaturation 95oC 45 sec     
Annealing 65oC (-1°C	every	cycle) 45sec            
Extension 72oC 1min   
 Denaturation 95oC, 45 sec  
Annealing 55oC 45sec  
Extension 72oC 1min   
final extension 72oC 5 min.  
 
	 40 cycles	
	 25 cycles	
	 10 cycles	
A)	
B)	
70	
	
2.3.1e. Gel electrophoresis: 
After PCR, the products were checked on a 1.0 % horizontal agarose gel, which separates 
fragments according to their molecular size. Visualising a single clear band at the correct size 
ensures that the DNA is successfully amplified without contamination. DNA has a negative 
charge; therefore, it should runs through the gel towards the positive anode.  
 
To prepare a 1% agarose gel, 2 gm of agarose powder is weighed and added to 200 ml TBE 
buffer (10X). The mixture is boiled in a microwave for 3 minutes and then cooled under tap 
water, followed by the addition of 2 µl of ethidium bromide dye. Ethidium bromide is an 
intercalating substance that reacts with the DNA and enables it to fluorescence under UV light, 
therefore enabling the bands to be clearly visualized. The prepared gel mixture is poured into the 
cast, with toothed combs to create wells, and it is left to cool and harden. After cooling, 4µl of 
loading dye is mixed with 6µl  of PCR product. The PCR-loading dye mix is added into the wells 
of the gel. A DNA size marker (100- bp ladder) is also mixed with 2 µl from loading dye and 
added to the first well. The gel is then run at 180V for 15-20 minutes.  The electrophoresis is 
stopped before the dye runs off the end of the gel. The gel is then viewed under a UV 
transilluminator (LKB, UK). The gel can then be photographed using a gel documentation 
system (CCD camera).  
2.3.2	DNA	Purification	method	
2.3.2a Exosap method 
Prior to Sanger sequencing, PCR products that have successfully shown a band under the UV 
light (working DNA) need to be cleaned up. This is done by using ExoSAP; a method used to 
remove unwanted dNTPs and primers, while maintaining the target sequence.. The ExoSAP kit 
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contains a variety of components, including Exonuclease I, Antarctic Phosphatase and Antarctic 
Phosphatase buffer.. In the experiment, for each 4µl  of exosap, 6µl  of PCR product was added 
and mixed gently with a pipette. The microtitre plate including the ExoSap-PCR product mix is 
then run on a tetrad or biometra PCR machine using a specific cleanup program, followed by an 
incubation step at 37°C for 15 min. Subsequent inactivation of enzymes was achieved by 
incubation at 80°C for 15 min.  
2.3.2b Alternative method of clean-up (microCLEAN) 
In most of the experiments in this thesis, the Exo-SAP-IT® PCR product clean up kit was used, 
however, a different method using a reagent known as microCLEAN was also used in a large 
number of the sequencing reactions. This was because microCLEAN was much cheaper and it 
gives the same quality of sequence.  
The protocol for microCLEAN involved adding 3µl of PCR product with an equal volume of 
microCLEAN to a 96-well microtitre plate, and then incubated for few minutes at room 
temperature and centrifuged then for 40 minutes at 4000RPM. This creates a DNA pellet on the 
bottom of the well, while the supernatant contains all of the impurities. After centrifuging, the 
supernatant is removed by centrifuging the plate upside-down on tissue paper at 500RPM for 30 
seconds. The slow speed enables the supernatant to be removed while maintaining the pellet at 
the bottom of the well.  
2.3.3 Sanger Sequencing reaction 
Sequencing was performed on whole genome amplified (WGA) DNA (acquired using Qiagen 
REPLI-g kits) in each PCR plate as well as normal DNA controls. All of the fragments were 
sequenced in both orientations (forward and reverse).  Any candidate variants that were 
identified during analysis were confirmed using original stock DNA samples, in order to avoid 
72	
	
any potentially false positive results that may have occurred using WGA DNA. PCR products 
were sequenced using a standard BigDye Terminator v3.1 cycle sequencing method on an ABI 
3730 automated genetic analyzer (Applied Biosystems). The data was processed by specific 
sequencing analysis software (i.e. Bioedit and/or mutation surveyor). Sequence traces for each 
amplified DNA sample was compared to a reference sequence obtained from the ENSEMBL 
database. 
 
After the clean up step described in sections 2.3.2a and 2.3.2b, a 10µl reaction mixture is 
prepared with the following: 
 Two different master mixes are made; one for the forward primer and the other for the reverse 
one. 4µl of exosap product is added to 6µl of the forward reaction. Another 4µl of the same 
exosap product is taken and added to the reverse sequencing reaction. The reactions are put into 
a thermocycler using a PCR program with conditions specific for sequencing.  The cycling 
conditions briefly involve a denaturing step for 3 minutes at 96°C, followed by an additional 30 
cycles of 96°C for 30 seconds, 50°C for 15 seconds, and 60°C for 4 minutes. 
 
After the sequencing run is complete, precipitation of the reaction is carried out. 1µl of 
precipitation buffer (including 250mM EDTA) is added into each well. Following this, 30µl of 
100% Ethanol is added to each reaction. The plate is then centrifuged for 20 minutes at 2000rpm, 
which precipitates the DNA. The plate is then centrifuged upside-down in tissue paper at 
400rpm/1minute, in order to remove the ethanol. Following this, 200µl  of 70% ethanol is added 
into each reaction, and again centrifuged for 20 minutes at 4000rpm. The plate is then 
centrifuged once more, upside-down in tissue paper at 400rpm/1minute. Finally, 10µl  of HiDi is 
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added to each well followed by a denaturing step is performed by heating the plate at 95°C for 5 
minutes. Following denaturation, the plate is cooled by placing it on ice, which prevents the 
products from reannealing. At this point, the plate can be loaded on the ABI 3730 automated 
sequencer. The sequencing results can then be viewed using BioEdit software and Mutation 
Surveyor to analyse the sequence.   
2.3.4. Mutational screening 
Sequence traces from each of the DNA samples analysed was compared to a reference sequence 
obtained from the ENSEMBL database, using the Mutation Surveyor software. Any variants of 
interest identified were then confirmed in original stock DNA of the patient.  
2.3.5 Linkage Studies 
In this project, two main approaches were used to conduct linkage studies: SNP microarrays and 
microsatellite marker analysis 
 2.3.5a SNP genotyping: 
Autozygosity mapping strategies were utilized to establish disease loci and identify novel 
disease-causing genes in consanguineous families. To perform this, a genome-wide linkage scan 
was undertaken in affected children and their unaffected siblings before this PhD started. This 
was carried out using the Affymetrix 250K Human SNP Array 5.0 (Affymetrix UK Ltd) in order 
to identify the shared common homozygous regions and/or genomic copy number variants. This 
SNP array technology allows the simultaneous genotyping of >500,000 single nucleotide 
polymorphisms (SNPs) for each individual’s DNA. This SNP genotyping study was kindly 
performed by Louise Tee (a research laboratory technician) according to the manufacturer‘s 
instructions (Affymetrix GeneChip Human Mapping SNP 5.0 Assay Manual).   
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In brief, 250ng of genomic DNA was digested with Sty 1 and Nsp 1 restriction enzyme. The Sty 
and Nsp adaptor molecules were then ligated to the product using a DNA ligase enzyme. For 
each DNA sample, PCR reactions were set up (Sty-3 reactions and Nsp-4 reactions) using a 
universal PCR primer. Once amplified, PCR products were run on a 1.5% agarose gel according 
to molecular size (sizes ranged from 200-1100bp). After that, products were pooled and cleaned 
up using magnetic beads (Ampure). The amplified DNA was then fragmented into product sizes 
of 200bp or less in length. Following this step, the amplified products were labelled and 
underwent a hybridization	step	to the SNP 5.0 chip (Affymetrix) for 16-18 hours. The DNA 
arrays were then washed and stained using a fluidics station (Affymetrix) A fluidics station. An 
Affymetrix GeneChip Scanner 3000 with GCOS 1.3 software was used for scanning the chips. 
Data analysis was then performed utilizing GCOS v3.0.2 software to derive SNP genotypes, 
marker order and linear chromosomal location.  
 
2.3.5b Microsatellite Markers:  
2.3.5b.i the technique significance and primer design 
Linkage analysis using microsatellite markers was, applied during the course of this study with 
varying conditions. The specific details can be found in the appropriate chapters (Chapters 3 and 
4). Microsatellites are di, tri or tetra tandem nucleotide repeats of DNA ranging from few a 
repeats up to 50 times or more with known location in the genome. A set of polymorphic 
microsatellite markers with high heterozygosity rates were selected using NCBI, UCSC and 
Ensembl genome browsers which located within a candidate homozygous region. Linkage 
analysis was carried out using fluorescently labelled microsatellite markers and an ABI PRISM 
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3730 DNA Sequencer. For each marker, a mixture of two oligonucleotide primers (Forward and 
Reverse) had been used in order to amplify the target sequence. The primers are fluorescently 
labeled (5` HEX, TET or FAM) with different dyes; FAM (blue), HEX (yellow) and TET 
(green). 
2.3.5b.ii PCR amplification 
Stock primers for the markers were diluted with dH2O according to the manufacturer’s 
instruction, and working dilutions were prepared at a 1:5 ratio; 20µl of the stock primer added to 
80µl of dH2O. A reaction master mix of 10µl was prepared as follow:    
Reagent Volume 
Forward primers (2.0pmol) 0.2µl 
Reverse primers (2.0pmol) 0.2µl  
Biomix  5µl 
dH2O 2.6µl 
DNA (20ng/µl) 2.0µl 
 
PCR reactions were then carried out according to standard protocols. After running the PCRs on 
a tetrad, 120µl  of water was added to each sample and mixed. A volume of 5µl  of 
LIZ®  standard was added to a 1ml tube of HiDi (if only running a half plate, only 2.5µl  
LIZ®  size standard was added to 500µl  HiDi), and mixed well. Aliquot 10µl  of HiDi/size 
standard mix into each well in a fresh PCR plate. To the HiDi mix, 1µl  of the diluted PCR 
product was added and mixed well. The plate was then denatured on a PCR block for 5mins at 
95ºC and then placed onto ice to snap cool. The plate is then ready to run on the ABI PRISM 
3730 DNA Analyzer (Applied Biosystems) under Genescan program (not a sequencing run). 
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Finally, the data obtained from the microsatellite products can be processed by GENEMAPPER 
v3.0 software.  
2.3.6 Next Generation Sequencing (NGS) 
2.3.6a Whole exome sequencing 
All whole exome sequencing data was provided by Prof. Eamonn Maher. Agilent SureSelect 
Whole Exome hybrid capture was used to enrich these fragments for exomic sequences. For each 
individual exome, nearly 25,000-30,000 variants were detected and have been analyzed and 
screened using a specific strategy outlined in figure 2.1. In addition to whole exome sequencing, 
the Trusight One panel kit (covering 4813 genes in total) was also used to acquire data  in this 
project. The reference genome hg18 was used for alignment. The SamTools software was 
applied to sort through SNPs and small insertion deletions, and sequence variations. These were 
screened against the 1000 Genomes Project and dbSNP131 to filter out common variants that are 
already present at high frequencies in dbSNP131 or the 1000 Genomes project database in order 
to highlight the novel variants which could be pathogenic (Ostergaard et al., 2011). Any variant 
found on public databases with a frequency of > 1% in the population was considered common, 
and therefore likely to be benign, and was therefore excluded. Also, synonymous variants that 
result in the same amino acid product were excluded. The variations considered to be most 
interesting were nonsense variants, frameshift and splice site variants because they are expected 
to cause the most damage in the protein function and/or structure. For splicing variants, any 
variant that was > 2bp from the exon-intron junction was excluded, as these were less likely to 
affect splicing. This resulted in a list of candidate variants ranging from (10-50 variations). Any 
novel variants that were present in candidate genes of interest, known to play a role in relevant 
disease pathways were selected for further analysis. However, we expect one causing gene per 
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each family. As a supportive tool in selecting candidate genes, prioritization software such as 
Toppgene software was used, which highlights the most relevant candidate genes according to a 
number of pathological considerations for each studied disorder.   
2.3.6b Assessment of Mutation Pathogenicity 
A few important steps have been followed to interpret the probability of pathogenicity of the 
detected variants. (a) The prediction of possible effects of any amino acid substitution was 
achieved with specific bioinformatics tools such as PolyPhen-2 and SIFTS tools (e.g. putative 
missense mutations). These tools mainly predict the consequences of amino acid substitutions 
based on the levels of  conservation of the region affected and whether the change has any 
occurred within an important functional domain. (b) Identifying if candidate genes are involved 
in relevant disease-associated pathways. For instance, for a disease that affects bone, a good 
starting point is to  assess the genes involved in bone development and/or  additional members of 
developmental pathways. . This can be achieved using genomic browsers (Ensembl, 
GeneDistiller, Gene cards, OMIM, PubMed, UCSC and others). (c) Information available from 
the literature (Mouse Genome Informatics, PubMed), in order to identify if the candidate genes 
have been associated with similar phenotypes in any animal models.  (d) Checking segregation in 
parents and other family members using Sanger sequencing. (e) Further frequency information in 
population-based controls for the candidate variants was sought from NHLBI Exome variant 
server [http://evs.gs.washington.edu/EVS/] if available. 
2.3.6c Definitions of the predictive bioinformatics tools 
2.3.6c.i Polymorphism Phenotyping v2 (PolyPhen-2)  
Polyphen-2 (http://genetics.bwh.harvard.edu/pph2) is a computational analysis tool for 
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Predicting the pathogenesis of missense variants on proteins. It uses a combination of two 
parameters; protein structure and protein function, to calculate the score of pathogenicity.Scores 
range from 0 (predicted to be benign) to 1 (predicted to be probably damaging). 
2.3.6c.ii Sorting intolerant from tolerant (SIFT):  
SIFT is a further bioinformatical tool (http://sift.jcvi.org/) used as a supportive tool beside 
Polyphen to predicts whether an amino acid substitution affects protein function or not, based on 
the degree of conservation of amino acid residues in sequence alignments derived from closely 
related sequences, collected through PSI-BLAST. It detes whether the variation tolerant or not. 
2.3.3c.iii. Splice site prediction by Neural Network 
This is an in silico method (http://www.fruitfly.org) to predict the effect of a splice-site mutation 
on gene splicing and proteins. 
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Figure	2.1	the	filtering	exome	strategy	to	identify	the	disease	causing	variants 
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Table	2.2	Web	based	resources.  
	
	
 
 
 
	
	
	
	
	
	
	
1000	Genomes	 http://www.1000genomes.org	
dbSNP	 http://www.ncbi.nlm.nih.gov./projects/SNP	
Ensembl	 http://www.ensembl.org	
NCBI	 http://www.ncbi.nlm.nih.gov	
NCBI	Nucleotide	 http://www.ncbi.nlm.nih.gov/sites/nuccore	
UCSC	 http://www.genome.ucsc.edu	
Gene	cards	 http://www.genecards.org	
PubMed	 http://www.ncbi.nlm.nih.gov./pubmed	
OMIM	 http://www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM	
ExonPrimer	 http://ihg2.helmholtz-muenchen.de/ihg/ExonPrimer.html	
BLAST	 http://blast.ncbi.nlm.nih.gov/Blast.cgi	
Primer3	 http://frodo.wi.mit.edu/primer3	
DECIPHER	 https://decipher.sanger.ac.uk/application	
Mouse	Genome	Informatics	 http://www.informatics.jax.org	
Gene	Distiller	2	 http://www.genedistiller.org	
PolyPhen-2	 http://genetics.bwh.harvard.edu/pph2	
SIFT	 http://sift.jcvi.org	
Splice	Site	Prediction	by	
Neural	Network	
http://www.fruitfly.org/seq_tools/splice.html	
Homozygosity	Mapper	 http://www.homozygositymapper.org	
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Chapter	Three:	Molecular	Genetic	Investigation	of	inherited	Oligodontia		
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3.1 Disease background 
The development of human teeth (known as odontogenesis) is a long, well-organized and 
complex process. It is regulated by specific interactions between epithelial cells and neural crest-
derived mesenchymal tissues (THESLEFF and HURMERINTA, 1981). The process starts 
prenatally after the first month of embryogenesis and continues through childhood before being 
completed at some stage in adolescence (18-25 years) when the third molars appear (Aiello et al., 
1991, Nieminen, 2009). Congenital teeth agenesis is the most common form of abnormal teeth 
development in humans and may be caused by inherited disorders or environmental factors such 
as local trauma, chemical radiation and chemotherapy (De Coster et al., 2009). Genetic disorders 
of ontogenesis are important to study and are the subject of this Results Chapter.  
Based on previous reports, the prevalence of dental agenesis is about 6.76% across different 
populations (Bozga et al., 2014) 
3.1.1 Tooth developmental anomalies 
Though much advancement has been made in understanding the developmental basis of tooth 
formation, the mechanism of dental development and the entire molecular basis of inherited 
tooth agenesis is still relatively unclear (Cobourne, 2007). Genetic tooth abnormalities normally 
studied using three main ways. First, the clinical features of the anomaly such as number of 
teeth, shape, or both. For instance, the presence of extra teeth (hyperdontia), the lack or reduction 
in the teeth (tooth agenesis), however, the shape of teeth can be abnormal such as taurodontism 
abnormality (enlargement of the body and pulp of the tooth). Second, determining whether the 
teeth abnormality is part of another condition (syndromic) or isolated trait (non-syndromic). 
Third, knowing the mode of inheritance by studying the family pedigree e.g. autosomal dominant 
or recessive manner (Klein et al., 2013).  Clinically, tooth agenesis is classified into three main 
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numeric teeth developmental abnormalities: i) the loss of one up to six teeth (excluding the third 
molar) is called as hypodontia (2-10% frequency). ii) Oligodontia is diagnosed when the patient 
has an agenesis of more than six teeth (excluding the third molar) (0.1-1% frequency) iii) 
Anodontia, where the patient has complete absence of teeth and this type is extremely rare (Goya 
et al., 2008). 
According to many researchers, it was noted that the prevalence of hypodontia is relatively 
higher amongst females compared to males , with a ratio of 3:2 and no reasons have been 
provided yet (Brook, 1975).  
	
Figure	3.1	The	main	three	phenotypes	of	tooth	agenesis	
with their prevalence and the form of inheritance for each different phenotype 
	
	
Hypodontia can either occur as a part of another genetic disease, or as an isolated non-syndromic 
feature, and this form is usually familial syndrome which occurs in a family fashion, but it can 
affect sporadic cases sometimes.). Online Mendelian Inheritance in Man (OMIM) lists more than 
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60 different syndromic disorders that included hypodontia phenotype as part of other clinical 
phenotypes spectrum of anomalies. A lot of candidate genes have been identified in both types 
(Cobourne, 2007, Klein et al., 2013).  
3.1.2 The known causing genes of tooth Agenesis  
The early stages of dental development are mostly similar in human and mouse, and the basic 
findings that discovered by investigating mice models have been confirmed in humans as well. 
Therefore, studying the dental mice genetics were very helpful approach to understand the 
mechanism of dental development and the genes involved in the process using several knockouts 
techniques. By knocking out PAX9, MSX1, PITX2, GLI2/3, P63 genes, Tooth development was 
stopped at the bud stage, while when Dlx1/2 gene was knocked out, only maxillary molars were 
lost (Matalova et al., 2008, Fleischmannova et al., 2008). More than 200 genes have been 
implicated in tooth development (Jernvall and Thesleff, 2000) but the most common genes that 
have been associated with dental agenesis are PAX9, MSX1, WNT10A and AXIN2 genes. 
Mutations in these particular genes were mostly associated with the familial non-syndromic 
hypodontia while other genes such as EDA, EDARADD, NEMO, P63 and others were reported in 
sybdromic hypodontia (Shimizu and Maeda, 2009). Most disorders of odontogenesis are 
inherited in an autosomal dominant manner (Larmour et al., 2005) though autosomal recessive 
and  X-linked patterns can exist in some cases (Cobourne, 2007)  In this project, I primarily 
focused on potential autosomal recessive causes within consanguineous families and screened 
specific associated genes and carried out a linkage analysis to determine potential evidence for 
novel causing genes. 
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Table	3.1	Summary	of	the	detected	mutations	and	the	included	patients	identified	with	non-syndromic	
Oligodontia	
according to a systematic literature review published in 2013 (Ruf et al., 2013a). 
 
Identified gene Mutations (no) Patients (n) References (no) 
PAX9 33 93 24 
MSX1 12 33 9 
EDA 10 51 9 
AXIN2 6 17 3 
Put/PAX9 1 7 1 
EDARADD 1 1 1 
NEMO 1 1 1 
KRT17 1 1 1 
 
3.1.3 LTBP3 as a possible cause of Oligodontia  
Recently, LTBP3, a gene encodes latent transforming growth factor-b (TGF-b) binding protein-
3, was reported in a consanguineous Pakistani family with multiple affected members who 
presented with congenital oligodontia associated with short stature. According to the published 
paper, both phenotypes appear to be inherited in an autosomal-recessive manner. After the 
exclusion of MSX1 and PAX9 by direct sequencing, SNP genotyping technique was applied to 
analyse DNA samples for four affected individuals and one unaffected individual using 
Affymetrix GeneChip Mapping 500K array that allows genotyping ~260,000 SNPs. In the 
results, a large homozygous area of between 41.381 and 69.263 Mb (UCSC May 2004) located 
on chromosome 11 was identified and shared between the four affected individuals but not the 
unaffected individual. Further analysis using Microsatellite markers for all eight available family 
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members (mother and seven of her offspring) across this region was carried out which confirmed 
the shared autozygous region. Then many genes from the identified region were analysed by 
direct sequencing of genomic DNA based on their known function and expression profiles e.g. 
FGF4, FGF19, FIBP, LRP5, EHD1, FOSL1, and LTBP3. Amongst all the analysed genes, they 
only identified a stop codon variant c.2322C > G, resulting in the nonsense mutation Y744X 
within LTBP3 gene. However, screening 240 unrelated unaffected individuals of Pakistani origin 
did not show this mutation (Noor et al., 2009) 
3.2 Method 
3.2.1 Patients and Clinical assessment 
 
Fourteen cases of non-syndromic oligodontia belonging to six different families were ascertained 
in order to study the genetic basis, which might cause the disease for each case.  All the 
ascertained families were consanguineous and were all of Pakistani origin (Table 3.2). All of the 
affected subjects were diagnosed with severe hyopdontia/oligodontia at the time of diagnosis. All 
patients and their parents gave written informed consent and the study was approved by the 
Research Ethics Committees.  
A Specialist Registrar in Orthodontics (Dr Joyti Vasudev) undertook full dental and medical 
assessment. A family pedigree was recorded for each case and indicated potential autosomal 
recessively inherited manner. Blood samples were taken from affected individuals and the 
available parents, and then sent to the West Midlands Regional Genetics Laboratory in 
Birmingham Women’s Hospital for DNA extraction. 
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Table	3.2	Oligodontia	families,	which	are	included	in	our	study	to	study	their	genetic	background	
Family Phenotype Origin Consanguinity Affected 
individuals 
available 
Parents  
OD001 NS Oligodontia Pakistani Yes 1 mother 
OD002 NS Oligodontia Pakistani Yes 2 Father 
OD003 NS Oligodontia Pakistani Yes 1 Mother 
OD004 NS Oligodontia Pakistani Yes 1  Both 
OD005 NS Oligodontia Pakistani Yes 1  Both 
OD006 NS Oligodontia Pakistani Yes 8 Both 
 
Apart from the pedigree of the large family (OD006) in figure 5.1, Dr Joyti Vasudev wrote all 
the clinical information and the pedigree for each single studied family are available to access in 
a previous dissertation in 2014.   
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Figure	3.2	the	pedigree	of	members	of	family	OD006	
with 8 affected individuals and showing autosomal recessive manner. 
	
	
3.2.2 Genetic Analysis:  
3.2.2a Sequencing the candidate genes: 
Three known candidate genes (MSX1, PAX9 and WNT10A) were highly suggested for 
sequencing based on the literature review that prove their significant role in dental development 
and their association with non-syndromic oligodontia/severe hypodontia (see Table 3.3).  PAX9 
and MSX1 gene products play a significant role in the development process of teeth and several 
studies have reported mutations in these genes in patients suffering with hyopdontia/oligodontia  
(Peters and Balling, 1999) while mutations in the WNT10A gene were also reported to be 
strongly associated with isolated hyopdontia in a further study (van den Boogaard et al., 2012).  
Though inherited mutations in MSX1, PAX9 and WNT10A had previously been associated with 
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autosomal dominant forms of oligodontia, biallelic mutations in WNT10A were subsequently 
described with more severe disease, and it was decided to investigate whether these three genes 
might also be implicated in the presumed autosomal recessively inherited forms that present in 
these consanguineous cases. 
Table	3.3	mapping	and	transcript	details	of	the	screened	genes	(obtained	from	Ensembl)	
Gene  Transcript ID Location Number of exons 
PAX9 NM_006194 Chr14q13.3  4 coding exons 
MSX1 NM_002448 Chr4p16.2  2 coding exons 
WNT10A NM_025216 Chr2q35 4 coding exons 	
I carried out sequence analysis of all the affected probands and their available unaffected parents 
to identify causative mutations in these genes. The primers were designed to cover all the coding 
exons and the exon-intron boundaries for each examined gene (Appendix). For all the genomic 
DNAs, amplification was done using PCR and the amplified products were sequenced after that 
using 3730 DNA Analyzer using direct Sanger methodology. Sequencing results were compared 
to the normal reference gene obtained from human Ensembl database or UCSC genome 
browsers.	
3.2.2b Linkage analysis using microsatellites: 
When no mutations could be identified in the selected genes (MSX1, PAX9 and WNT10A), I 
undertook linkage analysis to determine if it was possible to exclude linkage to candidate genes 
for autosomal recessive forms of oligodontia in OD001-OD005. Thus a set of microsatellite 
markers close to LTBP3 were genotyped in all available family members.  
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Table	3.4	Microsatellite	markers	used	for	linkage	analysis	of	the	homozygous	regions	in	
oligodontia	families	
Gene/Marker Location Start End Min 
size 
Max size color 
D11S4191 Chr 11 59756135 59756421 111 135 FAM 
D11S4076 Chr 11 61119711 61119869 151 163 FAM 
D11S1883 Chr 11 63130300 63130583 224 266 FAM 
D11S913 Chr 11 65692737 65693068 220 227 FAM 
D11S1889 Chr 11 67069719 67069901 183 207 FAM 
D11S4136 Chr 11 69324867 69325101 160 202 FAM 
 
By applying this technique, I aimed to check for any shared homozygosity close to LTBP3. If 
homozygosity was detected, then I would proceed to direct sequencing of LTBP3. For each 
microsatellite marker, a mixture of two oligonucleotide primers (Forward and Reverse) has been 
used in order to amplify the target sequence. The primers were fluorescently labeled (5` HEX, 
TET or FAM) and the PCR then was carried out according to standard protocols. Microsatellite 
products were loaded on ABI PRISM 3730 DNA Analyzer (Applied Biosystems) under the 
genescan protocol and data was processed by GENEMAPPER v3.0 software.  
 3.3 Results  
3.3.1 Mutation analysis: 
Apart from detecting benign polymorphisms (P>0.01) which unlikely to cause the disorder, the 
screen mutation analysis for the three candidate genes (MSX1, PAX9 or WNT10A) did not reveal 
any candidate mutation or plausible candidate rare variants within the coding regions or at exon–
intron junctions in any of the selected genes in the 14 affected individuals or the available 
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parents. According to these negative findings, we could not confirm any association of these 
genes in causing oligodontia in these families. The next stage of the project was to undertake 
linkage analysis to see if linkage to the candidate gene LTBP3 could be excluded. 
 3.3.2 Linkage Analysis:  
Mapping analysis was conducted for all the oligodontic patients and their parents in order to 
determine possible linkage of LTBP3 gene. The analysis was performed with six microsatellite 
markers which are located across the genomic region on chromosome 11 (59,756,135 to 
69,325,101) which containing LTBP3 gene (from 65,306,030 to 65325699 according to UCSC 
databases.  As shown below (figure 3.3&3.4), there was no evidence of homozygosity by descent 
linked to the targeted gene. Amongst all the patients of the five families, only one proband of 
family 5 has showed homozygosity close to the LTBP3 gene - an ~ 8Mb homozygous region was 
defined by five microsatellites markers (D11S4191, D11S4076 D11S1883, D11S913 and 
D11S1889). Though linkage to LTBP3 could not be excluded in this family it was decided not to 
proceed with direct sequencing of LTBP3 as linkage was excluded in the other four families and 
there remained the possibility that the region of homozygosity in family 5 was a chance finding.  
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Figure	3.3	Microsatellite	analysis	for	Oligodontia	examined	families	
The	affected	children	are	shaded	in	black.	LTBP3	gene	is	located	in	the	region	between	65306030	and	
65325699.Microsatellite	markers	are	organised	according	to	their	physical	distance	(MB).	Haplotypes	for	these	
markers	for	the	5	examined	families	are	shown	and	the	homozygous	region	is	shaded	in	yellow.	Only	this	family	
(OD005)	showed	homozygosity	in	5	out	of	6	microsatellites	which	is	the	same	region	the	gene	is	contained.	
Family OD001 Family OD002
marker
D11S4191 104 106 108 121 104 106
D11S4076 156 156 154 156 148 154
D11S1883 252 252 248 248 252 252
D11S913 218 220 218 218 218 222
D11S1889 195 195 223 199
D11S3136 358 181 177 181 358 181
marker
D11S4191 106 120 106 121
D11S4076 148 156 148 156
D11S1883 252 252 248 252
D11S913 218 220 218 218
D11S1889 195 197 195 197
D11S3136 177 177 177 177
Family OD003 Family OD004
marker
D11S4191 112 123 117 125 106 117
D11S4076 147 156 147 147 147 150
D11S1883 248 252 252 252 252 252
D11S913 222 222 218 222 218 218
D11S1889 195 197 191 195
D11S3136 184 186 177 184
marker
D11S4191 112 118 117 125
D11S4076 148 156 147 147
D11S1883 248 252 252 252
D11S913 218 222 218 222
D11S1889 197 197 180 191
D11S3136 177 184
Family OD005
marker
D11S4191 104 104 104 112
D11S4076 156 158 148 156
D11S1883 252 261 252 252
D11S913 220 220 218 220
D11S1889 194 196 192 196
D11S3136 179 186
marker
D11S4191 104 104
D11S4076 156 156
D11S1883 252 252
D11S913 220 220
D11S1889 196 196
D11S3136 179 192
N/A
N/A
93	
	
	
 
             	
Figure	3.4	Drawings	illustrating	the	autozygous	linked	region	for	Oligodontia	family	OD05	
The green coloured regions represent homozygosity; the blue arrow indicate the location of LTBP3 gene. 
Only subject 4 (Father of F2) and subject 11 (Proband of F5) have shown homozygosity. 
 
3.4.3 Whole Exome Sequencing (WES)  
For genetically heterogeneous conditions such as oligodontia analyses by Sanger sequencing of 
all the candidate genes individually is a time consuming and labour intensive process. I found no 
evidence of coding sequencing mutations PAX9, MSX1 and WNT10A by direct sequencing and 
excluded LTBP3 in most cases by microsatellite genotyping due to the absence of homozygous 
region except in one family (OD005).  
Though direct sequencing does not detect exon deletions/duplications it was decided that further 
analysis of LTBP3, PAX9, MSX1 and WNT10A would be less effective than a NGS techniques 
such as whole exome sequencing (WES). Hence ~3 µg of genomic DNA from one of the 
proband OD001 
Mother OD001
proband OD002 
Father OD002
Mother OD002
proband OD003 
Mother OD003
proband OD004 
Father OD004
Mother OD004
proband OD005 
Father OD005
Mother OD005
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affected individuals of the OD006 family was sent to Kings College London (KCL) for singleton 
exome sequencing (March 2013).  
3.3.3a Whole exome sequencing (WES) at King’s College London (KCL) 
The scientists at KCL (directed by Professor Michael Simpson) used the 50Mb Agilent 
SureSelect enrichment kits to target the coding regions of most human genes and then proceeded 
to NGS. After several months, the raw exome data was available and annotated at KCL using 
genomic databases, software prediction tools and their own in-house database. The annotation of 
the variants with respect to genes and transcripts was done by the help of the Annovar tool. They 
annotated the variants as SNP if it found on the dbSNP or a novel variant if it is not already 
published and not presents in the in-house genomic database. All the variants that caused no 
change in the amino acids of the corresponding protein were reported as synonymous and filtered 
out in the next stage. Also they annotated whether the variant is heterozygous or homozygous. A 
total of 25,034 variants were identified. All this exome data was provided to me in an excel 
spreadsheet (Microsoft) 
3.3.3b Analysing WES data to identify the causing gene 
From the large amount of WES data provided by KCL, I created an Excel file to analyze all the 
variants using specific filtering strategy. The first step was excluding all the common variants 
with a high minor allele frequency (MAF). It was reported in many studies that MAF ≥5% is 
considered common, while MAF between 1-5% is defined as low frequency variants, and when 
the variant has a MAF <1% will be considered as a rare variant  (Genome of the Netherlands, 
2014). Also I filtered out all the synonymous variants and (SNPs) that already present in 
dbSNP131 or the 1000 Genomes project database with a frequency of > 1% in the population 
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and this highly reduced the number of variants from total 25,034  variants to, only 2,856 variants 
and I only focused one the nonsynonymous pathogenic variants that might have a significant 
effect on the protein level such as stop codon, frameshift and splicing site changes. Looking into 
the rare and functional variants reduced the number from 2856 to 337 variants in 74 genes 
(Appendix). As the affected proband was from a consanguineous family and because the family 
pedigree was consistent with autosomal recessive inheritance, I concentrated on the homozygous 
variants and this reduced the number of variants down to 21. At this stage, the remaining variants 
were assessed to determine if they were within a gene that had previously been associated with 
oligodontia, hypodontia or dental abnormalities (e.g. PAX9 , MSX1 , EDA , AXIN2 , Put/PAX9 1 , 
EDARADD , NEMO , KRT17 (Ruf et al., 2013b) WNT10A, IRF6,TGFA, , FGR1 ,EDAR 
(Galluccio et al., 2012, Cobourne and Sharpe, 2013), HYD2 (Ahmad et al., 1998) STHAG5 and 
LTBP3). However none of the variants were within these genes.   
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Figure	3.5	Filtering	criteria	Applied	to	identify	the	causing	gene	from	Exome	Sequencing	Data	for	
Oligodontic	patient 
3.4 Discussion:  
3.4.1 The selection of candidate genes for sequencing 
Based on large studies investigating the genetics of tooth agenesis, oligodontia is genetically 
heterogeneous condition. The marked phenotypic variability in this condition could result from 
defect in various genes implicated in the disease and also the distribution of mutations within 
individual genes (i.e. locus and/or allelic heterogeneity). (Mostowska et al., 2003, Hu et al., 
1998, Nieminen, 2009).  
The PAX9 gene is a member of the paired box (PAX) family. It contains a paired box domain, an 
octapeptide and encodes for transcription factors during embryogenesis and fetal development. It 
maps to chromosome 14q12 and consists of 4 exons. It is believed that PAX9 plays a significant 
role during the process of odontogenesis by taking part in the signalling interactions between 
25,034		variants
Filter 1:	removing	common	variants	and	SNPs
2856	variants	
Filter	2:	removing	synonymous	and	non-splicing	
variants	
337	variants	
Filter	3:	removing	heterozygous	
variants	
21	variants	
filter	4:	looking	into	the	
previous	related	genes
0	variant
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epithelial cells and mesenchymal cell layers. A published study discovered mutations within 
PAX9 gene which might cause isolated hypodontia (Das et al., 2003). Also, two more studies 
identified frameshift and missense  mutations amongst patients affected with tooth agenesis and 
particularly congenital oligodontia (Lammi et al., 2003, Frazier-Bowers et al., 2002). Depending 
on the clinical phenotypes of the tooth agenesis cases for prioritizing the candidate genes to be 
sequenced is not a precise method.  
MSX1 gene is a member of homeobox family that plays essential role in the progression of many 
organs during the fetal development, however, the gene located on chromosome 4p16.1 and 
encodes for MSX1 protein which is expressed in odontogenesis and taking part in inhibiting the 
transcription and, same as PAX9, it participates in regulating the signalling pathways of 
odontogenesis  (Vieira et al., 2004, Ogawa et al., 2005) . MSX1 has been screened in 92 affected 
unrelated individuals belonging to 82 nuclear families and resulted in identifying  a novel 
missense mutation which suggested a significant role in causing tooth agenesis acording to the 
researchers (Lidral and Reising, 2002). Nieminen et al. (2003) analysed MSX1 gene in 8 Finnish 
patients diagnosed with Wolf-Hirschhorn syndrome. Five of the patients were presenting 
oligodontia. Using FISH technique, the 5 patients with oligodontia showed a heterozygous 
deletion in MSX1 gene, while the other three individuals were completely normal. Therefore, 
they suggested in the conclusion that haploinsufficiency for MSX1 could be as a mechanism that 
play a significant role in causing a selective tooth agenesis with other factors (Nieminen et al., 
2003).  Mice homozygous for a deletion in MSX1 gene demonstrate craniofacial and limb 
anomalies plus decreased development of teeth agenesis whereas the heterozygous PAX9 mice 
seems completely normal (Peters et al., 1998, Peters and Balling, 1999). Mice with homozygous 
deleted Msx1exhibit craniofacial abnormalities in cleft palate, and impairment in mandibular and 
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maxillary alveolar development and also demonstrate malformations in tooth development 
process in particular during moving from bud to cap stage. In contrast, heterozygous mice for 
Msx1 deletion show normal status (Satokata and Maas, 1994).  
WNT10A is a member of the WNT gene family. It is mapped to chromosome 2q35and composed 
of 4 exons. The expression of its protein is mainly expressed in the cell lines of promyelocytic 
leukaemia and Burkitt's lymphomas. So athough this gene is not as known as PAX9 and MSX1 
but mutations were detected in 19 individuals (56%) of total 34 unrelated patients of non 
syndromic tooth agenesis, 8 mutations of them were homozygous, 4 compound heterozygous, 
and 7 of them were heterozygous for the mutations. Also, it is found that 3% of patients have 
mutations within MSX1 and 9% of the patients were found they have mutations in PAX9 gene 
(van den Boogaard et al., 2012). Furthermore, in a cohort of 94 families affected with isolated 
oligodontia, Arzoo and others identified several mutations in 26 affected individuals (27.7%), 17 
of them were homozygous while 11 were heterozygous (Arzoo et al., 2014).  
3.4.2 Linkage analysis for LTBP3 and the use of WES 
Using direct sequencing, no mutations were identified within the coding and splicing regions of 
PAX9, MSX1 or WNT10A genes except the normal polymorphisms that are unlikely to cause 
disease. Thus, the cause of oligodontia in the examined families appeared most likely to be in 
other genes that were either already associated with oligodontia or in novel oligodontia genes 
(though the possibility of intronic or regulatory mutations in PAX9, MSX1 or WNT10A could not 
be excluded). After the negative outcome of sequencing the three selected genes, it was decided 
to evaluate the use of microsatellite genotyping. I applied this strategy for the LTBP3 gene which 
had previously been reported as a cause of the disease in a consanguineous Pakistani family that 
diagnosed with congenital oligodontia and short stature (Noor et al., 2009). However, in most 
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cases (assuming the proband would be homozygous for a mutation) linkage was excluded - only 
proband of family OD005 has showed homozygosity that could be linked to LTBP3 in a ~8Mb 
region which harbours five microsatellites (D11S4191, D11S4076 D11S1883, D11S913 and 
D11S1889). In all the other families, no extended region of homozygosity was noted in the 
genotyped microsatellites, so in conclusion the LTBP3 gene is unlikely to be a common cause in 
this cohort of cases. Following the negative results from analysis of PAX9, MSX1 and WNT10A 
and the exclusion of LTBP3 (in most cases), it was decided to screen the whole exome by 
applying NGS techniques due to the high efficiency of WES in finding the rare disease causing 
mutations in a variety of Mendelian diseases.  
In view of the high cost of WES (in 2013) it was planned to sequence a single individual from 
the largest family and then screen other family members for candidate mutations and then 
proceed to testing the relevant gene in affected cases from the other five families. After analysing 
large number of variants provided by exome sequencing using specific filtering criteria to 
attempt to identify the disease causing variant, none of the known candidate genes appeared to 
contain a pathogenic mutation. Nevertheless, the cohort of consanguineous families with a 
common ethnic origin might contain a novel genetic cause for oligodontia or severe hypodontia 
and we would suggest pursuing WES in additional cases from the cohort.    
This study is not the first to fail to find positive linkage between mutations in the known genes 
tested genes and tooth agenesis. In five unrelated families affected with hypodontia, Nieminen 
and colleagues did not identify any association of the MSX1 gene. Also, no mutations were 
discovered in MSX1 in other 20 patients with hypodontia (Scarel et al., 2000). Moreover, in a 
Vietnamese study involving 20 families, PAX9 and MSX1 were analyzed but no mutations were 
identified (Frazier-Bowers et al., 2003).  In addition, the small size of the patient cohort could be 
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considered a major limitation of this study. Therefore, a larger number of affected families is 
needed in order to be more confident about the contribution of the genes tested to tooth agenesis 
disorders in individuals of Pakistani descent.  
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Chapter	Four*:	Genetic	Investigations	of	FADS/LMPS	by	Autozygosity	Mapping	&	Gene	sequencing	
	
	
	
	
	
	
	
	
	
	
	
	
*This	chapter	contains	work	published	as	part	of	the	paper	by	Mckie	et	al	(2014)	(with	AlSaedi	as	joint	first	author)	
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4.1 Introduction:  
4.1.1 Clinical background of MPS disorders 
Multiple pterygium syndrome (MPS) is a congenital multiple anomaly disorder. MPS is 
characterised by the presence of skin webs (pterygium) and the lack of muscle movement 
(akinesia) associated with muscle weakness and joint contractures (arthrogryposis) (Gillin and 
Pryse-Davis, 1976, Morgan et al., 2006a). Other clinical features of MPS include scoliosis, cystic 
hygroma, micrognathia, cleft palate, and lung abnormalities (McKie et al., 2014b). MPS is a 
heterogeneous rare disorder, inherited mainly in an autosomal recessive manner, though 
autosomal dominant and X-linked inherited cases can also occur (McKeown and Harris, 1988, 
Tolmie et al., 1987). According to the severity, MPS is divided into two main clinical forms; the 
milder Escobar multiple pterygium syndrome (EVMPS) [OMIM 26500] and the lethal multiple 
pterygium syndrome (LMPS) [OMIM 253290]. LMPS is a severe disorder and is fatal either 
during pregnancy or shortly after birth whereas EVMPS patients can survive into adulthood. 
There is a clear genetic and phenotypic overlap between Fetal Akinesia Deformation 
Sequence  (FADS [MIM 208150]) and the lethal form of MPS especially with overlapping 
clinical features and certain genes may cause both disorders (Vogt et al., 2008). FADS is as the 
classical form of MPS which characterised by most of the common clinical MPS features such as 
decreased fetal movements, intrauterine growth restriction, craniofacial anomalies, joint 
contractures and pulmonary hypoplasia. FADS can be caused by environmental factors such as 
curare exposure and circulating maternal antibodies against the fetal acetylcholine receptor 
(Michalk et al., 2008) Also, the phenotype can occur as a result of genetic mutations that affect 
the normal function of the associated organs (Michalk et al., 2008) and this will be discussed 
with more details in this chapter.  
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4.1.2 Genetic causes of MPS disorders  
 Many genes have been identified as potential causes of MPS-related diseases in the literature. 
However, at the time this work was commenced, the best recognised genetic causes were related 
to defects in the components of embryonal acetylcholine receptor (AChR). Thus, AChR 
components are significant cause of recessively or dominantly inherited myasthenic syndromes 
with variable age of onset and clinical severity. AChR protein is located in the membrane of 
skeletal muscle cells and it is essential for neuromuscular signalling pathway between axon and 
muscles which is necessary for the movement in both fetus and adult. During fetal development, 
AChR consists of two α1, one β1, one δ, and one γ subunit {(CHRNA1 [MIM 100690], 
CHRNB1[MIM 100710],CHRND [MIM 100720], CHRNG [MIM 100730] respectively}.  
CHRNG gene is naturally expressed until the thirty third week of the pregnancy when it is 
replaced by the epsilon (ε) subunit, which is produced by the CHRNE gene, to form the adult 
AChR protein (figure 4.1). All these subunits are clustered in a complex process to produce the 
signal transduction. However, some other genes are involved in the AChR assembly such as 
AGRN, MUSK, DOK7 and RAPSN (Sanes and Lichtman, 2001). 
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Figure	4.1	drawing	shows	the	structure	of	AChR	and	its	genetic	pathway	
Part A) shows the structure of AChR at the postsynaptic membrane in muscle cells that consists of 5 
subunits: Two α1, one β1, one δ (2 CHRNA1, CHRNB1, CHRNG). These 4 subunit are always naturally 
present in the fetus while The fifth subunit ɛ (CHRNE) is appearing around 33 weeks of gestation in 
humans when γ subunit expression stops and convert to ɛ, thereby replacing fetal-type AChR by adult-
type AChR. Other contributing proteins in the process of AChR assembling and activation includes  agrin 
(AGRN), muscle skeletal tyrosine kinase (MUSK), however, in part B) a diagram obtained String website 
shows a network of most of the proteins contribute in the AChR pathway or they have interactions of the 
AChR componenets. 
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Mutations in the (CHRNG) have been implicated in both FADS and LMPS. Numbers of 
associated mutations have been identified in the lethal and the Escobar types of MPS. For 
instance, Hoffmann et al. (2006) identified 8 mutations in CHRNG amongst 7 families diagnosed 
with Escobar syndrome. In addition, Morgan et al. (2006) was able to find 6 homozygous 
mutations in 6 families with lethal or Escobar variants (Hoffmann et al., 2006, Morgan et al., 
2006a). In addition, genes encoding other components of the AChR complex (e.g. CHRNA1, 
CHRND, RAPSN, DOK7 and MUSK) that are predicted to cause severe dysfunction of the 
neuromuscular junction have been described in autosomal recessively inherited LMPS/FADS 
(Vogt et al., 2008, Michalk et al., 2008, Vogt et al., 2012). Furthermore, many other genes which 
involved in the neural and skeletal muscle development have been described in some 
neuromyopathies (e.g. motor neuropathies associated with central or peripheral nervous system 
disease or muscular dystrophy) that have been associated with a LMPS/FADS phenotype. Also, 
mutations in genes associated with inherited arthrogryposis  have occasionally been linked to 
EVMPS (e.g. TPM2, TNNI2,  MYH3) (Ravenscroft et al., 2011, Chong et al., 2015) which are 
summarized in Table 4.1. Nevertheless, many cases of FADS and MPS do not have a mutation in 
a known FADS/MPS gene and this is the main reason I undertook further genetic investigations 
in these conditions.  
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Table	4.1		summary	of	the	reported	genes	that	have	been	associated	with	MPS	phenotypes	in	
the	literature						(table is obtained from a review paper by Ravenscroft et al 2011).	
Gene																																									MIM																																	Mode	of	inheritance																			Disease	entry	
Genes	involved	in	the	neural	development	
SMN1																																								600354																																				AR																																														FADS	
ERBB3																																								190151																																			AR																																														LCCS2	
GLE1																																											603371																																			AR																																														LCCS1	
PIP5K1C																																					606102																																			AR																																															LCCS3	
Genes	function	on	neuromuscular	junction	
CHRNA1																																					100690																																			AR																																															FADS	
CHRND																																							100720																																			AR																																															FADS	
CHRNG																																							100730																																			AR																																															MPS/FADS	
DOK7																																											610285																																		AR																																																FADS	
RAPSN																																									601592																																		AR																																																FADS	
Genes	encoding	adult	skeletal	muscle	proteins	
ACTA1																																										102610																																	AD																																																FADS	
DMPK																																											605377																																	AD																																																FADS	
NEB																																															161650																																AR																																																	FADS		
RYR1																																													180901																																AR/AD																																										FADS	
TPM2																																												190990																																AR/AD																																										EVMPS	
 
4.2 Method 
4.2.1 Patients 
A total of 66 families with features of non-syndromic FADS/LMPS/EVMPS with unknown 
underlying genetic cause were selected for molecular genetic studies. Each involved family had 
at least one affected individual. In 36 families, the clinical phenotype was FADS/LMPS while in 
the remaining 30, the phenotype was EVMPS. Consanguinity was recorded in 48% of the 
FADS/LMPS families and 20% of the EVMPS families. The examined families were from 
various ethnic backgrounds including South Asian (Pakistani and Indian), African, white and 
mixed race (Table 4.2). My work was a part of collaborative study and whilst Dr. Arthur McKie 
(a Postdoctoral Research Associate in Prof Maher group) performed analysis of RYR1 in the 
EVMPS families, I performed RYR1 analysis in the LMPS/FADS families. In this chapter I will 
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only include the results of RYR1 analysis in the LMPS/FADS cases but in the next chapter 
(Chapter Five), I will describe “Clinical Exome” analysis for both groups of patients. 
Each family gave informed consent and the study was approved by the South Birmingham 
Research Ethics Committee and performed in accordance with the ethical standards in 
accordance with the Helsinki Declaration in 1964. DNA samples were isolated from the 
probands, the available parents and other family members by the Regional Molecular Genetics 
Centres. DNA from unaffected family members was studied to check the segregation of 
interesting genetic variants. Clinical information such as family history, ethnicity and pregnancy 
history were collected from the families by clinical collaborators (Dr Julie Vogt, Professor 
Eamonn Maher and others). Relevant phenotype information such as brain scans and muscle 
biopsy investigations were recorded where available. 	
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Table	4.2	the	available	Clinical	features	of	the	LMPS/FADS	recruited	patients	
 
Family number               Phenotype             Ethnicity            Consanguinity 
MPS001                           LMPS                       White                     Yes 
MPS002                           LMPS                       South Asian           Yes    
MPS003                           LMPS                         Middle Eastern      Yes 
MPS004                           LMPS                       South Asian           Yes 
MPS005                           LMPS                       South Asian           Yes 
MPS006                           LMPS                       South Asian           Yes 
MPS007                           LMPS                       Not available          No 
MPS008                           LMPS                       White                     No 
MPS009                           LMPS                       White                     No 
MPS010                           FADS                       Middle Eastern      Yes 
MPS011                           LMPS                       Not recorded         Yes 
MPS012                           LMPS                       North African         Yes 
MPS013                           LMPS                       White                     No 
MPS014                           LMPS                       South Asian           Yes 
MPS015                           LMPS                       White                     No 
MPS016                           LMPS                       Not available         Yes 
MPS017                           LMPS                       North African         Yes 
MPS018                           FADS                       White                     No 
MPS019                           LMPS                       White                     No 
MPS020                           LMPS                       White                     No 
MPS021                           LMPS                       South Asian           Yes 
MPS022                           FADS                       Middle Eastern      Yes 
MPS023                           LMPS                       Middle Eastern      Yes 
MPS024                           LMPS                       White                     No 
MPS025                           FADS                       Mixed race             No 
MPS026                           FADS                       White                     No 
MPS027                           LMPS                       Not available         Yes 
MPS028                           LMPS                       Not available         No 
MPS029                           FADS/LMPS            Not available          No 
MPS030                           FADS/LMPS            Not available          No         
MPS031                           LMPS                       White                     No 
MPS032                           LMPS                       White                     No 
MPS033                           LMPS                       White                     No 
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4.2.2 Molecular Genetic analysis:  
Before I commenced my PhD studies a candidate locus for LMPS/FADS was mapped to 
chromosome 19 by other members of the Maher laboratory. The details of these mapping studies 
are reported briefly below: 
4.2.2a. Autozygosity mapping 4.2.2a.i	Genomewide	Scan 
To identify candidate novel genes utilizing autozygosity mapping techniques, two FADS/MPS 
patients from a single consanguineous family (MPS001) were investigated to identify regions of 
homozygosity.  Using high-resolution commercial Affymetrix 250K SNP arrays 5.0, genome-
wide linkage scan was carried out on DNA from a stored fetal material of the two affected 
siblings and the scan excluded linkage to known FADS/LMPS genes and resulted in finding a 
homozygous region of nearly 10 Mb on chromosome 19. This SNP genotyping work was 
performed by Louise Tee. 
4.2.2a.ii	Microsatellite	marker	analysis	
From the SNP genotyping results, the defined homozygous region was selected	 for further 
analysis using fourteen polymorphic microsatellite markers from the same candidate region to 
confirm the autozygous region of the three affected fetuses and their parents (Figures 4.2 &4.3). 
Genotyping of the family with microsatellite markers within the interval on chromosome 19 
defined the candidate autozygous region as Chr19; 35108829–44484993bp. A microsatellite 
marker (D8S373) that mapped within the only other candidate autozygous region >2 Mb was 
demonstrated to be heterozygous in two affected fetuses and so excluded linkage to chromosome 
8 (data not shown).	 
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  Location on Paternal Maternal Fetus 1 Fetus 2 Fetus 3 
Marker Chr 19 Genotype Genotype genotype Genotype Genotype 
       
    
     D19S222 33417730 239-239 
 
239-242 239-242 239-242 
 D19S433 35108829 199-199 201-203 199-203 199-203 199-203 
 D19S430 36994291 127-127 127-127 127-127 127-127 127-127 
 D19S224 41219912 241-255 237-241 241-241 241-241 241-241 
 Chr19r2-15xAC41 41435658 242-242 242-244 242-242 242-242 242-242 
 D19S220 43123390 280-285 283-289 280-280 280-280 280-280 
 D19S228 43181340 203-205 203-205 205-205 205-205 205-205 
 D19S421 43562946 187-189 187-189 187-187 187-187 187-187 
Chr19R2-15Xtat 44221282 164-164 164-175 164-164 164-164 164-164 
Chr19r2-22xGT44 44659155 252-252 248-252 252-252 252-252 252-252 
	
Figure	4.2	Genetic	Mapping	of	a	consanguineous	family	(MPS001)	using	Microsatelites	
Area coloured in green showing the shared a common homozygous region of the three affected 
siblings (F1, F2 &F3) between 28,725,890 - 44,669,155 located on chromosome 19. 
	
	
	
 
111	
	
Table	4.3	List	of	Microsatellite	markers	employed	in	Mapping	MPS001	of	chromosome	19	
Marker  Genomic position  Source  
D19S222 Chr.19-28,725,890-
28,726,217 bp 
http://rgd.mcw.edu/rgdweb/report/marker/main.
html?id=1341900  
D19S433 Doesn’t map to Chr.19 
assembly 
http://rgd.mcw.edu/rgdweb/report/marker/main.
html?id=1298168  
D19S430 Chr.19-32,302,451-
32,302,741 bp 
http://rgd.mcw.edu/rgdweb/report/marker/main.
html?id=1657125  
D19S224 Chr.19-35,493,932-
35,494,196 bp 
http://rgd.mcw.edu/rgdweb/report/marker/main.
html?id=1336138  
Chr19r2-
15xAC41 
Chr.19-41,435,658-
43,123,394 
ftp://ftp.broad.mit.edu/pub/human_STS_releases/  
D19S220 cHR.19-34,8798,595-
34,879,871 BP 
http://rgd.mcw.edu/rgdweb/search/markers.html?
term=D19S220&speciesType=1  
D19S228 Chr.19-34,937,645-
34,937,798 bp 
http://rgd.mcw.edu/rgdweb/report/marker/main.
html?id=1338234  
D19S421 Chr.19-38,871,106-
38,871,460 bp 
http://rgd.mcw.edu/rgdweb/report/marker/main.
html?id=1337182  
Chr19R2-
15xTAT 
Chr.19-44,221,282-
44,669,155 
ftp://ftp.broad.mit.edu/pub/human_STS_releases/  
Chr19r2-
22xGT44 
Chr.19-44,221,282-
44,669,155 
ftp://ftp.broad.mit.edu/pub/human_STS_releases/  
 
4.2.2b Candidate gene analysis from autozygosity mapping 4.2.2b.i	Candidate	gene	selection	
When I started my PhD studies I inspected the results of the autozygosity mapping in MPS001 
and looked for likely candidate LMPS/EVMPS genes from within the chromosome 19 region of 
homozygosity that contained 345 known or predicted genes. To select the best candidate 
gene/genes for further genetic analysis, I undertook a literature research for each gene based on 
the gene function and expression to see whether it had any kind of association with the disease 
pathway. This procedure involved (a) researching on the genomic databases (OMIM, PubMed, 
UCSC, Ensemble and others) to find the putative function if available, (b) reading the relative 
published literature to look for any reported results or linked studies that indicate any role for the 
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gene relevant to MPS/FADS (c) any information on animal model experiments such as model 
organism genomic databases (MGI). According to this strategy, RYR1 gene, mapped to 
Chromosome 19: 38,433,830-38,587,420 was highlighted to be the best candidate for further 
analysis to screen any pathogenic mutations in all the studied cases. It is a very large gene (15.3 
kb coding sequence) and encodes RYR1 protein which is found mainly in the skeletal muscle 
and known as skeletal muscle calcium release channel. Mutations within RYR1 found to be 
implicated in many histological subtypes of congenital myopathies in humans and mouse 
models. Further details about the clinical associations and the pathogenicity of RYR1 can be 
found the Discussion section of this chapter. 
4.2.2b.ii	RYR1	sequencing:	
After selecting RYR1 as the best candidate gene for further analysis, I then proceeded to 
sequence the entire coding exons of the gene in all the 36 LMPS/FADS families to search for 
mutations and to establish a frequency figure of any detected mutations. PCR amplification and 
sequencing was carried out using direct Sanger method for all the genomic DNAs using specific 
primers that cover the whole RYR1 open reading Frame (ORF), including the coding exons (106 
exons) and the exon-intron boundaries. RYR1 sequencing and mutational screening was 
undertaken in all LMPS/FADS affected individuals and the segregation of any detected variants 
was checked in parents and other family members (when available) as well. 
4.2.3 Histopathological investigations:  
Our laboratory collaborators in the Department of Pathology, VU University Medical Centre, 
Amsterdam, Netherlands undertook histopathological analysis in order to assess any role of the 
RYR1 mutations. Autopsy tissues of intercostal skeletal muscle were obtained from the two 
affected fetuses of family MPS001 (12 + 6 and 14 + 0 weeks GA, respectively) and two age-
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matched controls (13 + 0 and 13 + 4 weeks GA, respectively). The tissue was taken from the 
autopsy archive of the VU University Medical Center, and was the only available tissue for both 
patients. In the experimental details provided by the team, the tissue sections were fixed by 
formalin and embedded by paraffin and the processing was consistent with the standard 
protocols (Bancroft and Gamble, 2008). A variety of stains were used including Hematoxylin & 
Eosin, Gomori trichrome and alizarin red S for calcium and each stain has different use. After 
heat-induced antigen retrieval in 0.01 M citrate buffer (pH6), immunohistochemical staining was 
performed with antibodies against desmin (Abcam, 1:500), myosin heavy chain slow (Abcam, 
1:100), active caspase 3 (Dako, 1:500), CD3 (Dako, 1:250), CD20 (Dako, 1:50) and CD45 
(Dako, 1:100). Immunoreactivity was detected with 3, 3′-diaminobenzidine as chromogen. The 
photographs for the tissue sections were taken by Leica DM6000B microscope (Leica 
Microsystems). Omitting primary antibodies yielded no significant staining. The 
histopathological examinations included an Ultrastructural analysis for all the muscle tissue 
which fixed in formalin solution. The tissue was deparaffinised in xylene (60 minutes at 70°C), 
rehydrated,fixed with 2% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4), post-fixed 
in 2% osmium tetroxide and embedded in epoxy resin. Ultrathin sections were stained with 
uranyl acetate and lead citrate and viewed in a FEI Technai 12 electron microscope. The pictures 
were acquired as TIFF files and images were optimized for brightness and contrast using 
Photoshop, version 7.0 (Adobe systems, San Jose, CA). 
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4.3 Results 
4.3.1 MPS001 family  
 
4.3.1a Clinical assessment of MPS001 
Clinical details for the families in this project were provided by Dr. Julie Vogt from West 
Midlands Regional Genetics Laboratory and other collaborators. MPS001 is a consanguineous 
family originally from the Netherlands. It had had six pregnancies affected by FADS/MPS. 
According to the family history, the first pregnancy (F1) was terminated because of increased 
nuchal translucency of 12 mm, fetal akinesia and a unilateral club foot whereas Proband (F2), 
presented in the second pregnancy, was terminated at 12+6 weeks of gestation as a consequence 
of increased nuchal translucency of 9mm, fetal akinesia and joint contractures. There was no 
intrauterine growth retardation.  The post mortem examination evidently showed a cystic 
hygroma, lung hypoplasia, webbing of both elbows and knees and arthrogryposis. As a result of 
birth trauma, the calvaria was absent however there were no clear evidence of any skeletal 
abnormalities. Additionally, the third, fourth, sixth and seventh pregnancy were terminated, 
because of increased nuchal translucency and fetal akinesia. The fifth pregnancy ended in an 
early miscarriage. 
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4.3.1b Molecular findings of MPS001 
Sequencing of RYR1 in an affected fetus (F1) from this family revealed a homozygous RYR1 
nonsense mutation (c.6721C>T; p.Arg2241*) in exon 41 of the gene. Further analysis 
demonstrated that the other affected sibling (F2) has been identified with the same homozygous 
change while both parents were heterozygous carriers (Figure 3.2). According to EVS6500-
Exome databases, c.6721C>T mutation was previously detected (rs200563280), in the 
heterozygous state only in one case of 6503 individuals genotypes listed in the exome variant 
server (http://evs.gs.washington.edu/EVS) but no homozygous genotypes were detected at an 
average read depth of 49. 
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6841 GCTATTTCTGCCGAATCAGCCGGCAGAACCAGCGCTCCATGTTTGACCACCTGAGCTACC   6900 
6710 GCTATTTCTGCCGAATCAGCCGGCAGAACCAGCGCTCCATGTTTGACCACCTGAGCTACC   6769 
2237 C--Y--F--C--R--I--S--R--Q--N--Q--R--S--M--F--D--H--L--S--Y--   2256 
	
Figure	4.3	homozygous	RYR1	stop	codon	detected	in	MPS0001	family	
homozygous	stop	codon	c.6721	(p.Arg2242*)	was	detected	in	MPS0001	family	of	two	affected	sibling	(F1	&	F2	
chromatograms)	and	both	parents	were	heterozygous	for	the	mutant	alleles	(3rd	&	4th	chromatograms).	
	
 
4.3.1c Pathological findings of MPS001 
The quantitative histopathological examination performed by the Dutch collaborators showed 
some structural abnormalities in the affected siblings tissues, including fibre loss, increased fibre 
size variability and increased endomysial spacing with fibrosis (Figure 3A, B). Centrally 
positioned nuclei were notified in the examined muscle fibres in both patients and controls. In 
Normal	reference	
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contrast, thin muscle fibres with intense eosinophilic cytoplasm were seen only in the patients, 
while the controls were completely normal under the microscope (Figure 3.3 A,B) and this had 
nothing to do with calcium accumulation according to the specialized team (Figure 3.3 J). 
Moreover, staining against desmin, an intermediate filament protein which normally exists in 
muscle, showed no core-like structures (Figure 3.3C,D). Further significant staining against the 
slow and fast myosin heavy chain was carried out by the group in order to assess fibre type 
distribution, however, the results showed a notable reduction in the level of myosin slow 
immunoreactivity, which indicates preferential hypotrophy of type I fibres (Figure 3.3 E-H). 
Labelling for active caspase 3 excluded apoptotic loss of muscle fibres (Figure 3.3 I). Further 
fine investigations showed hypotrophy associated with profound myofibrillar disarray and Z-disc 
loss (Figure 3K,L). The analysis of the spinal cord did not show any loss of motor neurons or 
other abnormal pathological features in the anterior horns and all the proximal segments of the 
motor neural system and this confirm that the histopathological findings are mostly myogenic. 
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Figure	4.4	:	Histological	and	ultrastructural	findings	in	RYR1-mutant	fetal	skeletal	muscle	in	
MPS001	family.	
(A,B) Hematoxilin & Eosin stain shows increased fiber size variability in the RYR1-mutant muscle (A, 
fetus F1) compared to an age-matched control (B). Some RYR1-mutant fibres have intensely eosinophilic 
cytoplasm (A, arrows). The nuclei are localized centrally in all fibres, compatible with the gestational 
age. The perinuclear clear halo present in many fibres is an artefact due to formalin fixation. (C,D) 
Labelling against desmin reveals a similar pattern of immunoreactivity and no evident core-like 
structures in both RYR1-mutant (C, fetus F1) and control tissue (D). (E-H) Labelling against the myosin 
heavy chain fast (E,F) and slow (G,H) shows that the numbers of myosin fast-positive type II fibres is 
comparable between the patient (E, fetus F2) and the control (F), whereas myosin slow-positive type I 
fibres are markedly reduced in RYR1-mutant (G, fetus F2) compared to control muscle (H). (I) Labelling 
for active caspase 3 is negative, excluding apoptosis, also in atrophic RYR1-mutant muscle fibres (fetus 
F2). (J) Alizarin red S staining shows no detectable accumulation of calcium inside the RYR1-mutant 
muscle fibres (fetus F1). (K,L) Ultrastructural analysis reveals profound myofibrillar disarray with 
disappearance of the Z-bands in the RYR1-mutant muscle fibres (K, fetus F2). By contrast, Z-bands are 
easily detected in control tissue (L). Magnifications: (A-J) 400x; K,L 30000x. (lower panels) (McKie et 
al., 2014b) 
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3.3.2 Family MPS002 
 
3.3.2a Clinical assessment of MPS002  
 
In the clinical data of MPS002, the family presented at eighteen weeks of pregnancy with a 
female fetus with bilateral talipes and fixed flexion of the elbows. There was evidence of fetal 
hydrops on the ultrasound scan including a large cystic hygroma, subcutaneous oedema, ascites 
and pleural and pericardial effusions. A cardiac ventriculoseptal defect was also suspected. The 
pregnancy was terminated at 19 weeks of gestation. Post mortem examination revealed no 
intrauterine growth retardation, but the fetus was considered to be dysmorphic (protuberant eyes, 
hypertelorism, a flat nose, low set ears) and had a complete cleft palate. There was fixed flexion 
of all the limb joints and a fracture of the proximal left humerus. Pterygia were present between 
the inferior margin of the mandible and the anterior chest wall and across the elbows. The heart 
was normal. There were no other congenital abnormalities noted. The brain was structurally and 
histologically normal. The muscle appearance was striking but non-specific. There was variation 
in myofibre size with larger hyalinised rounded fibres and smaller rounded atrophic fibres with 
an apparent increase in fibrous tissue. Fast and slow myosin were co-expressed on a proportion 
of fetal myofibres. Occasional scattered chronic inflammatory cells were confirmed on CD3 and 
CD20 staining. Additional CD45 staining was interpreted as non-specific. Gomorri trichrome 
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staining was negative for nemaline rods and ragged red fibres. The couple had a previous 
intrauterine death at 23 weeks of gestation of a similarly affected male fetus. 
4.3.2b Molecular findings of MPS002  
Mutation screening in this family revealed a novel in-frame deletion of 27 nucleotides (c.2096-
2123del). This was absent from the known genomic database and our in-house database. This 
27bp deletion is located in exon 18 and the two affected fetuses of the family (F1&F2) were 
homozygous for the deletion while both parents were heterozygous carriers (Figure 3.4 ) (no 
sequence data for F2 due to the insufficient DNA). This novel deletion was predicted to result in 
a missense substitution (p.Glu699Asp) followed by a deletion of 9 amino acids; located within 
the SPRY1 domain of the RYR1 gene product. All these deleted amino acids were conserved in 
vertebrate RYR1 orthologues including zebrafish and 6 of 9 amino acids were conserved in 
C.elegans (Figure 3.4b).  
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Figure	4.5	A	chromatogram	homozygous	in-frameshift	deletion	in	RYR1	
 27bp homozygous inframe shift deletion in X18 (c.2096-2123) is clearly shown in the above sequence of 
one of the affected fetus resulted in result in a missense substitution (p.Glu699Asp) followed by a 9 amino 
acids deletion compared to the sequence of normal control and this mutation was inherited from 
herterozygous mutant parents as shown. . the 9 deleted amino acids were all conserved in vertebrate 
RYR1 orthologues (taken from UCSC) 
	
 
Control	
MPS002/F
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4.3.3 Family MPS003 
 
 
4.3.3a Clinical assessment of MPS003 
The family presented in the third pregnancy with possible polyhydramnios and reduced fetal 
movements and joint contractures were detected on ultrasound examination.  The fetus had a 
cystic hygroma, a hydrothorax, a short neck, a kyphosis and a short trunk due to a scoliosis. The 
pregnancy was terminated at 23 weeks of gestation. Post mortem examination demonstrated no 
evidence of intrauterine growth retardation but craniofacial anomalies (downslanting palpebral 
fissures, hypertelorism, a small mouth and high arched palate and low set ears) were noted. 
There were flexion contractures of the shoulders, elbows, wrists, hips, knees and ankles. There 
were clenched hands but no finger contractures. There was webbing of the axillae, elbows, knees 
and groins and rocker bottom feet.  There were no CNS abnormalities however there was 
evidence of a severe congenital myopathy.  
4.3.3b Molecular Finings of MPS003: 
A homozygous in-frame deletion (c.7039delGAG) was detected in the single affected proband 
from this consanguineous family of Palestinian origin diagnosed with LMPS. The variation was 
located within exon 45 (Figure 4.5).  It was present in both parents in the heterozygous state and 
unfortunately, there were no other relatives available for analysis. This deletion variant was not 
present in >13,000 RYR1 alleles reported on the exome variant server 
(http://evs.gs.washington.edu/EVS), but it was described, in the heterozygous state, in affected 
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members (n=2 and 3) of two unrelated families that presented with malignant hyperthermia. This 
c.7039delGAG deletion is predicted to result in loss of a glutamic acid residue at codon 2347 in 
the MH/CCD hotspot region 2 of the RYR1 gene product (Figure 4.6). This residue is conserved 
in in zebrafish and although the amino acid sequence around this residue is divergent in C. 
elegans, the glutamic acid is conserved.  
 
	
Figure	4.6	homozygous	in-frame	deletion	in	X45	(c.7039delGAG)	
it	was	detected	within	the	family	(MPS002).	As	shown,	3bp	(GAG)	was	deleted	in	the	affected	proband	
compared	to	the	normal	reference	resulting	in	a	missing	of	glutamic	acid	(codon	2347)	which	is	
conserved	in	vertebrate	and	zebrafish.	
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4.3.3c Pathological findings of MPS003 
The muscle analysis (performed by collaborators) for the affected probands demonstrated non-
specific abnormalities. The myofibre size had marked variation, and the fibres were large, 
hyalinised and rounded. In contrast, the atrophic fibres were smaller but rounded with an 
increased size of the fibrous tissue. Staining against the slow and fast myosin heavy chain 
showed co-expression in a section of myofibres. CD3 and CD20 staining showed signs of 
scattered and chronic inflammations of the cells (Figure 4.7) 
	
Figure	4.7	histological	findings	in	RYR1-mutant	(Family	MPS003) 
Hematoxilin	&	Eosin	stain	of	formalin	fixed	and	paraffin	embedded	psoas	muscle	shows	loss	of	fibres	
with	increased	fibre	size	variability	and	mild	fibrosis	in	the	RYR1-mutant	muscle	(A,B)	compared	to	an	
age-matched	control	(C).		
 
4.4 Discussion: 
4.4.1 Autozygosity mapping analysis 
As discussed in the Introduction chapter, autozygosity mapping is regarded as a powerful 
strategy for investigating the molecular basis for recessively inherited diseases and identifying 
the causative gene in consanguineous families. Prior to starting my project, this method was 
applied to a consanguineous family (MPS001 family), with three affected siblings. These studies 
identified a large region of homozygosity on chromosome 19. However, in MPS001, even after 
A B C 
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the candidate region was refined by genotyping with microsatellite markers, the target interval 
contained a large number of genes (345 genes). I followed a specific prioritization procedure 
(previously explained) to identify candidate genes and selected RYR1 as the promising candidate.  
4.4.2 Mutational analysis of RYR1  
RYR1 is a very large gene (15.3 kb) which composed of 106 exons and encodes a large RYR1 
protein (565kDa) that is a key component of the excitation-coupling (EC) process in skeletal 
muscle. RYR1 is a subtype of Ryanodine receptors (RyRs) which are intracellular calcium 
(Ca2+) release channels located on the endo/sarcoplasmic reticulum (ER/SR) and represent the 
major Ca2+ reservoir inside the cell. RyR1 facilitates the rapid and coordinated release of Ca2+ 
from the sarcoplasmic reticulum stores to initiate the skeletal muscle contraction  The excitation-
coupling process  converts electrical signals/increased Ca2+ levels into mechanical output (i.e. 
muscle contraction). Ca2+ ions play a significant signalling role in activating the channel and 
regulating the signal. In this mechanism, plasma membrane is depolarised and cause an 
activation of L-type voltage-gated calcium channels (Cav). These Cav channels signal RYR1 
located on the SR to release Ca2+ to activate muscle contraction (Rios and Brum 1987, Gordon 
et al. 2000, des Georges et al. 2016) 
It is a well-recognized cause of a variety of human congenital myopathies in particular 
congenital central core disease (CCD; MIM# 117000) and the malignant hyperthermia 
susceptibility (MHS), congenital skeletal muscle disorder, (MIM# 145600). As these conditions 
are inherited as an autosomal dominant trait, most reported mutations are heterozygous variants 
(Brandom et al., 2013, Broman et al., 2011). However, in recent years the further 
histopathological phenotypes have been associated with RYR1 mutations including multi-
minicore disease (MmD),congenital fiber-type disproportion, and centronuclear myopathy 
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(CNM) and also King Denborough syndrome, a dysmorphic syndrome with associated MHS. 
Indeed RYR1 associated congenital myopathies might represent one of the most common forms 
of congenital myopathy (Amburgey et al., 2013b, D’Arcy et al., 2008). Both dominant and 
recessive forms of RYR1-related congenital myopathies have been reported. In the year 2000, 
McCarthy and others noted most of RYR1 mutations occurring either within N-terminal region 
(amino acid residues 35-614) or within the C-terminal region  (residues 2163-2458) and the two 
regions were known later as  (MH/CCD region-1 and MH/CCD region-2 respectively)(McCarthy 
et al., 2000) and they observed that the majority of these clustered mutations were found in 
patients with autosomal dominant myopathies. In contrast, the mutations associated with 
autosomal recessively inherited RYR1 myopathies are widely distributed throughout the whole 
protein sequence (Amburgey et al., 2013a).  
After selection as the best candidate gene, screening for RYR1 gene mutations in MPS001 
revealed a homozygous nonsense mutation (c.6721C>T; p.Arg2241*) in two affected 
individuals. I then proceeded to screen for RYR1 mutations in the other LMPS/FADS families in 
this project. The large size of the gene made this a laborious and time consuming undertaking but 
mutation analysis in the other families resulted in the detection of a homozygous novel in-frame 
deletion of 27 nucleotides (c.2096-2123del) in family MPS002 in two affected siblings and also 
another homozygous in-frame deletion (c.7039delGAG) in the single affected proband from 
MPS003 family. In conclusion, the screening for mutational changes amongst all the 36 FADS  
probands resulted in finding three candidate homozygous mutations Table 4.3  (McKie et al., 
2014b). 
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Table	4.4		Summary	of	the	identified	rare	RYR1	variants	detected	in	families	with	LMPS	
 
The overall frequency of RYR1-related disease was 8.3% (3/36; 95% CI 0 to 19.5%) in our 
FADS/LMPS cohort. The case for pathogenicity of the three identified variants is supported by 
their low frequency in the population and also their absence from large repositories of genetic 
variation in control individuals, in addition to the co-segregation of the variants within the 
relevant families and evolutionary conservation of the mutated/ deleted amino acid residues, and 
finally the location of these variants within conserved domain sites. All these factors are 
considered very important for the pathogenicity assessment of any causative genetic variants 
(MacArthur et al., 2014). The novel in-frame deletion of 27 nucleotides (c.2097_2123del 
p.(Glu699_Gly707del)) detected in Family MPS002 is predicted to result in a missense 
substitution (p.E699N) followed by a deletion of 9 amino acids (GWGGNGVGD) within the 
SPRY2 predicted protein-protein interaction motif (Peralvarez-Marin et al., 2011). Previously 
missense substitutions within or adjacent to this deletion (c.2113G > C; p.Gly705Arg and 
p.Asp708Asn) have been reported in recessively inherited myopathies (Klein et al., 2012). The 
exon 45 in-frame deletion (c.7043delGAG) identified in Family MPS003 was predicted to result 
in loss of a glutamic acid residue at codon 2347. A missense mutation at a nearby residue 
(p.Arg2355Trp) has been reported in both dominantly and recessively inherited myopathies (Kim 
et al., 2013) and it is interesting that this deletion was previously described in the heterozygous 
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state, in two unrelated families with malignant hyperthermia (Sambuughin et al., 2001). 
p.Glu2347 is contained within the MHS/CCD mutation hotspot in N-terminal region 2 (stippled 
box Figure 4). Though no history of malignant hyperthermia syndrome was reported in Family 
MPS003, incomplete penetrance is well recognised in malignant hyperthermia and mutation 
carriers may not have been exposed to trigger events.  
Though my findings further established recessive RYR1 mutations as a cause FADS/LMPS, 
further work is required to fully establish the precise frequency of RYR1 mutations in 
FADS/LMPS cohorts and to address how novel missense or in-frame deletions/insertions might 
be reliably interpreted in a clinical diagnostic setting. It is noted that the identified mutations are 
located within the mutation hotspot regions (MHS/CCD 1 &2) where most of the previous 
mutations of RYR1 was located. Also, interestingly, the three mutations also located within RIH 
domain which is a conserved structure RYR1 protein. The 27bp novel in-frameshift deletion 
occurred within RIH-1 domain (in the interval 440-643 amino acids) while the nonsense 
mutation plus the 3-bp in frame deletion occurred in the RIH-2 domain (in the interval  2157-
2365 amino acids) and this domain is in fact situated in the second main hotspot of RYR1 
mutations (Sorrentino et al., 2000) see the below figure 4.8. 
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Figure	4.8	A	diagram	showing	the	location	of	the	identified	mutation	within	the	cDNA	of	RYR1 
nonsense	mutation	 in	MPS001	(X)	 ,27bp	 in	frame	deletions	 in	Family	MPS002	(red	triangle)	and	3bp	 in	
frame	deletion	in	Family	MPS003	(black	triangle)	in	relation	to	exon	structure	and	RYR1	protein	domains.	
Malignant	 Hyperthermia/central	 core	 disease	 mutation	 hot	 spots	 shown	 as	 stippled	 boxes,	 SPRY2	
interacting	 domains	 1,2	 &	 3	 as	 grey	 boxfibres,	 RIH	 domains	 as	 blue	 boxes,	 Homer	 binding	motifs	 as	
hatched	boxes. 
 
4.4.3. Genotype-Phenotype correlation 
Looking into the genotype-phenotype correlations in both modes of inheritance has provided 
insights into likely clinical-functional relationships. In a large cohort of RYR1-associated 
myopathies, dominant mutations were generally associated with milder phenotypes while the 
recessively inherited cases were mostly associated with severe phenotypes and an earlier age at 
onset of the disease than in dominantly inherited cases (Klein et al., 2012, Maggi et al., 2013). 
Although the age the clinical appearance of recessive RYR1 myopathies is quite variable, in a 
recent series all patients were reportedly presented the clinical features before age 10 years. The 
vast majority of CCD and the MHS are dominant missense mutations, and in few cases small 
deletions and duplications while in the recessively inherited RYR1 phenotypes, they are typically 
associated with compound heterozygosity for a missense mutation in combination with a 
nonsense, splice-site or frameshift mutation (Clarke et al., 2010, Jungbluth et al., 2007, 
Amburgey et al., 2013a). In a cohort studies involved 118 patients with RYR1-associated 
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recessively inherited myopathies, 61.5% of the cases had a truncating/in frame deletion/splice 
site mutation in combination with a missense mutation while 38.1% of the cases had two 
missense mutations (Klein et al., 2012, Maggi et al., 2013, Jungbluth et al., 2007). 
In my investigations I identified a homozygous null mutation in LMPS/FADS affected 
individuals from Family MPS001 and this finding is consistent with a previous study 
investigating the role of the  RAPSN gene in FADS/LMPS. The study concluded that 
homozygosity for a null (frameshift) mutation can cause FADS/LMPS whereas other compound 
mutations with only a single null mutation can cause a milder phenotype (Vogt et al., 2008) . 
Also, it is consistent with the observation that in mice Ryr1 knockout was lethal in the perinatal 
period due to heart and lung abnormalities (Takeshima et al., 1994). Our finding also agreed with 
the fact that fetal akinesia caused by RYR1 recessive mutations had earlier onset of the disease in 
comparison to the dominantly inherited mutations (Klein et al., 2012). In addition, a study 
reported seven fetuses/infants from six unrelated families affected by central core disease in 
whom there was a history of fetal akinesia (Romero et al., 2003). In that study: four cases from 
three families were found to harbour RYR1 mutations: three cases (from two families) were 
compound heterozygotes for RYR1 missense mutations and in one case only a heterozygous 
missense mutation was detected. Three of the four cases presented at birth and though in one 
case the fetus died at 32 weeks gestation (following termination of pregnancy after a previously 
affected sibling). Thus the phenotype in these cases was less severe than in the cases I studied 
and my findings demonstrated that the association between RYR1 mutations and fetal akinesia 
extends to severe early onset lethal FADS and that histopathological evidence of central core 
disease is not a prerequisite for molecular investigation of RYR1 in fetal akinesia. In a recent 
review of congenital myopathies treated at a single referral centre, a genetic diagnosis was 
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established in two-thirds of cases and almost 60% of those with a genetic diagnosis had a RYR1-
related myopathy (Maggi et al., 2013).   
My findings suggest that RYR1-related neuromuscular disease may be a significant cause of 
FADS/LMPS. Though recessively inherited RYR1-related myopathies have been associated with 
certain histopathological subtypes such as minicore, centronuclear and congenital fibre-type 
disproportion myopathies, RYR1 mutations may be associated with other histological subtypes or 
only nonspecific myopathic features. Extrapolating from these observations, it can be suggested 
that in cases of FADS/LMPS, RYR1 mutation analysis should be performed as part of a 
multigene diagnostic strategy (e.g. by second generation sequencing analysis) rather than being 
specifically targeted to cases with histopathological features that are considered characteristic of 
a RYR1-associated myopathy. The identification of RYR1 mutations as a cause of familial 
LMPS/ fetal akinesia enables accurate reproductive risk prediction and reproductive options 
including prenatal diagnosis and pre-implantation diagnosis but also might lead to the 
identification of relatives at risk of malignant hyperthermia. 
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Chapter	Five:	the	application	of	CES	in	MPS	disorder	
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5.1 Introduction 
Clinical exome sequencing (CES) is a NGS-based approach that focuses on specific 
genes/regions which have been associated with disease causing-mutations and reported in the 
Human Mutation Database (Lee et al., 2014). This targeted exome component represents nearly 
25% of the whole exome (~5000 genes).  Many users will analyse only a subgroup of genes in a 
disease specific panel which is updated continuously. The first existence of clinical diagnostic 
exome panel was in 2011 by Ambry Genetics (Aliso Viejo, CA, USA). Then, Illumina Inc. (San 
Diego, CA, USA) has designed a new kit for CES that composed of 2800 genes based on 
Nextera enrichment method (TruSight™ One). However, this particular kit has been developed 
to contain further 2000 genes (4813 genes in total) which was used in this project.  
There are some advantages of the application of clinical exome in the diagnosis of rare inherited 
disorders. First, it is a cost-effective method compared to the whole exome as it only focuses on 
the clinical associated genes with deep achievable coverage and less data to be analysed.  
Second, the number of resulting non-significant variants or variants of uncertain significance is 
considerably less than the data generated by whole exome/whole genome sequencing. Therefore, 
analysing the data would be faster and easier  with this approach (Klein et al., 2014). Multiple 
pterygium syndrome (MPS) and its related phenotypes are characterised by marked genetic 
heterogeneity which makes molecular diagnosis very challenging as many genes could be 
involved in the disease.  
Screening for RYR1 mutations that I performed in 36 LMPS/FADS families -in the previous 
chapter- has only resulted in identifying three homozygous mutations in three affected families 
while the others screened patients remained genetically undiagnosed. Hence, further analysis 
needed to be done for these families. Furthermore, many other families diagnosed with MPS 
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subtypes (EVMPS/arthrogryposis etc.) were recruited to this study in order to investigate the 
genetic causes of these families. Instead of sequencing the candidate genes by Sanger sequencing 
on an exon-by-exon basis, it was decided that a more efficient approach would be to use a NGS- 
based sequencing technology. 
 In collaboration with Dr.Arthur Mckie in Cambridge, I investigated the application of “clinical 
exome” sequencing (Illumina TruSightOne assay for ~4800 human disease genes) to study the 
genetic basis of MPS-related phenotypes. I wished to evaluate whether clinical exome 
sequencing in MPS-related phenotypes (FADS, LMPS, EVMPS, distal arthrogryposis) could 
provide a more cost-effective molecular genetic analysis strategy for clinical diagnostic testing 
than the whole exome sequencing (WES) and also whether this analysis might provide a new 
insight into genotype-phenotype correlations in MPS-related disorders.  
5.2 Patients:  
Fifty-three patients were recruited in this study. All the cases were clinically diagnosed by MPS-
spectrum disorders (LMPS/FADS/EVMPS/arthrogrypposis) and the diagnosis was done by 
clinicians from across the UK (Table 5.1). All the clinical details and family history for the 
patients were provided by clinical geneticists (Dr Julie Vogt, Professor Eamonn Maher and 
others).  Also, DNA from parents and unaffected family members was extracted to test the 
segregation of any candidate mutation.  Eight probands out of 53 who underwent clinical exome 
analysis were known to harbour a mutation in an MPS-related gene (including two cases with 
RYR1 mutations reported previously in this chapter that have been published) (McKie et al., 
2014a) and these were included as positive controls for the study. The remaining 45 cases were 
genetically undiagnosed though most of them had undergone a variable amount of pre-study 
genetic analysis either in the NHS diagnostic laboratory or by the Maher research group and had 
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generally been investigated previously for mutations in CHRNG, DOK7, RAPSN and RYR1 but 
no mutations were identified in these genes. The clinical features of the cases without a known 
molecular diagnosis are summarised in Table 5.1. Autosomal recessive inheritance was assumed 
in cases with and affected sibling and/or parental consanguinity and autosomal dominant 
inheritance when there was an affected parent. Isolated cases were listed as sporadic and no 
assumptions were made regarding inheritance. All families gave written informed consent and 
the study was approved by the South Birmingham Research Ethics Committee.  
Table	5.1	Summary	of	recruited	undiagnosed	probands	analysed	by	clinical	exome	sequencing	
Clinical	
Exome	ID	
Phenotype	 	 Consanguinity	 Inheritance	
CE01	 LMPS	 	 N	 Sporadic	
CE02	 FADS/LMPS	 	 Y	 Autosomal	Recessive	
CE03	 LMPS	 		 Y	 Autosomal	Recessive	
CE04	 LMPS	 	 N	 Autosomal	Recessive	
CE05	 LMPS	 	 Y	 Autosomal	Recessive	
CE06	 LMPS	 	 Y	 Autosomal	Recessive	
CE07	 Arthrogryposis	 	 N	 Sporadic	
CE08	 LMPS	 	 Y	 Autosomal	Recessive	
CE09	 LMPS	 		 Y	 Autosomal	Recessive	
CE10	 LMPS	 	 Y	 Autosomal	Recessive	
CE11	 LMPS	 	 Y	 Autosomal	Recessive	
CE12	 EVMPS	 		 N	 Autosomal	Recessive	
CE13	 EVMPS	 	 N	 Sporadic	
CE14	 Arthrogryposis	 		 N	 Sporadic	
CE15	 EVMPS	 	 N	 Sporadic	
CE16	 LMPS	 	 N	 Autosomal	Recessive	
CE17	 Arthrogryposis	 	 N	 Autosomal	dominant	
CE18	 Arthrogryposis	 		 N	 Sporadic	
CE19	 EVMPS	 	 N	 Sporadic	
CE20	 EVMPS	 	 Y	 Autosomal	Recessive	
CE21	 EVMPS	 	 N	 Autosomal	Recessive	
CE22	 LMPS	 	 Y	 Autosomal	Recessive	
CE23	 EVMPS	 	 Y	 Autosomal	Recessive	
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CE24	 LMPS	 	 N	 Autosomal	Recessive	
CE25	 LMPS	 	 N	 Sporadic	
CE26	 LMPS	 	 Y	 Autosomal	Recessive	
CE27	 Athrogryposis	 	 N	 Sporadic	
CE28	 EVMPS	 	 N	 Autosomal	Recessive	
CE29	 EVMPS	 	 N	 Sporadic	
CE30	 EVMPS	 	 N	 Sporadic	
CE31	 LMPS	 	 Y	 Autosomal	Recessive	
CE32	 LMPS	 	 Y	 Autosomal	Recessive	
CE33	 EVMPS	 		 N	 Sporadic	
CE34	 EVMPS	 		 N	 Sporadic	
CE35	 EVMPS	 		 N	 Sporadic	
CE36	 EVMPS	 		 N	 Autosomal	Recessive	
CE37	 LMPS	 		 N	 Autosomal	Recessive	
CE38	 LMPS	 		 Y	 Autosomal	Recessive	
CE39	 FADS	 		 N	 Sporadic	
CE40	 FADS	 		 N	 Sporadic	
CE41	 LMPS	 		 N	 Sporadic	
CE42	 EVMPS	 	 N	 Sporadic	
CE43	 Arthrogryposis	 	 N	 Sporadic	
CE44	 EVMPS	 	 N	 Autosomal	dominant	
CE45														LMPS	 	 Y	 Autosomal	Recessive	
E46	 LMPS	 	 Y	 Autosomal	Recessive	
5.3 Molecular Genetic Analysis:  
DNA samples were extracted by West Midlands Regional Genetics Laboratory mainly from 
blood samples using a standard extraction methodology. The targeted resequencing was 
performed using Illumina TruSightTM Rapid Capture kit to cover coding sequences from 4813 
clinically relevant genes from the TruSightOne panel. In our analysis, 53 probands were 
analysed (8 were diagnosed with known mutations in MPS candidate genes while 45 without a 
previous diagnosis).  The Trusight One assay was applied first to the 8 diagnosed probands to 
test the efficiency of the test before proceeding to use it in all other non-diagnosed cases. The 
panel has successfully detected all the 8 previously known mutations (in CHRNG, LMNA, 
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RAPSN, RYR1). Then, we decided to use the panel to most of the undiagnosed cases. The panel 
contains all the required reagents for the amplification, amplicon enrichment, indexing of the 
samples and the use of NextSeq 500 (Dello Russo et al., 2014). Using Nextera library 
preparation technology, genomic DNA was fragmented and tagged prior to multiplex pre-
enrichment sample pooling, an average 400bp fragment library size is achieved and a final 
pooled library concentration of 8-12Pm was assembled. For the assessment of the genomic 
library quality, 2100 Bioanalyzer tools (Agilent Technology) were used. The sequencing was 
then performed on NGS Illumina’s HiSeq2500 analyser employing a pair-end 150-cycle 
sequencing run. The Trusight One sequencing assay was performed by members of the Stratified 
Medicine Core Laboratory in Cambridge. I then analysed the clinical exome data to identify 
candidate mutations. Bioinformatics analysis and annotation of rare genetic variants were 
performed. Any variant reported >2% heterozygote frequency in 1,000 genomes project and 
variant exome server data (www.1000genomes.org/ and http://evs.gs.washington.edu/EVS/ 
respectively) was removed. Sequence data was inspected in two stages: I primarily focused on 
the gens that present in the clinical diagnostic gene panel (n=39 genes) and then in a wider set of 
further 47 potential MPS-related genes giving a total of 86 genes that were thought to be of 
potential relevance to MPS-related phenotypes. Finally, if no candidate mutations were 
identified, then all rare variants were inspected (Figure 5.1 & Table 5.2).  
The variants identified as pathogenic mutations were confirmed by Sanger sequencing in the 
proband sample and, when available, segregation was checked in DNA from other family 
members on whole genome amplified DNA (Qiagen REPLI-g kits) and stock DNA. PCR 
products were sequenced in forward and reverse orientations using a standard sequencing 
method (BigDye® Terminator v3.1 Cycle Sequencing Kit, Applied Biosystems®).  
138	
	
 
		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	5.1	An	example	of	the	clinical	exome	file	and	the	filtering	steps	to	find	the	causing	gene	
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Table	5.2	the	list	of	genes	included	in	the	diagnostic	and	the	MPS-related	panels	
genes	included	in	the	clinical	diagnostic	gene	panel	(n=39	genes)	and	the	whole	MPS-related	genes	n=86	
genes)	that	were	thought	to	be	of	potential	relevance	to	MPS-related	phenotypes	
Panel	for	Diagnostic	Testing	
(n=39)	
Extended	panel	(if	diagnostic	panel	failed	to	demonstrate	a	mutation)	
(n=86)	
ACTA1	
BIN1	
CHRNA1	
CHRNB1	
CHRND	
CHRNG	
CNTN1	
DMPK	
DNM2	
DOK7	
EGR2	
ERBB3	
FGFR2	
FKBP10	
FKRP	
FLVCR2	
GBE1	
GLE1	
IRF6	
LMNA	
	
MPZ	
MUSK	
MYBPC1	
MYH3	
MYH8	
NEB	
PIEZO2	
PIP5K1C	
RAPSN	
RIPK4	
RYR1	
SYNE1	
TNNI2	
TNNT3	
TPM2	
TPM3	
UBA1	
UTRN	
PLA2G6	
	ACTA1	
AGRIN	
ALG1	
ALG11	
ALG12	
ALG2	
ALG3	
ALG6	
ALG8	
ALG9	
ANO5	
BIN1	
BRAT1	
C14orf133	
CFL2	
CHRNA1	
CHRNB1	
CHRND	
CHRNG	
	
COG5	
COG7	
COG8	
CRYAB	
DAG1	
DDOST	
DMPK	
DNM2	
DOK7	
DOLK	
DPAGT1	
DPM1	
DPM3	
EGR2	
ERBB3	
FGFR2	
FKBP10	
FKRP	
FKTN	
	
GLE1	
IRF6	
KBTBD13	
KLHL40	
LARGE	
LMNA	
MEGF10	
MGAT2	
MOGS	
MPDU1	
MPI	
MPZ	
MTM1	
MUSK	
MYBPC1	
MYH3	
MYH8	
NEB	
PIP5K1C	
	
POMGNT1	
POMT1	
POMT2	
RAPSN	
RFT1	
RIPK4	
RYR1	
RYR3	
SLC25A19	
SLC35A1	
SLC35C1	
CNTN1	
COG1	
COG4	
VPS33B	
PLA2G6	
PMM2	
UBE1	
UTRN	
SRD5A3	
SYNE1	
TMEM165	
TNNI2	
TNNT3	
TPM2	
TRIM32	
TTN	
	
 
5.4 Results 
5.4.1 Detection of known mutations in CHRNG, DOK7, LMNA, RAPSN and RYR1  
The Eight previously diagnosed probands had 8 rare pathogenic variants in five genes associated 
with MPS-related phenotypes. They were analysed by CES method and the analysis resulted in 
identifying all these variants. Two homozygous RYR1 mutations (c.6721C > T; p. Arg2241* and 
c.7043delGAG; p.Glu2347del) (E45 & E46 respectively) associated with LMPS/FADS were 
detected in two consanguineous families (MPS001 and MPS003) which have been reported 
earlier in this chapter (McKie et al., 2014a) (Figures 5.2 &5.3).  The third detected variants was a 
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previously characterised mutation in RAPSN (homozygous c.264C>A, p.Asn88Lys, associated 
with congenital myasthenic syndrome (CMS) in sample CE36 (figure 5.4) that shows NGS 
sequence and no patient’s DNA was available to validate this variant by Sanger method . Further 
two samples contained heterozygous variants in LMNA (c.1445G>A, (p.Arg482Gln) and 
c.357C>T)  were confirmed. Two samples contained CHRNG mutations: one sample contained 
two heterozygous frameshift mutations in CHRNG (c.458delCinsCA (p.Val154SerfsTer24) and 
c.753_754delCT (p.Val253AlafsTer44) and another sample was homozygous for one of the 
frameshift mutation (c.458delCinsCA (p.Val154SerfsTer24). Last exome sample contained a 
homozygous splice donor site mutation in DOK7 (c.331+1G>T).  
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Figure	5.2	Sequence	analysis	of	RYR1	c.6721C	>T	(p.Arg2241Ter)	mutation	
Pathogenic	nonsense	homozygous	mutation	was	identified	in	Pakistani	consanguineous	families	
(MPS001)	diagnosed	with	LMPS	phenotype.		Homozygous	RYR1	c.6721C	>T	(p.Arg2241Ter)	was	
confirmed	by	Sanger	method	in	both	affected	siblings(homozygous)	and	in	the	parents	in	a	heterozygous	
state	(figure	4.3)	of	this	thesis		(McKie	et	al	2014)	
Sample	–	CE45;	location-	19:38987106;	Gene	-	RYR1 
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Figure	5.2	Sequence	analysis	of	RYR1	c.7043delGAG	(p.Glu2347del)	
Pathogenic	27b	homozygous	deletion	was	identified	in	Pakistani	consanguineous	families	(MPS002)	
diagnosed	with	LMPS	phenotype.		Homozygous		RYR1	c.7043delGAG	(p.Glu2347del)	variant	was	already	
confirmed	by	Sanger	in	figure	4.6	of	this	thesis	(McKie	et	al	2014)	
Deletion 
Sample	–	CE46;	location-	19:38990284;	Gene	-	RYR1 
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Figure	5.4		Sequence	analysis	of	the	variants:		RAPSN	c.264C>A	(p.Asn88Lys)		
homozygous	missense	RAPSN	c.264C>A	(p.Asn88Lys)was	identified	in	fetus	affected	with	with 
congenital myasthenic syndrome 
	
5.4.2 Identification of previously uncharacterised mutations by clinical exome analysis 
Amongst total 45 undiagnosed analysed patients, 7 cases (15.5 %) have shown 7 potential 
mutations in five MPS-related disease genes (CHRNG, CHRNA1, NEB1, RYR1 and TPM2). 
These variants are below: (see Table 5.2). 
CHRNG: A pathogenic homozygous missense substitution, (NM_005199.4 CHRNG c.715C>T 
(p.Arg239Cys) was detected in the proband (exome: CE26)	from a consanguineous Turkish 
Sample	–	(CE36)	G53;	location-	11:47469631;	Gene	-	RAPSN 
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family that presented with LMPS and the segregation analysis using Sanger method showed that 
parents where heterozygous carriers for the mutation (Figures 4.5 & 4.6). This mutation had been 
previously described in homozygous status in two affected members of two unrelated 
consanguineous families from Lebanon and Turkey and they were diagnosed with EVMPS and 
LMPS respectively (Hoffmann et al., 2006). 
	
		
	Figure	5.5	Sequence	analysis	of	the	rare	variant:	CHRNG	c.715C>T	(p.Arg239Cys)	
Pathogenic	homozygous	missense	substitution	was	identified	in	a	Turkish	consanguineous	family	
diagnosed	with	EVMPS.	As	shown	in	NGS	file	(exome:	CE26)		
Sample	–	(CE26);	location-	2:233407702;	Gene	-	CHRNG 
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Figure	3.6	Sanger	confirmation	for	the	variant:	CHRNG	c.715C>T	(p.Arg239Cys)	and	the	
conservative	location	of	the	amino	acid	
This	variant	was	confirmed	by	Sanger	Sequencing.	The	affected	sibling	was	homozygous	for	the	mutation	
(NM_005199.4	CHRNG	c.715C>T	(p.Arg239Cys)	while	both	parents	were	heterozygous	carriers.	The	
amino	acid	sequence	is	showing	the	conservation	of	the	amino	acid	residue	in	different	species.		
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CHRNA1:  
The second identified mutation was a homozygous insertion (duplication) of 17 nucleotides of 
CHRNA1 gene (NM_000079.3 CHRNA1; c.117_133dupGCGGCCAGTGGAAGACC 
(p.His45ArgfsTer19) which was detected in a proband (exome: CE22) (Figure 5.7) that was 
diagnosed with FADS and born to a consanguineous parents from Somalia, resulting in a 
frameshift mutation with a subsequent premature stop codon (a1.H25RfsX19). This mutation 
was previously reported in a family of African origin diagnosed with FADS (Michalk et al, 
2008). According to the provided clinical history, the male fetus had a severe septated cystic 
hygroma, early hydrops and fixed flexion deformity of all four limbs detected on antenatal 
ultrasound scan. Microarray analysis for copy number abnormalities (CNA) was normal. 
Autopsy was declined. The couple had had three previous male pregnancy losses between 20 and 
23 weeks of gestation with cystic hygroma, hydrops and fixed flexion contractures. Prior testing 
of CHRNG and DOK7 had not identified any pathogenic sequence variants. Confirmation by 
Sanger sequencing revealed the insertion was a tandem duplication of 17 nucleotides and 
appropriate segregation was demonstrated in two unaffected siblings and the parents.  
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Figure	5.7		Sequence	analysis	of	the	rare	CHRNA1	variant	insertion:	p.His45ArgfsTer19	
further	homozygous	CHRNA1	insertion	was	detetected	in	a	Somalian	consanguineous	family	diagnosed	
with	FADS	phenotype.	As	shown	in	NGS	file	(exome:	CE22),	the	variant	was	homozygous	for	the	insertion;		
Sample	–	(CE22)	location-	2:175624271;	Gene	-	CHRNA1 
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Figure	5.8	Sanger	sequencing	for	the	rare	CHRNA1	variant	insertion:	p.His45ArgfsTer19	
This	insertion;	c.117_133dupGCGGCCAGTGGAAGACC	(p.His45ArgfsTer19)	was	confirmed	by	Sanger	
Sequencing	as	shown	(by	Arthur	Mckie).	The	affected	sibling	was	homozygously	deleted	while	both	
parents	were	heterozygous	carriers.	
 
 
RYR1: A novel homozygous nonsense mutation in (Exome:CE08) was identified in RYR1 gene 
(c.12882G>T; p.E4294*) in a female fetus (F1) affected with LMPS from a consanguineous 
family (MPS013) of Pakistani origin (Figure 5.9) . Sanger sequencing confirmed this nonsense 
mutation and showed a segregation in another affected (male) fetus (F2) by detecting it in a 
homozygous state and in the parents who were heterozygous for the nonsense mutation. This 
mutation has not been previously reported in any patients with MPS- related syndromes.  The 
proband (F1) had an antenatally detected large cystic hygroma and intrauterine death occurred at 
18 weeks of gestation. At post mortem intrauterine growth retardation (IUGR), cystic hygroma, 
cleft palate, micrognathia, scoliosis of the vertebral column and multiple joint contractures with 
skin webs at the elbows, axillae and knees were noted. The muscle bulk was significantly 
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reduced with no muscle identified in the extremities. All the muscles were autolytic with severe 
degeneration of the fibres and variability in the shape and size of the muscle cells. There was 
some positive staining of slow and fast myosin in the muscles. PAS and DiPAS stains were 
negative excluding a glycogen storage disease.  Lymphocytic infiltration of the muscle cells was 
considered suggestive of a possible inflammatory myopathy. The second affected fetus was 
terminated at 19 weeks following the antenatal detection of a large cystic hygroma. Post mortem 
examination revealed an affected male fetus with IUGR, a cystic hygroma, cleft palate, flexion 
contractures of the upper and lower limbs and skin webs at the elbows, groins and knees. There 
was bilateral talipes and prominent heels.  The thoracic cavities were narrow and the ribs 
appeared shorter than usual. The long bones were gracile. The muscle bulk was significantly 
reduced and microscopicy revealed degenerative and regenerative changes with very scattered 
myocytes. There was no slow fibre staining and a few fibres stained with fast myosin. The a-
laminin staining was weak and patchy.  There was no family history of malignant hyperthermia.  
 
 
 
 
 
 
 
 
 
 
150	
	
 
	
	
Figure	5.9	Sequence	analysis	of	the	rare	RYR1	nonsense	variant:	(c.12882G>T;	p.E4294*)	
A	novel	homozygous	RYR1	stop	codon	variation	was	detected	in	a	Pakistani	consanguineous	family	
diagnosed	with	LMPS	phenotype.	As	shown	in	NGS	file	(exome:	CE08)	the	affected	female	fetus	was	
homozygous	for	the	mutated	allele;	(c.12882G>T;	p.E4294*)	
 
 
 
 
 
Sample	–	(CE08);	location-	19:39055740;	Gene	-	RYR1 
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NEB:  Another novel variant was detected in NEB gene. It was a homozygous null NEB 
nonsense mutation (c.10075G>T; p.Glu3359*) that identified in the proband CE03) and two 
other affected siblingss of a consanguineous Pakistani couple (MPS058). The children presented 
LMPS phenotype. The NEB mutation created a SpeI RFLP. in the clinical details, the first 
pregnancy was terminated at 21 weeks’ gestation following the detection of a cystic hygroma 
and fetal akinesia. At post mortem examination the fetus was appropriately grown but a large 
posterior cystic hygroma, fetal hydrops and pulmonary hypoplasia were noted. There were four 
limbs contractures and pterygia. The brain and spine appeared normal however the muscle bulk 
was severely reduced. The fetus appeared dysmorphic with down-slanting eyes, an upturned 
nasal tip, a small mouth with a high arched palate, micrognathia and low set ears. The muscle 
was composed of loose connective tissue with some fatty tissue. The surviving muscle fibres 
showed abundant central nuclei and degenerative and regenerative changes. There were some 
multi-nucleated fibres and vacuolation was prominent and appeared to contain abundant 
glycogen. The excess glycogen in the muscles was confirmed on electron microscopy. In the 
second pregnancy fetal akinesia sequence was detected on ultrasound scan at 13 weeks and there 
was an intrauterine death at 28/40. At post mortem the male fetus had features of LMPS. There 
was severely reduced muscle bulk with almost complete lack of muscle fibres in the psoas 
muscle and diaphragm with severe degeneration of the muscle. There was a large variation in the 
size of the muscle fibres and groups of multinucleated giant muscle cells containing small 
vacuoles. There was no evidence of the accumulation of glycogen. In the third pregnancy a 
cystic hygroma, bilateral pleural effusions and fetal akinesia were detected. There was an 
intraterine death at 23 weeks. The male fetus had features of LMPS. In addition, there was a 
bilateral cleft palate and abnormal ossification of the vertebral column. There were contractures 
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and the vertebral column appeared short with block and hemivertebrae. There was deficient 
ossification of the sacrum.  The muscle contained connective tissue and lacked muscle fibres. 
There were very thin muscle fibres and very large giant cells with multiple nuclei. There were no 
vacuolar or PAS positive inclusions.  
Maternal Myotonic dystrophy genetic testing was normal and maternal AChRAbs were negative. 
Karyotyping and genetic testing of PFKM for glycogen storage disease type VII was normal. 
Prior to CES analysis, no pathogenic sequence variants were detected in CHRNG, CHRNA1, 
CHRND, RAPSN, or DOK7.  
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Figure	5.10	Sequence	analysis	of	the	rare	NEB	variant:	c.10075G>T;	p.Glu3359*.	
Further	homozygous	NEB	nonsense	mutation	:	c.10075G>T;	p.Glu3359*was	detected	in	a	Pakistani	
consanguineous	family	is	shown	in	NGS	file	(exome:	CE03).			
Sample	–	(CE03);	location-	2:152484105;	Gene	-	NEB 
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Figure	5.11	Sanger	confirmation	of	the	rare	nonsense	NEB	variant:	c.10075G>T;	p.Glu3359*	
NEB	nonsense	variant;	c.10075G>T	was	successfully	validated	by	Sanger	Sequencing	as	shown.	The	
affected	sibling	(CE03)	who	diagnosed	with	LMPS	phenotype	was	homozygous	for	the	mutation;	
c.10075G>T;	p.Glu3359*.	Also,	the	variation	was	detected	in	two	other	affected	siblings	in	a	homozygous	
state	while	both	parents	were	heterozygous	carriers.	
	
TPM2: An identical heterozygous TPM2 missense substitution (ENST00000360958 c.379C>T 
c.502G>A; p.Arg133Trp) was detected in three apparently unrelated probands CE07, CE18 and 
CE30) (figures 5.12 &5.13). CE07 and CE18 were diagnosed with Distal Arthrogryposis (DA) 
whereas CE30 presented EVMPS clinical features. This mutation is located in a highly 
conserved amino acid residue of TPM2 and has been previously described in 2 female patients 
diagnosed with DA type 2B and muscle weakness (Tajsharghi et al., 2007) 
CE07 was a female patient born to unrelated white parents. From 34 weeks gestation there were 
concerns about poor growth and reduced fetal movements. The delivery was normal and she was 
born with a birth weight of 2.944 kg, a length 45 cm and a head circumference 33cm. She was a 
poor feeder and required readmission after because of weight loss. She had multiple joint 
contractures. She had removal of a left brachial cyst remnant and required grommets. On 
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examination she had mild restriction of her wrist movement with ulna deviation and flexion 
contractures of fingers 2-5, most severe in her third fingers. She had smooth hands with a paucity 
of palmar creases. Pseudocamptodactyly was not present. She had bilateral congenital talipes 
equinovarus, slightly worse on the left and full heels. She had full flexion of her knees but lacked 
30 degrees of extension. Both hips and spine were normal. Her muscles appeared normal and she 
had normal power in both quadriceps. Facially she had periorbital fullness of the eyelids, a 
slightly anteverted nose and a smooth philtrum. She had a small mouth with normal mouth 
opening. Her palate appeared normal. She had a low posterior hairline. Prior CHRNG analysis 
was normal. 
CE18 was a male child of unrelated white parents. Decreased fetal movements, bilateral talipes 
equinovarus, clenched hands, pleural effusions and polyhydramnios were detected antenatally.  
He was delivered by Caesarian section at 38 weeks with a birth weight of 3.34 kg and a head 
circumference was 36 cm.  He was self-ventilating but required tube feeds for the first 4 weeks 
of life. He had multiple joint contractures, a small atrial septal defect and bilateral undescended 
testis. At the age 5 years his diet is supplemented with high calorie milk. His height and weight 
are around the 2 percentile. He has Movicol for constipation. He has recurrent infections and 
tired easily. Psychomotor development was delayed but he was making progress.  
CE30 is a male patient was born to non-consanguineous parents originating from South 
America. Reduced fetal movements were noted towards the end of the pregnancy. His birth 
weight was 2.83 kg and there were no neonatal problems. He had down-slanting palpebral 
fissures, hypertelorism and low set ears. He had a low posterior hairline and neck webbing. He 
had sloping shoulders and contractures of his shoulders, elbows, wrists and fingers, with ulna 
deviation at the metacarpalphalangeal joints and soft tissue syndactyly of fingers 2-5. He had 
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contractures of the hips, knees and ankles. He had a mild thoracic kyphoscoliosis and eleven 
pairs of downward sloping ribs. He required bilateral inguinal hernia repairs and bilateral tendon 
releases between his 1st and 2nd fingers of both hands and his feet. He also had release of a 
tongue tie. At the age of 6 he was short with poor muscle bulk. His height was on the 0.4 
percentile, his weight below the 0.4 percentile and his head circumference between the 0.4 -2 
percentile. There were no other concerns about his health or development. On x-ray there was 
bilateral forefoot valgus deformities and hindfoot valgus. There was bilateral coxa vara. Previous 
CHRNG analysis was normal. 
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Figure	5.12	Sequence	analysis	of	the	rare	TPM2	missense	variant	(c.379C>T	c.502G>A;	
p.Arg133Trp)		
NGS	detected	a	heterozygous	TPM2	missense	variant	(c.379C>T	c.502G>A;	p.Arg133Trp)	was	detected	in	three	apparently	
unrelated	probands	(CE07,	CE18	G399,	G419	who	diagnosed	with	arthrogryposis	and	CE30	who	diagnosed	with	EVMPS	;	
however,	this	particular	attached	sequence	belongs	to	CE07	but	the	others	sequences	(CE18	&	CE30)	are	exactly	the	same.		
	
Sample	–	(CE07);	9:35685526;	Gene	-	TPM2 
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Figure	4	Sanger	confirmation	of	the	rare	TPM2	missense	variant	(c.379C>T	c.502G>A;	p.Arg133Trp) 
	
Figure	5.13:	Confirmation	of	TPM2	missense	variant	(c.379C>T	c.502G>A;	p.Arg133Trp)		
	The	variation	was	detected	using	NGS	clinical	exome	panel	and	confirmed	by	Sanger	sequencing.	the	amino	acid	sequences	
shows	that	mutation	is	located	in	a	highly	conserved	amino	acid	residue	of	within	TPM2	protein	(taken	from	UCSC).	
 
5.4.3 Identification of potential pathogenic mutations by clinical exome analysis 
The second type of detected rare genetic variants has been called as potential pathogenic 
mutations with uncertain significance. Three different candidate mutations were detected; two 
variations were detected in known MPS-related genes (NEB, RYR1) and whilst the third was 
detected in another MPS-related gene, RIPK4. Thus a novel rare homozygous RIPK4 missense 
substitution c.481G>C (p.Asp161His) was detected in a fetus (CE06) with LMPS from a 
	C	G		A	A		A	A	C		C		G	G	G	C	C 
																																	T		(R/D) 
G399 G419 G439 
TPM2 heterozygous missense  
Control 
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consanguineous family of Indian origin. It occurred at a highly-conserved residue and was 
predicted to be pathogenic by in silico analysis (figures 5.14 & 5.15).  In addition, two further 
heterozygous truncating mutations; NEB frameshift deletion; c.7523_7526delTCAA 
(p.Ile2508ThrfsTer14) and RYR1 nonsense variation c.481G>C (p.Asp161His) were detected. 
Both known genes (RYR1 & NEB) may cause autosomal dominant and autosomal recessively 
inherited muscle disorders. It could be postulated that the proband might harbour a second 
mutation in trans (e.g. an exon deletion that would not be detected by NGS or that a rare 
missense variant might be pathogenic).   
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Figure	5.14		Sequence	analysis	of	the	rare	RIPK4	missense:	c.481G>C	(p.Asp161His)	
A	novel	homozygous	RIPK4	missense	variation	was	detected	in	Indian	consanguineous	family	and	shown	
in	NGS	file	(exome:	CE06)		
	
	
Sample	–	CE06;	location-	21:43171399;	Gene	-	RIPK4 
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Figure	5.15		Sanger	analysis	of	the	rare	RIPK4	missense:	c.481G>C	(p.Asp161His) 
The	variant	was	validated	by	Sanger	Sequencing	as	shown	in	the	chromatogram.	The	amino	acid	
sequence	is	showing	the	conservation	of	the	Arginine	amino	acid	residue	in	different	species	(Taken	from	
UCSC).		
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Table 5.3 Summary of the detected rare mutations using Clinical Exome Trusight One Panel in 
different MPS-related genes. 
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5.5 Discussion 
 5.5.1 Why we selected CES strategy to investigate MPS disorders? 
We undertook “clinical exome sequencing” (CES) of a cohort of families with MPS-related 
disorders and detected both previously characterised (positive control) and previously unknown 
mutations in MPS-related disease genes. A major advantage of CES or whole exome sequencing 
(WES) for diagnostic testing is the ability to cost-effectively sequence large numbers of 
candidate genes in parallel. Traditionally molecular genetic analysis of MPS-related disorders 
has been undertaken by sequential analysis of single genes (CHRNG, DOK7, RAPSN and RYR1) 
for most of the cases. Apart from few identified mutation, known MPS genes were not reported 
as a cause for most cases. According to The United Kingdom Genetic Testing Network 
(http://ukgtn.nhs.uk/find-a-test/), the cost of single gene sequencing analysis of CHRNG or 
RAPSN in a clinical diagnostic laboratory as at least £423 while genetic testing of extremely 
large genes such as RYR1 (106 exons) and NEB genes (160 exons) is more expensive. Both 
genes (but not RAPSN or CHRNA1 or CHRNG) are included in a panel test of congenital 
myopathy (n=22 genes) that cost nearly £1300. In contrast, the cost for testing our diagnostic 
panel of 39 MPS-related genes (including the RYR1 and NEB) in a clinical diagnostic laboratory 
is £650 (unpublished data). Furthermore, if no mutation is detected in the 39 genes selected for 
the “MPS clinical diagnostic panel” sequence information for additional candidate genes can be 
interrogated. WES and WGS offer a wider choice of candidate genes but involves higher costs. 
Also, the interpretation of large obtained data is difficult. Hence, target gene capture sequencing 
using gene panels has been recently applied in genetic diagnosis of Mendelian diseases. For 
instance, in a recent Japanese study, they applied Trusight One panel to investigate the genetic 
aetiology of 17 families with different mendelian diseases such including Sotos syndrome, 
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Joubert syndrome and others (Okazaki et al., 2016). According to the study, the overall rate of 
accurate molecular diagnosis was 35% which was relatively higher than the diagnostic rate of the 
whole exome option (25%) when it had been applied in 250 patients. Most cases (80%) were 
children diagnosed with mendelian neurologic conditions (Yang et al., 2013). In very recent 
study, whole exome sequencing was applied for 52 patients (from 48 kindreds) with clinical 
presentation of arthrogryposis.  Several candidate variants have been detected in known 
arthrogryposis-associated genes including homozygous variants in 35.4% of probands (e.g. 
CHRNG in 6 subjects and ECEL1 in 4 subjects). In addition, they identified variants in candidate 
arthrogryposis-causing genes such as FBN3, MYO9A, pleckstrin and PSD3 (Bayram et al., 
2016).  In contrast, a very recent paper has concluded that WES has a very high rate in detecting 
the pathogenic variants in heterogeneous disorders such as inherited retinal disease by detecting 
pathogenic variants (single-nucleotide variants, indels, or structural variants) for 404/722 (56%) 
individuals (Keren and McKenna, 2016). However, differences in the composition of the patient 
cohorts studies and the extent of prior genetic testing prevent a direct comparison of the results 
of CES and WES testing in this study and that reported by Bayram et al (2016). Nevertheless, 
number of genes that harboured variants in the cohort reported by Bayram et al (2016) were not 
included in our MPS-related gene panels including candidate or potential arthrogryposis linked 
genes (CENPJ, COL6A3, ECEL1, ERCC2, FBN3, GPR126, ICAM1, IDS, LIFR, MYBPC2, 
MYO9A, MYO18B, POLR3A, PSD3, VPS8). Resequencing theses implicated genes using 
Trusight One panel did not reveal any reported mutations. However, ECEL1 was not included in 
the version of the Illumina TrusightONE gene panel used by us.  
Both CES and WES diagnostic strategies for MPS-related disorders are limited by the inability to 
reliably detect heterozygous exon deletions (or duplications) and failure to detect mutations in 
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parts of a gene that are not captured by the exome probes (e.g. much of the intronic sequences). 
Though WES has the potential to identify novel genes for MPS-related phenotypes, the 
preference is shifted to the application of CES. That is mainly because of economic advantages 
of restricting the sequencing to known human disease genes and analysing candidate mutations 
to the genes known to be associated with MPS-related disorders which will result in reducing 
number of variants of uncertain significance and incidental findings. The overall frequency of 
pathogenic mutations in our cohort was 16% (7/45) and a further (3/45) 7% of probands had 
candidate (possible pathogenic) mutations that might, in time, prove to be diagnostic. So, the 
overall frequency of the detected candidate mutation in this study is 13/45 (29%) of the 
examined patients which suggest that clinic al exome method (Trusight One) is a successful 
approach for studying FADS/LMPS/EVMPS phenotypes. Many of our cases had been 
previously screened for mutations in single candidate genes (e.g. CHRNG, RAPSN, DOK7, and 
RYR1) and the mutation detection rate expected to be higher in a previously unscreened cohort 
and/or a cohort of exclusively familial cases. Though CES/WES can provide a powerful strategy 
for the diagnosis of MPS-related disorders, that correct diagnosis requires careful interpretation 
of variants, determination of the pathogenicity and clinical significant of the variants which is a 
big challenge.  
5.5.2 RIPK4 as a novel potential gene for MPS disorder 
 The detection of rare missense mutations in known MPS-related genes can pose problems of 
interpretation if no functional assay is readily available and clinical or histopathological findings 
are not specific. This was illustrated by the finding of a homozygous rare missense variant 
(p.Asp161His) in RIPK4 in a fetus with autosomal recessively inherited FADS. Biallelic 
mutations in RIPK4 cause the frequently lethal autosomal recessively inherited form of popliteal 
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pterygium syndrome (Bartsocas-Papas syndrome) which is characterized by marked popliteal 
pterygium and multiple congenital malformations (Mitchell et al., 2012, Kalay et al., 2012).  So, 
RIPK4 is not previously known to be associated with inherited MPS disorder in particular 
LMPS. Though the p.Asp161His substitution was predicted to be damaging by in silico tools and 
was not present in the ExAC database, it had not previously been reported in FADS. Review of 
the clinical data revealed that affected fetus was the second affected pregnancy of a 
consanguineous couple. Also it was reported that the presence of pterygia (axillae, elbows, 
groins, knees and there were pterygia between the two lower limbs) and developmental defects 
(retracted eyelids, hypertelorism, depressed nasal bridge, cleft palate, absent mandible and digits 
and indeterminate genitalia) led to an independent clinical diagnosis of Bartsocas-Papas 
syndrome. The congruence of the presumptive clinical and molecular diagnoses supported the 
case for pathogenicity but familial segregation studies have not been possible because of 
unavailability of DNA samples. 
5.5.3 Genotype/phenotype correlations of RYR1 and NEB genes  
Previously, others and we have described LPMS/FADS associated with biallelic RYR1 mutations 
(Romero et al., 2003, McKie et al., 2014a, Kariminejad et al., 2016) and here we describe few 
additional candidate variants identified by CES panel. It seems likely that the frequency of this 
disorder has been underestimated because the large size of RYR1 gene (15.3 kb coding sequence 
in 106 exons) which made genetic sequencing and analysis using standard method is expensive 
and time consuming. As NGS-based diagnostics approaches such as CES or WES were applied 
more commonly, we expect additional cases of RYR1-related FADS/LMPS to be identified. 
RYR1 mutations are associated with a range of muscle disease phenotypes including a variety of 
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histological subtypes of congenital myopathies and malignant hyperthermia (MH) (Manning et 
al., 1998, McCarthy et al., 2000, Wilmshurst et al., 2010, Ghassemi et al., 2009). 
 RYR1-associated congenital myopathies may be inherited as autosomal dominant or recessive 
trait with recessively inherited cases tending to be more severely affected and having an earlier 
age-at-onset. RYR1 mutations described in recessively RYR1-myopathies have predominantly 
consisted of a combination of a null mutation with a missense mutation (Amburgey et al., 2013b, 
Bharucha-Goebel et al., 2013, Klein et al., 2012, Zhou et al., 2007) whereas RYR1-associated 
cases of severe LMPS/FADS appear to be more likely to be associated with biallelic truncating 
mutations. Though a potential implication of detecting RYR1-associated LMPS/FADS is to 
indirectly identify parents and other mutation carriers at risk of malignant hyperthermia, to date 
MH not been observed in the cases we have studied and we note that MH-associated RYR1 
mutations are usually missense mutations and cluster in specific protein domains (Brandom et 
al., 2013, Kim et al., 2013, Broman et al., 2011) 
Similar to RYR1, mutations in nebulin (NEB) have been associated with a variety of congenital 
myopathies including autosomal recessively inherited nemaline myopathy, one of the most 
common congenital myopathies (Anderson et al., 2004, Lawlor et al., 2011, Lehtokari et al., 
2006). Also, it was implicated, less commonly, with early-onset distal myopathy without 
nemaline bodies (Wallgren-Pettersson et al., 2007), distal nemaline myopathy (Lehtokari et al., 
2011) and childhood distal myopathy with rods and cores (Scoto et al., 2013). In a recent 
comprehensive review of NEB mutations (212 mutations in 159 kindreds), it was noted that 83% 
of patients were compound heterozygotes and only 2% had a prenatal presentation (in two cases 
there was a LMPS/FADS phenotype and in one case FADS (Lehtokari et al., 2014) As with 
RYR1-associated FADS/LMPS it appears that NEB-associated FADS/LMPS cases mostly have 
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biallelic truncating mutations suggesting a genotype-phenotype correlation with the most severe 
mutations causing prenatal presentation (Todd et al., 2015). It is interesting to note that in the 
three cases with homozygous NEB null mutation (c. 10278C>A; p.Glu3359Ter) described here 
there were severe muscle abnormalities (the muscle was composed of connective tissue with a 
severe lack of muscle fibres). Like, RYR1, NEB is a very large gene (~26 kb coding sequence and 
183 exons) which is not routinely screened and cases of NEB-associated MPS-related disorders 
have probably been underdiagnosed. 
An interesting observation was that we identified multiple probands with heterozygous 
truncating (or candidate missense) mutations in MPS-related gens (NEB, RYR1, TTN, COL6A2). 
The interpretation of these findings can be challenging as such cases might represent autosomal 
recessively inherited cases in which the second mutation has not been detected. Conversely it 
might be that the mutation is acting in a dominant manner or might be contributing to an 
oligogenic phenotype. In the study of 48 families with arthrogryposis, it was noted that 8 
families with a homozygous mutation in an arthrogryposis-associated gene also had a second 
locus with a homozygous/ compound heterozygous variant in a further candidate gene. These 
potential diagnostic uncertainties illustrate the complexity of the interpretation of NGS-based 
approaches that can generate large numbers of potentially relevant genetic variants (Bayram et 
al., 2016) 
5.5.4 TMP2 gene: a further implicated gene in MPS disorder? 
Though autosomal recessively inherited forms of MPS are the most commonly recognised, in 
sporadic cases recessive, dominant and X-linked causes should be considered. We detected an 
identical heterozygous p. R133W missense substitution in TPM2 (which encodes beta-
tropomyosin) in three sporadic individuals. Two of them were diagnosed with Arthrogryposis 
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(CE07,	CE18	) while the third proband (CE30) has presented EVMPS phenotype. This particular 
mutation was initially described in a mother and daughter with distal arthrogryposis type 2B and 
muscle weakness without progressive muscle wasting (Tajsharghi et al., 2007). Also it was 
reported in various overlapping muscle phenotypes including nemaline myopathy, cap 
myopathy, core-rod myopathy, congenital fibre-type disproportion, distal arthrogryposis and 
trismus-pseudocamptodactyly (Donner et al. 2002, Sung et al. 2003, Ohlsson et al. 2008, Clarke 
et al., 2012, Dowling et al., 2012). Although most disease causing TPM2 mutations are 
dominant, autosomal recessive TPM2 mutations have been described in association with EVMPS 
and a nemaline myopathy on histology (Monnier et al 2009). Interestingly, the three patients we 
identified with a TPM2 mutation were referred to our study because of clinical features 
reminiscent of multiple pterygium syndrome, although there was an absence of joint webbing. 
The three cases that harboured this mutation in our series demonstrated overlapping but variable 
features. It has been shown that TPM2 mutations causing increased calcium sensitivity result in a 
hypercontractile phenotype with limb and jaw contractures compared to the non hypercontractile 
mutations (Marttila et al., 2014). However although in vitro studies did not demonstrate an 
increased sensitivity of the contractile proteins to calcium it resulted in reduced myosin–actin 
interactions causing muscle weakness without muscle wasting (Ochala et al 2007).  
5.6 Conclusion  
The “MPS spectrum disorders” are genetically heterogeneous and although, in some cases, a 
diagnosis of a specific primary myopathy, metabolic or neurodevelopmental disorder can be 
made by clinical and pathological investigations, the underlying aetiology is unknown in the 
majority of cases (Cox PM et al., 2003). Thus, establishing the cause of MPS by clinical and 
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histopathological investigations is challenging because in many cases the histopathological 
features may be non-specific or autolysis prevents accurate characterisation of muscle pathology. 
Hence comprehensive molecular genetic analysis can greatly facilitate the diagnostic process. 
Extensive genetic analysis by CES or WES enables almost all candidate MPS genes to be 
examined and so CES/WES provide better strategies to determine the relative frequencies of 
individual genetic causes of MPS than sequential testing of single genes. Thus, our data suggests 
that after, CHRNG, mutations in RYR1 may be the second most common cause of autosomal 
recessive LMPS/FADS. As NGS strategies for genetic diagnosis become more readily available 
mutations in large genes such as RYR1 and NEB are more likely to be identified. Additionally, as 
the expanded phenotypes that can be associated with mutations in genes such as TPM2 (i.e. 
EVMPS as well as distal athrogryposis) become better recognised the proportion of cases of 
MPS-related disorders with a molecular diagnosis should increase. Testing mutation negative 
cases for whole exon deletions/duplications should further increase diagnostic rates but, 
considering that currently a molecular diagnosis is only reached in a minority of cases, it seems 
likely that further MPS genes remain to be identified. 
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6.1 Summary: 
This thesis demonstrates the evolution of genetic advances in the field of mutation identification 
in autosomal recessively inherited diseases; in particular, amongst families with parental 
consanguinity, progressing from genetic mapping, candidate gene analysis to NGS based 
approaches. Two main outcomes can be concluded from this thesis and these will be discussed in 
detail in this chapter. Firstly, the benefit of applying autozygosity mapping in studying the 
autosomal recessively inherited diseases. Secondly, the power of using NGS techniques in 
investigating such rare disorders. In this project, NGS was applied as a main investigative tool in 
an attempt to identify genes associated with a range of different rare autosomal recessive 
disorders in consanguineous families. Two different “exome strategies” were applied in the 
project. Whole exome sequencing (WES) was applied to one affected patient of congenital 
Oligodontia in order to investigate the genetic basis of the disease whilst the clinical exome 
sequencing (CES/Trusight One) was used for the genetic analysis of MPS disorders.  The use of 
enriched exome panel (Trusight One) for studying MPS disorders has shown good detection rate 
(31%) in identifying pathogenic variations in known candidate genes. However, applying whole 
exome sequencing for one patient affected with Oligodontia did not result in identifying any 
pathogenic variants. Though no mutation was identified by WES in the analysed oligodontia 
patient, this method is highly suitable for mutation detection in diseases with genetic 
heterogeneity and for gene discovery in such cases. In the future, a larger WES study of patients 
with inherited oligodontia.   
6.2 Application of Autozygosity mapping for investigating autosomal recessive diseases  
Linkage analysis can be used to identify genetic markers linked to disease genes but is 
particularly powerful in consanguineous families for excluding linkage to candidate genes. This 
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was illustrated in this project in excluding LTBP3 gene involvement for oligodontia, in most 
patients, by analysing microsatellite markers located across the genomic region on chromosome 
11 (59,756,135 to 69,325,101) which contain the target LTBP3 gene. However, no evidence of 
linkage was identified in 4 families and only one proband of family 5 has showed nearly ~8Mb 
homozygous region that contains LTBP3 gene in five microsatellites markers (D11S4191, 
D11S4076 D11S1883, D11S913 and D11S1889). Therefore, the gene was not selected to be a 
candidate for the disease in the majorities of families. Linkage analysis in addition to excluding 
candidate genes is also used to identify candidate region particularly when studying 
consanguineous families with multiple affected members with the presence of parents and 
unaffected members. This was illustrated in my project by analysing two FADS/MPS patients 
from a single consanguineous family (MPS001) to identify regions of homozygosity.  This was 
carried out using Affymetrix 250K SNP arrays 5.0, genome-wide linkage scan on DNA of the 
two affected siblings. The SNP genotyping work was performed by Louise Tee (a research 
laboratory technician) prior to starting my project. After excluding linkage to known 
FADS/LMPS genes, a candidate homozygous region of nearly10 Mb on chromosome 19 was 
identified. As the locus was mapped to chromosome 19, the target region was genotyped using 
fourteen polymorphic microsatellite markers from the same candidate region, over 345 genes 
were found within the target interval. Amongst these genes, RYR1 was selected as the best 
candidate to be sequenced using specific prioritization strategy. 
 A homozygous null mutation (c.6721C > T) was identified within the RYR1 gene in two affected 
siblings of the family MPS001. Then, I proceeded to sequence RYR1 using Sanger method in a 
cohort of 36 unrelated probands with FADS/LMPS and revealed two additional homozygous 
deletions. Thus, the frequency of RYR1mutations in the analysed probands with FADS/LMPS 
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was 8.3%. These findings suggest that RYR1 gene is a significant cause of FADS/LMPS. 
Accordingly, it was recommended adding this gene to the diagnostic panel for the disease in the 
future testing.  
As introduced in the introduction chapter, our findings agree with many studies that autozygosity 
mapping is an effective approach in searching for homozygous regions in particular amongst 
consanguineous families.  However, the method becomes less informative in case of studying 
single cases with no relatives. Over the past decade, Professor Maher’s research group utilised 
the autozygosity mapping studies as a main approach in studying different rare recessive 
disorders and they have successfully identified a large number of novel genes including genes 
for: Achromatopsia (GNAT2) (Aligianis et al., 2002), ARC syndrome (VPS33B, VIPAR) 
(Gissen et al., 2004; Cullinane et al., 2010), Beckwith-Wiedemann syndrome (NLRP2) (Meyer 
et al., 2009), Faisalabad histiocytosis/3 Rosai- Dorfman disease (SLC29A3) (Morgan et al., 
2010), Fowler syndrome (FLVCR2) (Meyer et al., 2010), Hermansky-Pudlak syndrome 
(BLOC1S3) (Morgan et al., 2006b), Immunodeficiency syndromes (TRAC) (Morgan et al., 
2011), Infantile neuraxonal dystrophy (PLA2G6) (Morgan et al., 2006a), Infantile parkinsonism 
(DAT) (Kurian et al., 2009), Martsolf syndrome (RAB3GAP2) (Aligianis et al., 2006), Meckel-
Gruber syndrome (MKS3) (Smith et al., 2006), Multiple pterygium/Fetal akinesia syndrome 
(CHRNG, RAPSN, DOK7) (Morgan et al., 2006c; Vogt et al., 2008) Also, many other genes 
were identified by the help of this efficient method and they can be found in the literature either 
of the Maher group or of the many other genetic researchers.  
6.3 The Application of NGS in investigating rare inherited disorders:  
Linkage mapping and gene-by-gene analysis based on Sanger Sequencing in a disease interval is 
a time consuming and expensive process. Several factors could affect the power of that approach 
176	
	
such as the small size of studied samples or families, reduced penetrance and locus heterogeneity 
(Bamshad et al., 2011). Exome and NGS sequencing techniques in general have revolutionised 
human genetics and helped in understanding the genetic basis of many inherited disorders 
through identifying the pathogenic variants underlying the rare and complex diseases. NGS is 
regarded as the best tool to elucidate disease causing mutation not only in the large extended 
families with possibility of performing linkage analysis to identify the candidate genomic region 
but also can be efficient in sporadic cases to search mainly for de novo mutations (Veltman and 
Brunner, 2012). Exome sequencing became a standard technique because it is more cost-
effective compared to WGS as it only captures the highly interpretable coding region which 
represents 1% (about 38 Mb) of the whole human genome. In addition, it contains the majority 
(85%) of the reported genetic changes (Wang et al., 2013).  Partial exome approach was adopted 
in our study for investigating MPS disorder by applying an enriched clinical exome (Trusight 
One) panel whereas whole exome sequencing method was used for investigating one patients 
who is diagnosed with a severe oligodontia disorder. 
In genetically heterogeneous diseases such as MPS, large number of candidate genes is usually 
involved in the investigation process. Different gene panels can be tested including specific 
diagnostic panel which might comprise up to 50 genes (e.g. NHS diagnostic panel for MPS=39 
genes). In addition, whole exome sequencing (WES) can be applied for the extreme 
heterogeneous diseases and was used in my project to investigate the genetic causes of 
congenital oligodontia.  In the results, this project has proven the power of clinical exome 
techniques in investigating the autosomal receive disorders by identifying pathogenic mutations 
and potential candidate genes that could play a significant role in the genetic basis of MPS 
disorders.  
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6.4 Evaluation of Clinical Exome Sequencing for use in MPS diseases/Autosomal recessive 
Clinical exome sequencing was applied using the Trusight One panel which screens more than 
4,800 genes involved in the clinical phenotypes associated with inherited human disorders. 53 
patients were analysed using this clinical panel. 8 analysed patients were already identified with 
known mutations in MPS-related genes and the clinical exome was used as a confirmatory 
method for them. 45 recruited patients had no previous genetic diagnosis but they have 
undergone mutation-screening analysis in number of candidate genes (CHRNG, DOK7, RAPSN 
and RYR1) and it was decided to apply clinical exome sequencing to determine if a pathogenic 
variant could be identified in another candidate gene. 
For each individual, the panel detected nearly 14,800 variants in total. For those whose family 
history and parental consanguinity suggested autosomal recessive inheritance of MPS, I focussed 
my attention on homozygous variants or compound heterozygous variations while in no-
consanguineous cases, single heterozygous were not excluded as the autosomal dominant 
inheritance is considered. After using specific filtering strategy, the total candidate variants are 
summarised in table. All 8 previously mutations in CHRNG, LMNA, RAPSN, and RYR1 were 
successfully detected with 100% accuracy. In the undiagnosed cases, 7 out of 45 cases (~16%) 
novel mutations in known MPS-related genes (CHRNG, CHRNA1, NEB1, RYR1 and TPM2) 
within seven different affected patients. Other rare genetic variants which classified as 
potentially associated with MPS phenotype were identified in 6 probands in five genes; two of 
them are known genes which already reported with pathogenic mutations (NEB, RYR1) and 3 
(RIPK4, TTN, COL6A2) were less well characterised genes. Therefore, clinical exome 
sequencing has successfully identified the causing genetic variants in 13 out of 45 total 
individuals which demonstrate a 29% success rate in identifying associated mutations within 
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MPS-related phenotypes (FADS, LMPS, EVMPS, distal arthrogryposis) in both consanguineous 
and non-consanguineous cases including the most pathogenic cases summarised in Table 5.3. 
The method is a cost-effective strategy for investigating these inherited diseases compared to 
WES and provided new insights into genotype-phenotype correlations. 
These research findings could be helpful in the diagnostic process in the future because many 
newly detected genes in such research and studies were quickly added to the pipelines of number 
of designed diagnostic testing. Sometimes, it takes only few months from the publication of a 
new gene to its incorporation into commercial diagnostic gene panels (Lohmann and Klein, 
2014).  
6.5 Limitations of applying NGS in investigating rare autosomal recessive disorders: 
Due to the huge number of data, interpretation of these detected variants is the biggest challenge 
for applying the NGS approach in genomic medicine. NGS techniques have some disadvantages 
that need an improvement in the future such as the risk of false positive findings from 
sequencing errors and the insufficient coverage for a particular gene or nucleotides that reduce 
the method specificity.  Exome Sequencing approach suffers from an inability to reliably detect 
heterozygous exonic deletions or duplications and/or rearrangements that occur within the 
targeted regions of associated genes. Though these changes might be reported in HGMD, they 
would not be detected due to the limitations exome technology. However, number of alternative 
techniques can be used to detect these changes including Multiplex Ligation-dependent Probe 
Amplification (MLPA technique) or high-density cytogenetic technologies (e.g. aCGH) that 
designed by Oxford Gene Technology and regarded as the most accurate method for detecting 
CNV. Another approach that can detect these changes is whole genome sequencing (WGS). 
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Second, there is inadequate and different coverage of the region that contains a causal variant, 
which could result in missing variants and false positive findings. 
For exome technology, the kits can only target exons that already identified, however, as 
knowledge of all truly protein-coding exons in the genome is still incomplete, so the kit might 
miss the non-covered exons. A pathogenic variant may be present, but if it is not targeted in 
analysis it may not be detected depending on the filtering NGS parameters.  
Currently, whole genome sequencing can be good alternative approach but is still more 
expensive than exome sequencing. WGS offers some advantages compared with exome 
sequencing comprises the unbiased analysis of the genome. First, it allows more reliable 
detection of structural variants (e.g. CNV) as well as identifying the noncoding variation 
(Gilissen et al., 2014, Spielmann and Klopocki, 2013). Also, the potential protein-coding regions 
that have not yet been annotated as genes are included in the genome sequence analysis and it 
would not face the technical challenges seen in WES such as exon capture and coverage. 
However, although the costs of WGS only higher than WES  2–4 times but the larger data 
storage and longer analysis time makes WES a convenient technology To some extent, the 
results in this project revealed both the strengths and limitations of using WES/CES as a tool to 
evaluate genes related to rare autosomal recessive conditions. 
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6.6 The future of human gnomes and national genome projects  
One of the limitations of gene identification studies is the rarity of the patients with the disease 
of interest.  In familial diseases, the method can be most successful in large extended families 
with multiple affected individuals. In addition, it can be a powerful tool to investigate the 
genetics for sporadic disease in the presence of many affected individuals displaying similar 
phenotypes. Finding those vulnerable people is very difficult for the rare inherited disorders. 
However, as genomic medicine continues to progress, many projects could help overcoming this 
problem by providing big database based on large number of recruited patients. One of these 
large-scale projects is the UK 100,000 Genomes Project that aims to sequence 100,000 genomes 
from around 70,000 people including 17,000 rare disease patients and 33,000 healthy relatives. 
Another global example of genomic projects is the Saudi Genomic Project to sequence 20,000 
subjects including healthy people and patients affected with common or rare genetic disorders. 
One of the main project goal is eliminating the huge burden of recessive genetic disease which is 
very high in the kingdom (8% of the births) that can be achieved through identifying the causing 
gene variants that cause these diseases and then providing genetic counselling for those who at 
risk.  Also, if the costs of sequencing genome/exome continue to fall as expected with the 
accelerating advances in the genomic techniques, similar projects can emerge and support the 
process of identifying novel genes and associated pathways. Therefore, NGS can be very helpful 
not only in the prediction/diagnostic process through discovering novel genes but may also be 
beneficial for the therapeutic approach.  
6.7 Comparison of various genetic tests and their applications 
 NGS technology has made different types of tests available for the genetic diagnosis including 
single-gene tests, gene panel tests, exome sequencing and genome sequencing. Selecting the 
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appropriate test is a big challenge to giving a successful genetic diagnosis. In fact, a review study 
published in 2015 has critically discussed the approach of selecting the best genetic test for the 
examined individual. According to the study, single-gene testing is mostly chosen in the case of 
minimal locus heterogeneity with a clear clinical diagnosis based on distinctive clinical features. 
Also, an existing association between the diagnosed disease and a disease-causing gene needs to 
be already established.  Gene panel testing is more cost-effective than a single-gene approach 
and it should be the suitable test for heterogeneous disorders with otherwise unclear clinical 
diagnoses such as disorders with overlapping phenotypes or disorders which share specific 
manifestations but in which the overall phenotypes are different. Such disorders are generally 
associated with multiple genes.  
Exome Sequencing (ES) and Genome Sequencing (GS) normally selected for the disorders with 
extreme heterogeneity and de novo mutations are the major mutation. Also, it is a good option in 
the case of a diagnosis which is very difficult to make or when there are at least two possible 
phenotypes for one patient. In addition, if there are key phenotypic features are not present at the 
time of requesting the testing the real underlying cause of the disease will be very difficult to 
identify. Examples of these disorders are Autism and congenital heart disease. ES was 
specifically selected in my project for studying foetal akinesia because of the high heterogeneity 
of the disorder plus because it has many overlapping phenotypes. It has an advantage over the 
gene panel in that it is less biased regarding which set of genes to test as the latter assumes that 
the abnormal clinical features are restricted to be associated within the included genes in the 
panel itself (though the use of WES rather CES would have enabled a larger number of genes to 
be tested). Factors such as technical limitations involved in NGS technology, the risk of false 
positive especially for insertion/deletion and the weak coverage for a particular area make both 
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ES or GS are not completely independent methods. Because of this for diagnosis, aCGH and 
Sanger sequencing are currently required as a complement method to cover the shortcomings of 
NGS in order to detect the full spectrum of mutations and to validate those findings which are 
identified by NGS approaches. In this way the differences and difficulties associated with the 
used technology, test interpretation, clinical significance, and ethical problems, need to be well 
considered by the clinician who selects the gene test because they ultimately affect the correct 
order and the diagnosis for the patient (Xue et al., 2015) 
6.8 Future Directions: 
 
There are a number of limitations of this project that hopefully directed and improved in further 
studies in the future. Firstly, familial cases of congenital oligodontia (like many other congenital 
defects) are a valuable source to undertake genetic research and investigate the genetic basis of 
the disease. Identification and including more familial cases of oligodontia would facilitate the 
discovery of the causing genes of the disorder. This could help in performing conventional 
autozygosity mapping in consanguineous families to identify new candidate regions/genes for 
the disease or preferably, the method can be combined with WES technique. So, after performing 
the exome sequencing to identify rare mutations, the identified linked region can be further 
screened for candidate mutations. Also, large cohort of unrelated control subjects from the same 
ethnicity of the recruited patients would be suggested in future studies to screen the identified 
mutations in these subjects. This might be achieved through a collaboration with similar research 
groups within the UK and internationally. Such comparison would provide a further powerful 
filter for determining pathogenicity of any candidate variants as well as narrowing down 
mutations responsible for familial cases in which the absence of the candidate-causing variant 
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might support the hypothesis that the gene is playing a disease-associated role. Finally, 
functional studies in appropriate animal models will be helpful to characterise the pathogenicity 
of mutations in candidate regions/genes by recording any molecular or phenotypical changes and 
compare it to the human subjects.  
In MPS project, for the patients who had no mutations using the use clinical exome method, 
WES offers better choice as it includes all the coding genes in case the mutations present in 
genes out of the used panel. However, in case the WES failed to identify the candidate rare 
variant, moving to the whole genome (WGS) will become the next tool to investigate the genetic 
basis of the disease as it includes coding and non-coding region of the genome. In addition, it can 
detect the structural changes such as CNV and large genetic changes that cannot be detected 
neither by CES or WES.  
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